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ABSTRACT 
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s B-
cell lymphoma, accounting for about 30% of these lymphomas in the United States. 
Large-scale genome analyses of DLBCL have identified mutations in the related histone 
acetyltransferases (HATs) p300 and CBP in approximately 15% of patient samples and 
patient-derived cell lines. The research presented herein characterizes two human 
DLBCL cell lines, RC-K8 and SUDHL2, which express C-terminally truncated HAT 
domain-deficient p300 proteins, p300ΔC-1087 and p300 p300ΔC-820, respectively. It is 
shown that p300ΔC-820 localizes to sites of active transcription in the nucleus, interacts 
with NF-κB transcription factor REL, weakly enhances REL-dependent transactivation, 
and has a half-life similar to wild-type p300. Results demonstrate that knockdown of 
p300ΔC-820 in SUDHL2 cells reduces cell proliferation in vitro. In RC-K8 cells, 
p300ΔC-1087 suppresses expression of the NF-κB target genes A20 and IκBα, both of 
which are cytotoxic when overexpressed in RC-K8 cells. Microarray analysis of p300ΔC-
	  	   vii 
1087 knockdown compared to wild-type RC-K8 cells indicated that p300ΔC-1087 
suppresses an NF-κB gene expression program and activates a MYC gene expression 
program in RC-K8 cells. Bioinformatic analysis demonstrated that cancer cell lines—
regardless of tissue type—with truncating p300 mutations have altered expression of a 
MYC target gene set as compared to cancer cell lines with wild-type p300/CBP. Taken 
together, this research indicates that p300 truncations contribute to cell growth in DLBCL 
by modifying the transcriptional output of two lymphoid cell-specific oncoproteins, NF-
κB and MYC, to optimal levels and suggests that p300 truncating mutations similarly 
modify the activity of oncogenic drivers in other cancer cell types. Based on this work, 
p300 truncation is proposed to represent a new class of oncogenic mutation that serves to 
optimize the activity of context-specific oncogenic transcription factors, and it is 
suggested that such oncogenic mutations be termed “cancer modifying” mutations.  
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CHAPTER 1 
INTRODUCTION1 
1.1 Mutations in cancer: drivers and passengers 
The past 40 years of research have revealed that mutations lie at the heart of all non-
virally-induced animal and human cancers. In fact, even many virally-induced cancers 
use mutagenesis to induce cancer, either due to the viruses themselves acting as genomic 
mutagens or by their expression of mutant versions of cellular proteins. Thus, 
understanding the mutations that cause cancer and the molecular, cellular and organismal 
consequences of these mutations for the cancer phenotype has provided fundamental 
knowledge about cancer and has led to the development of diagnostics and therapeutics 
that target specific mutant proteins and processes driven by these mutations. This thesis 
describes the characterization of a type of mutation that occurs frequently in human B-
cell lymphoma, and the effect of this mutation on the encoded protein and on cellular 
growth and gene expression. 
The complexity of the human body is conferred in part by the ability of particular 
cell types to respond to stimuli and perform a range of functions. In order to do so, most 
cells in the human body contain the information encoded by the entire human genome 
and rely on the activity of various gene products to perform these specialized functions. 
For example, cells that comprise the immune system rely, in part, on the activity of genes 
that regulate proliferation and differentiation, which is critical for their ability to repair 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Adapted from Haery et al. 2015 
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and replenish damaged tissues or respond to pathogens. The presence of complete copies 
of the genome in almost every cell, however, is also associated with the risk that an 
individual cell’s genome can be mutated and that the mutation (often in the form of a 
mutant gene product) can cause a normal cell to acquire new and abnormal properties 
(Weinberg 2014). 
 Despite the vulnerability of the more than 1013 cells that comprise the human 
body to mutations, the activation of a single cancer-causing gene (oncogene) is usually 
not sufficient to transform a normal cell into a fully malignant cell (Weinberg 2014). 
Nevertheless, there are several molecular pathways that, when altered, can cooperatively 
transform human cells. Once a tumor is initiated, genetically unstable cells within the 
tumor begin to accumulate additional mutations and undergo clonal expansions, giving 
rise to a fast-evolving and genetically heterogeneous tumor population. Due to the 
tendency of many cancers to exhibit (1) disrupted DNA repair and cell-cycle arrest 
mechanisms, (2) high rates of cellular proliferation, and (3) low rates of cell death 
(apoptosis), cancer cells can quickly accumulate mutations across a broad range of 
genetic targets. Mutations in regulatory pathways that contribute directly to the 
transformed state are often termed driver mutations (Stratton et al. 2009). However, most 
mutations in a cancer cell are clonally expanded somatic mutations that either develop 
before the onset of cancer or arise in the genetically unstable environment of the cancer 
cell, and thus many of the mutations found in a mature tumor do not contribute to the 
malignant phenotype (Greenman et al. 2007, Stratton et al. 2009). These non-selected and 
	  	  
3 
often inconsequential passenger mutations are propagated through the tumor population 
and often complicate cancer genome analyses (Raphael et al. 2014). 
 Distinguishing driver mutations from passenger mutations is often a challenge in 
understanding cancer biology, and is complicated by the fact that passenger mutations 
substantially outnumber driver mutations in most cancers. Function-based and frequency-
based approaches have been developed to characterize the mutations present in cancer 
genomes. For example, due to their effects on cancer cell functions, driver mutations tend 
to cluster within the subset of approximately 350 protein coding genes (i.e., ~1% of 
genes) (Futreal et al. 2004), whereas passenger mutations—which do not affect the 
physiology of the cancer cells—are more randomly distributed across the genome 
(Stratton et al. 2009). Moreover, some evolutionarily well-conserved or functional 
domains (e.g., kinase domains) are more likely to harbor driver mutations than passenger 
mutations (Futreal et al. 2004, Greenman et al. 2007, Weir et al. 2007). Based on all of 
these criteria, identifying the impact of mutations in cancer genomes is a difficult but 
important and ongoing area of research in cancer biology. Specifically, it is thought that 
the understanding of mutations and altered pathways that contribute to cancer will lead to 
the development of individualized or precision approaches to cancer therapy for the many 
molecularly distinct tumor types that can be found across human tissue types (e.g., breast 
vs. kidney cancer) or even within a single tumor type (e.g., among different breast 
cancers) (Sawyers 2004). 
 One particularly confounding factor is that some mutations only offer a growth or 
survival advantage in the presence of other mutations. One well-characterized example of 
	  	  
4 
this is the two-hit hypothesis for tumor suppressor genes, wherein both alleles of a 
haplosufficient tumor suppressor gene are sequentially inactivated in cancer, and only the 
second mutation in this gene leads to tumor formation (Knudson 1971). In addition, one 
could imagine that cooperating mutations must occur in two separate genes to have an 
oncogenic effect, although examples of this occurring are not well established. 
1.2 NF-κB signaling and lymphoma 
NF-κB is a family of related transcription factors that regulates the development and 
immune function of lymphoid cells, and deregulation of NF-κB activity has been 
implicated in cancer development, especially in lymphoid cell cancers such as leukemia 
and lymphoma. Generally, chronic activation of NF-κB contributes to lymphoid 
malignancies, either by enhancing cell proliferation or blocking apoptosis.  
In particular, the NF-κB family member REL (human c-Rel) is affected by gene 
amplifications in approximately 15% of diffuse large B-cell lymphoma (DLBCL) cases 
(Courtois and Gilmore 2006). Furthermore, overexpression of REL can transform and 
immortalize primary chicken lymphoid cells in culture (Gilmore et al. 2001). Similarly, 
the relatively poorly responding aggressive activated B-cell like (ABC) subtype of 
DLBCL is defined by constitutive activity of the NF-κB pathway (Alizadeh et al. 2000). 
Inhibition of NF-κB signaling leads to cell growth arrest and/or apoptosis of ABC 
DLBCL cell lines, but not to cells of the germinal center B-cell like (GCB) DLBCL 
subtype, which is not defined by constitutively active NF-κB signaling (Davis et al. 
2001). Taken together, the bulk of experimental evidence makes it clear that overly active 
NF-κB signaling—particularly of NF-κB member REL— contributes to oncogenicity 
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(especially in B cells), and that cancers defined by active NF-κB signaling generally 
require the activity of this pathway for growth and/or survival.  
 Although enhanced NF-κB signaling is found in many lymphoma subtypes, 
reduced NF-κB protein activity in certain contexts has also been shown to contribute to 
tumorigenicity. In general, this type of altered NF-κB signaling is chronically active, but 
at a reduced level, and thus provides a sustained low level of NF-κB-induced target gene 
activation. For example, the v-Rel oncoprotein of the avian Rev-T retrovirus is a mutant 
version of the avian c-Rel proto-oncoprotein and v-Rel lacks part of the normal c-Rel C-
terminal transactivation domain (Richardson and Gilmore 1991). In addition, v-Rel is 
constitutively located in the nucleus of cells, whereas the normal c-Rel protein is in the 
cytoplasm (Gilmore and Temin 1988). Moreover, deletion of one of the C-terminal 
transactivation domains of human REL, which reduces its transactivation potential, 
enhances its transforming efficiency and nuclear localization in chicken spleen cells 
(Starczynowski et al. 2003). Taken together, these results indicate that while a certain 
threshold of NF-κB signaling is required for transformation, there is an intermediate level 
of NF-κB activity that is optimal for oncogenesis. It is not surprising, therefore, that 
modulation of NF-κB activity through genetic lesions affecting the activity of various 
proteins in the NF-κB signaling pathway has been implicated in human lymphoma 
(Arcaini and Rossi 2012). Understanding modulation of NF-κB signaling and the 
activation of gene expression in lymphomas, therefore, may provide insight into the 
behavior of these cancers. 
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 In this chapter, two related classes of transcriptional modulators (including 
modulators of genes regulated by NF-κB), namely histone acetyltransferases (HATs) and 
histone deacetylases (HDACs), and their roles in lymphoid malignancies are discussed. 
In particular, the roles of HATs and HDACs in normal B- and T-cell development and 
function are described, and alterations in HAT/HDAC activity in B- and T-cell 
malignancies are discussed. In addition, the current status of HAT and HDAC inhibitors 
as potential therapies for cancers affecting B and T cells is summarized. 
1.3 Introduction to the role of HATs and HDACs in B- and T-cell physiology 
B and T cells have a variety of cellular subtypes that arise through a complex series of 
developmental events. The function of these immune cell subtypes can be altered by 
numerous extracellular factors, including antigens, cytokines, and growth factors. Many 
of these developmental and functional processes are controlled by large-scale changes in 
gene expression, either due to epigenetic changes in chromatin structure or to the activity 
of specific transcription factors (TFs). As is discussed below, HATs and HDACs are 
opposing classes of enzymes that play widespread roles in regulating transcription either 
by altering chromatin structure or by modulating the activity of specific TFs. Thus, it is 
perhaps not surprising that HATs and HDACs play roles in maintaining hematopoietic 
precursors and in coordinating their maturation into various subtypes of B and T cells. 
For example, the HATs p300/CBP interact with 36 TFs and other proteins that are 
essential for B-cell development and function alone (Xu et al. 2006). 
 As with many proteins that have important roles in normal developmental and 
cell-specific proliferation and survival processes, HAT and HDAC activity is altered in 
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many B- and T-cell malignancies. Moreover, several HDAC inhibitors (HDACi) have 
been found to reduce the proliferation of B and T cancer cells in vitro and in vivo. As an 
outcome of such basic research, there are four FDA-approved HDACi being used 
clinically to treat T-cell lymphoma or multiple myeloma, and there are several clinical 
trials using HDACi for the treatment of B- and T-cell cancers.  
1.4 Overview of the regulation of transcription by HATs and HDACs 
HATs and HDACs carry out acetylation and deacetylation, respectively, of the ε-amino 
group of specific lysine residues on target proteins. The addition of an acetyl group 
prevents the formation of positive charges on the lysine amino group, and thus, can affect 
protein charge, and hence protein function. Through this reversible catalytic event, HATs 
and HDACs can regulate transcription in two general ways: 1) by altering histone 
acetylation patterns, thereby modulating chromatin structure and its accessibility to 
transcriptional regulatory proteins (Brownell et al. 1996, Taunton et al. 1996), and 2) by 
acetylating and thereby altering the activity of non-histone substrates that directly 
regulate transcription, including a diverse array of TFs (Glozak et al. 2005).  
 HATs are a subtype of transcriptional coactivators, in that they possess intrinsic 
acetyltransferase activity and can enhance the ability of a TF to activate transcription. In 
general, HAT-mediated acetylation of nucleosomal histones increases the accessibility of 
DNA to TFs and leads to increased transcription at a given DNA locus. Acetylation of 
specific TFs by HATs can also increase their ability to bind DNA, resist proteasomal 
degradation, or interact with other TFs or coactivators, and consequently, the direct 
acetylation of TFs can also be a transcriptional activating event (Glozak et al. 2005). In 
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addition, by serving as protein scaffolds, HATs can promote the formation of 
transcriptional activating complexes near gene regulatory regions. This scaffolding 
function does not necessarily require HAT enzymatic activity, but rather is defined by the 
protein-interaction domains of these relatively large molecules. 
 HDACs, on the other hand, generally act as transcriptional corepressors by 
deacetylating nucleosomal histones, which can lead to chromosomal condensation and 
the exclusion of transcriptional activating complexes. Additionally, large HDAC-
containing repressor complexes can localize to specific gene loci and exclude activating 
molecules, including HATs, from interacting with TFs. HDACs can also deacetylate 
specific TFs, decreasing their DNA-binding activity, inducing their degradation, or 
changing their subcellular localization or protein-protein interactions (Rundlett et al. 
1998).  
1.5 Families of human HATs and HDACs 
1.5.1 HAT families   
There are 17 human HATs, which are divided into five families based primarily on the 
extent of sequence similarity (Marmorstein 2001) (Figure 1.1). Although HATs can act 
on a broad range of substrates in vitro, HATs are usually directed to specific targets in 
vivo, and thus, HAT families generally have distinct biological functions. The non-
catalytic domains of HATs are responsible for dictating this substrate specificity, and 
HAT families generally have conserved protein-protein interaction and reader domains 
(e.g., bromodomains, PHD fingers), which enable them to localize to particular genomic 
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sites and recognize specific chemical or epigenetic modifications. The size of the 
catalytic HAT domain and the mechanism of catalysis also differ between HAT families. 
For example, CBP and p300 utilize a “hit and run” kinetic model defined by an initial 
binding of acetyl-CoA followed by transient binding to the target lysine (Liu et al. 2008, 
Wang et al. 2008), whereas the GNAT family HATs adopt a ternary complex during 
catalysis (Poux et al. 2002). 
 GNAT family HATs (GCN5, HAT1, PCAF, ATF2) are generally part of large, 
multi-protein complexes that contain TBP-associated factors (TAFs) and a single 
catalytic HAT subunit (reviewed in (Vetting et al. 2005)). Two well-characterized 
complexes found in humans are the 700 kDa (i.e., ATAC) and 2 MDa (i.e., TFTC, 
STAGA, and PCAF) complexes. These large HAT-containing complexes play roles in 
global chromatin acetylation (i.e., the deposition of acetyl marks on histones) and as 
coactivators of genes when recruited to DNA by specific TFs or regulatory proteins. 
Members of the GNAT family, especially PCAF, also acetylate specific TFs and 
modulate their activity (e.g., p53, BRCA2, PTEN). GNAT family members have a 
conserved C-terminal bromodomain, which has been shown to be an acetyl-lysine 
targeting motif. GNAT family member ATF2 is the only sequence-specific DNA-binding 
transcriptional activator with intrinsic HAT activity.  
 The CBP/p300 HATs are large (~300 kDa), highly related proteins with a single 
HAT domain, a bromodomain, and several cysteine–histidine-rich (CH) domains that 
participate in a variety of protein-protein interactions (Marmorstein 2001). Indeed, 
CBP/p300 have been shown to acetylate over 75 target proteins, including all histone 
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proteins, as well as numerous TFs. By virtue of their multiple protein-protein interaction 
domains, CBP/p300 can also promote transcriptional activation by nucleating 
transcriptional complexes at promoters in a non-enzymatic manner. Although they 
generally act as coactivators, in some cases, CBP/p300 appear to be involved in 
transcriptional repression (Guidez et al. 2005).    
The MYST family of HATs (TIP60, MOZ, MORF, HBO1, MOF) is characterized 
by a conserved MYST domain that contains the catalytically active HAT domain. The 
two largest family members, MOZ and MORF, also have a PHD zinc finger domain, 
which recognizes methyl-lysine-containing motifs (Kouzarides 2007), and a C-terminal 
transactivation domain that interacts with various transcription factors, including 
hematopoietic cell regulators PU.1 and Runx1 (Kitabayashi et al. 2001, Pelletier et al. 
2002, Katsumoto et al. 2006). Most MYST family HATs act as catalytic subunits of large 
multiprotein complexes, including the ING family of tumor suppressors (Doyon et al. 
2006).  
 The steroid receptor coactivators (SRCs) include three HATs (NCOA1, NCOA2, 
NCOA3) that enhance transcription of genes responsive to liganded nuclear receptors 
(Xu et al. 2009). In addition to the HAT domain, SRCs contain three conserved domains: 
1) an N-terminal bHLH-PAS (basic helix-loop-helix-Per/ARNT/Sim), which is necessary 
for interaction with other coactivators; 2) one or more LXXLL repeats, which mediate 
interactions with other nuclear receptors and cofactors; and 3) two C-terminal 
transcriptional activation domains (AD1 and AD2). Although SRCs have been associated 
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with various human cancers, currently they are not known to have a role in hematopoiesis 
or B-/T-cell function. 
 Other HATs that are not clearly part of a family include the following; TAF1 
(TAFII250), a subunit of the TFIID general TF complex; CLOCK, which is primarily 
involved in circadian rhythm; and the 90 kDa subunit of TFIIIC, which is involved in the 
control of general transcription in a complex with RNA polymerase III. 
1.5.2 HDAC families 
To counterbalance the impact of HATs on protein function and genome structure, there 
are 18 human HDACs, which are commonly divided into four major classes based on 
homology to yeast orthologs (Figure 1.1): class 1 (HDAC1, 2, 3 and 8), class 2 (HDAC4, 
5, 6, 7, 9, and 10), class 3 (aka sirtuins; SIRT1, 2, 3, 4, 5, 6, and 7), and class 4 
(HDAC11) (de Ruijter et al. 2003, Yang and Gregoire 2005, Yang and Seto 2008, Wang 
et al. 2009). HDAC classes differ in their structure, substrate specificity, enzymatic 
mechanism, subcellular localization, and tissue-specific expression. Even though most 
HDACs contain a nuclear localization signal (NLS) and, in some cases, a nuclear export 
signal (NES), HDACs often localize to specific subcellular regions due to protein-protein 
interactions with proteins that direct their cellular localization.  
 The “classical” HDACs are those in classes 1, 2a, 2b, and 4, and they have a 
conserved ~390 aa catalytic domain and Zn2+-dependent deacetylase activity. The 
conserved, ~275 aa catalytic domain of the class 3 sirtuins is NAD+-dependent and 
unrelated to the catalytic domain of the classical HDACs (Min et al. 2001, Grozinger and 
Schreiber 2002). These differences in their catalytic mechanisms have implications for 
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inhibition of HDAC activity, and thus, many of the HDAC inhibitors (HDACi) used in 
cancer therapeutics target the classical HDACs (discussed below). 
 Class 1 HDACs are ubiquitously expressed and localize almost exclusively to the 
nucleus. The class 2 HDACs are generally much larger than class 1 HDACs, show tissue-
specific expression patterns, and often shuttle in and out of the nucleus. In general, 
HDACs in both classes 1 and 2 are found in large transcriptional repressing complexes, 
and are recruited to DNA either by other proteins in those complexes or by other DNA-
binding proteins. These large protein complexes play roles in HDAC localization and 
substrate specificity, can act as scaffolds to recruit DNA-binding proteins, and provide 
the cofactors required for HDAC function. Indeed, lack of these cofactors limits the 
activity of some recombinant HDACs (Guenther et al. 2001). HDAC 11 is the only class 
4 HDAC, and although it shows sequence similarity to class 1 and 2 HDACs, it does not 
exist within any of the known HDAC complexes. 
 Class 3 sirtuins vary in their subcellular localization and interact with a diverse 
array of TFs and other, primarily non-histone, substrates (Yao et al. 2014). For example, 
SIRT1 can directly interact with substrates involved in the stress response, including p53, 
FOXO proteins, and NF-κB. The mitochondrially-localized sirtuins (SIRT3, 4, 5) can 
regulate mitochondrial function, respiration, and energy consumption (Shi et al. 2005). 
Some sirtuins (SIRT4 and 6) lack deacetylase activity, but possess ADP-ribosyl-
transferase activity and play roles in metabolism and DNA repair. 
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1.6 HATs and HDACs in B- and T-cell development 
1.6.1 HATs and HDACs in early hematopoietic development 
B- and T-cell development involves controlled stages of gene expression programs and 
genomic instability, which ultimately give rise to the diversity of cells that provide 
adaptive immunity. These developmental stages are tightly regulated by a large variety of 
TFs and are coupled with the accessibility of DNA to factors that coordinate 
chromosomal rearrangements. HATs and HDACs play major roles in normal B- and T-
cell development because they can interact with hematopoietic regulators and TFs, as 
well as affect DNA accessibility by modifying chromatin structure near relevant target 
genes. In this section, some roles of HATs and HDACs in normal hematopoiesis, 
lymphopoiesis, and B- and T-cell function are discussed (summarized in Table 1.1). 
 Much of what is known about the role of HATs and HDACs in the development 
of mammalian B and T cells comes from the study of whole knockout (KO) mice and of 
mice with tissue-specific inactivation of individual HATs and HDACs. In most cases, 
whole-mouse HAT and HDAC KOs are embryonic lethal. Therefore, to explore the roles 
of these HATs/HDACs in hematopoiesis, either hematopoietic progenitors have been 
isolated from KO mice or hematopoietic lineage-specific gene KOs have been generated.  
 Mice with cell-specific KOs of CBP or p300 have defects in maintenance and 
differentiation of hematopoietic stems cells (HSCs) (Kung et al. 2000, Kimbrel et al. 
2009). The defect in hematopoiesis in p300-null stem cell lines can be rescued by re-
expression of wild-type p300 or when an extra copy of CBP is placed under control of the 
p300 locus, suggesting that the total dosage of HAT activity by CBP/p300 is critical for 
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hematopoietic maintenance and differentiation rather than the specific activity of either 
individual HAT (Kung et al. 2000, Kimbrel et al. 2009). Likewise, in the MYST family, 
whole animal KO of MOZ is embryonic or perinatal lethal, and MOZ KO embryos show 
a dramatic reduction in the number and repopulation capacity of hematopoietic 
progenitors, whereas mice with heterozygous KO or with a HAT deletion of MOZ often 
show intermediate phenotypes, suggesting a dose-dependent requirement for activity of 
this HAT (Katsumoto et al. 2006, Thomas et al. 2006). 
 To study the role of specific p300 domains in hematopoiesis, a series of p300 
deletion mutants were re-expressed in p300-null embryonic stem cells (ESCs), and their 
ability to contribute to hematopoiesis was analyzed. These studies showed that p300 
mutants lacking the KIX or CH1 domain had reduced abilities to induce hematopoiesis, 
and these defects were similar to the parental p300-null cells (Kimbrel et al. 2009). This 
reduction in hematopoiesis is thought to be due to an inability of KIX and CH1 deletion 
mutants to interact with the TF MYB (Kasper et al. 2002, Kimbrel et al. 2009). 
Interestingly, the presence of a functional HAT domain in p300 appears to play a role in 
limiting the proliferation of hematopoietic precursors, in that expression of a HAT-
deficient p300 mutant in p300-null cells leads to increased numbers of hematopoietic cell 
populations, as compared to re-expression of wild-type p300 (Kimbrel et al. 2009). The 
dispensability of the CBP/p300 HAT domain for hematopoiesis may be due to their 
interaction with the HAT PCAF, which provides catalytic HAT activity in some 
CBP/p300 signaling contexts (e.g., myogenic differentiation) (Puri et al. 1997). Thus, 
unlike the MYST family, which relies on HAT activity for proper proliferation of HSCs 
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(described below), the HAT domains of CBP/p300 may actually reduce the proliferation 
of some hematopoietic cell types.  
 Among the MYST family proteins, the role of MOZ in hematopoiesis was 
determined by analyzing the hematopoietic progenitors in MOZ KO mice. Whole-mouse 
MOZ KO reduces the number of HSCs, and also affects the ability of these stem cells to 
renew and reconstitute the hematopoietic system (Katsumoto et al. 2006). HSCs from 
MOZ KO mice have reduced HOXA9 expression, which is known to reduce the 
differentiation potential of HSCs. MOZ is also a transcriptional coactivator of PU.1, and 
reduced PU.1 activity can explain many of the phenotypes seen in MOZ KO mice (Kim 
et al. 2004, Iwasaki et al. 2005, Katsumoto et al. 2006). In mice expressing HAT-
deficient MOZ, hematopoietic progenitors are severely defective in competitive 
repopulation assays, demonstrating a critical role of the MOZ catalytic domain in HSC 
functionality (Perez-Campo et al. 2009). These defects were linked to a marked 
deficiency in the proliferative capacity of HAT-deficient MOZ precursors (Perez-Campo 
et al. 2009). Loss of MYST family member MOF in ESCs is associated with a reduction 
in the expression of some hematopoietic genes, suggesting a role for MOF in 
hematopoiesis (Li et al. 2012). Additionally, conditional KO of the coactivator TRRAP, 
which can act as a subunit of TIP60 and PCAF HAT-containing complexes, leads to loss 
of HSCs (Loizou et al. 2009). 
 HDAC1 and 2 have overlapping critical roles in early hematopoiesis and HSC 
homeostasis, largely by acting in a SIN3A/HDAC1/2-repressor complex. While mice 
with bone marrow-specific deletions of either HDAC1 or HDAC2 show only moderate 
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phenotypes, the simultaneous deletion of HDAC1 and HDAC2 (or SIN3A alone) leads to 
nearly complete loss of hematopoietic progenitors, causing severe reduction in the 
numbers of spleen, thymic and bone marrow cells (Guan et al. 2009, Wilting et al. 2010, 
Heideman et al. 2014). During HSC emergence in zebrafish, HDAC1 is recruited to the 
erk promoter by SMAD1/5, and represses erk1/2 expression by deacetylating H3K9 and 
H3K27 (Zhang et al. 2014). Conditional KO studies have shown that HDAC3 is required 
for DNA replication in HSCs, which is essential for their ability to produce B- and T-cell 
progenitors (Summers et al. 2013).  
1.6.2 HATs and HDACs in B-cell development and function 
Disruption of p300 or CBP at the pro-B cell stage results in a 25-50% reduction in the 
number of B cells in the peripheral blood; however, the number of pro-B, pre-B, and 
immature B cells in the bone marrow is unaffected (Xu et al. 2006). Loss of CBP at this 
stage does not drastically perturb gene expression in resting B cells, as ~99% of 
microarray transcripts measured in CBP-null cells were within 1.7-fold of controls (Xu et 
al. 2006). These results indicate that loss of either p300 or CBP starting at the pro-B cell 
stage is not required for B-cell function, possibly due to functional redundancy of these 
two HATs. In contrast to the single KOs, the double KO of CBP and p300 in pro-B cells 
causes a dramatic reduction in the number of peripheral B cells (Xu et al. 2006).  
 With the exception of mature B cells, the HAT activity of MOZ is required for the 
cell proliferation required to maintain healthy numbers of hematopoietic precursors. That 
is, mice expressing a HAT-deficient MOZ protein show an approximately 50% reduction 
in the numbers of pro/pre-B cells and immature B cells, whereas the number of mature B 
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cells and their ability to carry out antibody responses is unaffected (Perez-Campo et al. 
2009).  
 KO of GCN5 in the chicken immature B-cell line DT40 showed that GCN5 
regulates transcription of the IgM H-chain gene, and GCN5 deficiency decreased 
membrane-bound and secreted forms of IgM proteins (Kikuchi et al. 2014). GCN5 also 
directly activates expression of the TF IRF4, which is required for B-cell differentiation 
(Kikuchi et al. 2014). PCAF acetylates the TF E2A, which plays a major role in the 
differentiation of B lymphocytes (Bradney et al. 2003).  
 HDACs also appear to play a role in signaling from the B-cell receptor (BCR). 
During BCR activation, HDACs 5 and 7 are phosphorylated by protein kinases D1 and 
D3 and exported from the nucleus, suggesting a link between BCR function and 
epigenetic regulation of chromatin structure (Matthews et al. 2006).  
 A major regulator of B-cell differentiation is the TF BCL6, which represses a set 
of target genes during proper germinal center (GC) development (Okada et al. 2012). 
BCL6 also serves as an anti-apoptotic factor during an immune response, which enables 
DNA-remodeling processes to occur without eliciting an apoptotic DNA damage 
response (Arguni et al. 2006, Basso and Dalla-Favera 2010). To achieve GC-specific 
gene expression, BCL6 is recruited to a large repressor complex that contains HDAC4, 5, 
and 7, and localizes to the nucleus to regulate its target genes (Lemercier et al. 2002). 
Treatment of cells with an HDACi results in hyper-acetylation of BCL6, which 
derepresses expression of BCL6 target genes involved in lymphocyte activation, 
differentiation, and apoptosis (Bereshchenko et al. 2002, Pasqualucci et al. 2003). 
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 In B cells, HDAC1 and 2 play a key, redundant role in cell proliferation and at 
certain stages of development. That is, in early B cells the combined KO of HDAC1 and 
2 results in a loss of further B-cell development and the few surviving pre-B cells 
undergo apoptosis due to a cell cycle block in G1, whereas individual KOs of these 
HDACs has no effect (Yamaguchi et al. 2010). In mature B cells, the combined KO of 
HDAC1 and 2 has no effect on cell survival or function in the resting state, but these 
double KO cells fail to proliferate in response to lipopolysaccharide and IL-4 
(Yamaguchi et al. 2010). 
1.6.3 HATs and HDACs in T-cell development and function 
HATs and HDACs also play roles in T-cell development and function. For example, the 
HAT p300 is important for the expression of chemokine CCR9, which is expressed in 
thymocytes during their migration and development into mature T cells (Krishnamoorthy 
et al. 2015). Early in this developmental process, NOTCH signaling prevents p300 
recruitment to, and acetylation of, core histones at two CCR9 enhancers, thus reducing 
CCR9 expression (Krishnamoorthy et al. 2015). This NOTCH-dependent repression of 
CCR9 occurs via effects on p300 in multipotent progenitor cells and is also observed in 
T-lymphoma cell lines (Krishnamoorthy et al. 2015). 
 Thymus-specific deletion of the bromodomain-containing protein BRD1, which is 
a subunit of the HAT HBO1 complex (Mishima et al. 2011), alters the pattern of 
CD4/CD8 expression in thymocytes and decreases the abundance of CD8+ mature T cells 
in the periphery (Mishima et al. 2014). Furthermore, the HBO1-BRD1 complex is 
	  	  
19 
responsible for activating CD8 expression by increasing global acetylation of H3K14 in 
developing T cells (Mishima et al. 2014). 
 T cell-specific KO of HDAC1 does not affect late T-cell development or the 
number of T cells in the periphery (Grausenburger et al. 2010). The lack of an effect is 
likely due to compensation by HDAC2, whose expression is increased when HDAC1 is 
inactivated (Grausenburger et al. 2010). Moreover, T cell-specific KO of both HDAC1 
and 2 results in arrested T-cell development (Dovey et al. 2013), similar to what is seen 
in HSCs and early B cells (see above). Nevertheless, T cell-specific KO of HDAC1 alone 
does cause an increased Th2-type inflammatory response in a mouse model of asthma, 
which is characterized by elevated expression of IL-4, IL-5, and IL-10, suggesting that 
HDAC1 represses cytokine production in activated T cells and during effector T cell 
(Teff) differentiation (Grausenburger et al. 2010). Of note, the HDAC1-deficient increased 
expression of IL-4 in T cells is seen only after several rounds of cell division, suggesting 
that the effect of HDAC1 on IL-4 expression occurs via an epigenetic mechanism, and 
that the removal of repressive marks occurs during DNA replication (Grausenburger et al. 
2010). In T cells, an HDAC1/mSIN3A complex represses IL-2 expression (Lam et al. 
2015), and during T-cell activation, HDAC1-mediated repression of IL-2 is relieved by 
phosphorylation of mSIN3A by CDK5, which disrupts the formation of the 
HDAC1/mSIN3A complex (Lam et al. 2015).  
 HDAC6-null mice exhibit normal B-cell development, but have reduced IgM and 
IgG levels following antigen stimulation (Zhang et al. 2008). This defect may be due to 
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the role of HDAC6 in immune synapse formation and T-cell migration (Serrador et al. 
2004, Cabrero et al. 2006).  
 In developing T cells, the interaction of class 2 HDACs with the TF MEF2D 
plays a major role in regulating T-cell receptor (TCR)-mediated apoptosis during 
negative selection of T cells with a TCR that interacts with self-antigen. For example, 
HDAC7 is recruited to the NUR77 promoter by MEF2D, where it acetylates chromatin 
and represses the expression of this apoptotic regulator (Dequiedt et al. 2003). In T cells 
undergoing negative selection, HDAC7 or class 2 HDACs become phosphorylated near 
their N-termini by protein kinase D, which allows recognition by 14-3-3, disruption of 
the interaction with MEF2D, and results in nuclear export of the repressive HDAC 
(Woronicz et al. 1994, Calnan et al. 1995, Dequiedt et al. 2003). In addition to its role in 
negative selection, HDAC7 regulates the expression of genes involved in positive thymic 
selection. For example, HDAC7 KO and mutation studies in mouse thymocytes have 
shown that transcription of HDAC5 is regulated by MEF2D but not by NUR77; thus, 
HDAC5 may be a direct target for transcriptional regulation by HDAC7 during positive, 
but not negative T-cell selection (Kasler and Verdin 2007, Kasler et al. 2011) 
 Class 4 HDAC11 represses the expression of IL-10 in antigen-presenting cells 
(APCs) by interacting with the distal region of the IL-10 promoter (Villagra et al. 2009). 
HDAC11 localization at the IL-10 distal promoter is coupled to increased binding of the 
transcriptional repressor PU.1 at the distal promoter and decreased acetylation of histones 
H3 and H4 at the proximal IL-10 promoter (Villagra et al. 2009). APCs that overexpress 
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HDAC11 are able to restore the responsiveness of tolerant CD4+ T cells (Villagra et al. 
2009). 
1.6.4 HATs and HDACs in the development of Regulatory T cells 
Regulatory T cells (Tregs) play an important role in limiting T-cell immune responses, 
and HATs and HDACs have a variety of roles in Treg function. p300 and other HATs 
maintain the stability and function of Tregs by acetylating the TF FOXP3, whose 
transcriptional output is required for Treg-mediated immunosuppression (van Loosdregt 
and Coffer 2014). FOXP3 expression in Tregs can be either positively or negatively 
regulated by the TF KLF10 through its association with PCAF or SIN3-HDAC1, 
respectively (Xiong et al. 2014). Interestingly, p300-deficient Tregs show many of the 
same defects in activity, survival and proliferation that occur in FOXP3-deficient Tregs 
(van Loosdregt and Coffer 2014), suggesting that the effects of p300 deficiency on Treg 
function are due to a reduction in FOXP3 activity. FOXP3 has also been found in a 
transcriptional regulatory complex with TIP60, HDAC7, HDAC9, and other proteins (Li 
and Greene 2007). 
 The acetylation of FOXP3 by either p300 or TIP60 both protects FOXP3 from 
degradation and increases its DNA-binding activity, and as a result, p300- or TIP60-
deficient Tregs have defects in activity, survival, and proliferation (Li et al. 2007, van 
Loosdregt and Coffer 2014). Deleting either p300 or CBP in FOXP3+ Tregs in mice does 
not affect the overall proportion of T cells under basal conditions, and thus, these two 
HATs appear to have redundant roles in Treg production under resting conditions (Liu et 
al. 2013, Liu et al. 2014). When the Tregs are activated, however, p300- or CBP-deficient 
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FOXP3+ Tregs undergo apoptosis, are unable to suppress homeostatic Teff cell 
proliferation, and reject transplanted allografts (Liu et al. 2013, Liu et al. 2014). Mice 
with simultaneous Treg-specific deletion of p300 and CBP develop severe autoimmunity, 
as both p300 and CBP interact not only with FOXP3, but also with many FOXP3-
regulating TFs including NFAT, STAT1, FOXO1, FOXO3, NF-κB, RUNX1, and 
STAT5 (Burchill et al. 2007, Kitoh et al. 2009, Ruan et al. 2009, Rudra et al. 2009, 
Ouyang et al. 2010, Liu et al. 2014). Nevertheless, p300 and CBP also have distinct roles 
in Tregs; for example, only p300 is required for efficient GATA-3 expression, which is 
important for FOXP3 expression and Treg accumulation (Liu et al. 2014).  
 Countering the HATs, the HDACs deacetylate FOXP3, which reduces Treg 
development and immunosuppressive function, and also provides a therapeutic target for 
enhancing immunosuppressive (and potentially anti-tumor) activity in patients (Tao et al. 
2007, de Zoeten et al. 2010, Beier et al. 2012). FOXP3 can be deacetylated by certain 
HDACs (i.e., HDAC3, 6, 7, 9 and SIRT1), which decreases FOXP3 protein levels and 
activity (Tao et al. 2007, Samanta et al. 2008, Wang et al. 2015). Of note, HDAC6, which 
is normally cytoplasmic, translocates to the nucleus of some Tregs where it can 
deacetylate FOXP3 (Beier et al. 2012). Treg-specific deletion of these HDACs or 
treatment with HDACi has been shown to enhance immunosuppressive activity and Treg 
function (de Zoeten et al. 2010). Taken together, these results suggest that acetylation of 
FOXP3 favors Treg development. However, while Treg development is important in 
limiting host autoimmunity, it may also reduce host immune responses and anti-tumor 
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activity. Thus, inhibition of FOXP3 acetylation is a promising anti-tumor strategy (Liu et 
al. 2013).  
1.7 Regulation of immune cell-related TFs by acetylation 
The activities of several TFs that play key roles in immune responses are affected directly 
and indirectly by HATs/HDACs. In most cases, the ability of CBP/p300 to acetylate a 
given TF and affect its activity has been investigated (summarized in Table 1.2). There 
are four general ways that direct acetylation has been shown to affect TF function: 1) 
lysine acetylation can increase protein stability by blocking ubiquitination of the same 
lysines that promote proteasome-mediated degradation; 2) lysine acetylation within the 
DNA-binding domain can decrease the ability of the TF to bind DNA; 3) lysine 
acetylation can increase (or decrease) protein-protein interactions with TF regulators; and 
4) acetylated lysines on TFs can serve as a docking domain for the bromodomain of 
HATs, which can increase their transactivation activity (Yang and Gregoire 2005). For 
example, NF-κB and STAT proteins are important regulators of B- and T-cell 
development and function. Both of these TFs undergo acetylation/deacetylation at several 
lysines, and acetylation at different residues can positively or negatively impact their 
activity in distinct ways depending on the lysine residue (Ghizzoni et al. 2011, Zhuang 
2013). Furthermore, the activity of NF-κB and STAT can be indirectly affected by 
acetylation, for example, by acetylation of their specific co-activators, the TFs that 
interact with them, or histones at their target gene promoters. Moreover, the ability of 
acetylation to affect NF-κB and STAT activity can depend on the specific target gene 
studied. 
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 In a small number of cases, it is known how acetylation alters the activity of a TF 
in a way that affects B- or T-cell function. As described above, the TF FOXP3 is a direct 
substrate of p300 and other HATs, and acetylation of FOXP3 plays a key role in Treg 
development and maintenance (van Loosdregt and Coffer 2014). Acetylation increases 
FOXP3 activity by stabilizing the protein and enhancing its DNA-binding activity at 
certain promoters (van Loosdregt and Coffer 2014).  
 BCL6 is a transcriptional repressor that is essential for GC formation and 
lymphocyte function and proliferation (Dent et al. 1997, Ye et al. 1997). p300 can 
directly bind to and acetylate BCL6, which interferes with its ability to bind HDAC-
containing complexes and consequently inactivates its repressor activity (Bereshchenko 
et al. 2002). CBP/p300 mutant proteins found in some diffuse large B-cell lymphomas 
(DLBCLs) show a reduced ability to acetylate BCL6 (Pasqualucci et al. 2011), and 
therefore such lymphoma cells have increased BCL6 activity, which is related to the 
oncogenic state of these cells. 
  GATA-3 plays a key role in T-cell differentiation and survival, and acetylation 
has been shown to increase GATA-3 transactivation activity (Yamagata et al. 2000). 
Moreover, overexpression of an acetylation-defective GATA3 protein affects T-cell 
homing to lymph nodes and increases T-cell survival after antigen stimulation (Yamagata 
et al. 2000). 
1.8 HATs and HDACs in B- and T-cell malignancies 
Given the broad role of acetylation in controlling lymphoid cell gene expression and TF 
activity, it is not surprising that misregulated protein acetylation is found in many 
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cancers. As described in more detail below, in B- and T-cell cancers one often finds gene 
deletions and mutations that inactivate or reduce HAT activity (e.g., in CBP/p300) or 
overexpression of non-mutant forms of HDACs. As a consequence, reduction of global 
histone and TF acetylation is associated with B- and T-cell proliferation and survival, 
whereas increased acetylation is associated with B- and T-cell tumor growth arrest and 
cell death. 
1.8.1 Mutations of HATs in B- and T-cell leukemia/lymphoma  
Although chromosomal translocations involving p300, CBP and MYST are well-
documented in acute myeloid leukemia (Shima and Kitabayashi 2011), they have not 
been found in B- and T-cell malignancies. However, other types of HAT gene mutations 
are common in certain types of B- and T-cell cancers. Namely, the genes encoding CBP 
and p300 harbor point mutations or deletions in approximately 20–40% of DLBCL 
(Morin et al. 2011, Pasqualucci et al. 2011, Pasqualucci et al. 2011), about 70% of 
follicular lymphomas (FL) (Pasqualucci et al. 2014), and less frequently in T-cell 
leukemia, acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (Shigeno 
et al. 2004, Inthal et al. 2012). The TIP60 gene frequently suffers mono-allelic loss and 
reduced expression in several types of B-cell lymphoma (Gorrini et al. 2007). Moreover, 
our analysis of the Cancer Cell Line Encyclopedia (CCLE) database (Barretina et al. 
2012) finds that mutations in CBP/p300 and other HATs (especially MORF) are common 
in a variety of B- and T-cell cancer cell lines (Table 1.3). With CBP and p300, the 
majority of these lymphoma mutations occur within or near the HAT domain or introduce 
frame-shifts or stop codons N-terminal to the HAT domain (see Figure 1.2). Thus, many 
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of the CBP/p300 mutations found in DLBCL and FL are predicted to reduce 
acetyltransferase activity (Pasqualucci et al. 2011). Indeed, several of these point 
mutations have been demonstrated to impair the affinity of CBP for acetyl-CoA and 
consequently compromise the ability of CBP to acetylate the TFs BCL6 and p53 
(Pasqualucci et al. 2011). Of note, acetylation of BCL6 decreases its gene repressing 
activity, whereas acetylation of p53 is required for its gene activation function (Table 1.2) 
(Avantaggiati et al. 1997, Bereshchenko et al. 2002). Thus, DLBCL cells with HAT gene 
mutations have higher levels of active BCL6 and lower levels of active p53 (Pasqualucci 
et al. 2011), consistent with decreased acetylation being associated with increased tumor 
cell growth. 
 In contrast to the more common point mutations, genomic alterations that 
completely remove the HAT domain in CBP or p300 are present in a minority of DLBCL 
and FL tumors and cell lines (Pasqualucci et al. 2011, Pasqualucci et al. 2014). 
Expression of C-terminally truncated CBP/p300 proteins missing the HAT domain has 
been demonstrated in some DLBCL cell lines (Garbati et al. 2010, Pasqualucci et al. 
2011, Haery 2014). The activity of these mutants and their role in DLBCL is further 
explored in this study and is discussed in detail in Chapter 5.  
 Interestingly, the TF BCL6, which is upregulated in and required for the growth 
of approximately 70% of DLBCLs (Ci et al. 2008), appears to be a direct transcriptional 
repressor of the p300 gene (Cerchietti et al. 2010). Furthermore, induced expression of 
p300 is required for the anti-proliferative effects of BCL6 inhibitors on DLBCL cell lines 
(Cerchietti et al. 2010). Consequently, DLBCL cell lines with defective p300 proteins are 
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resistant to the anti-growth effects of BCL6 inhibitors, and in these cell lines, HDACi 
synergize with BCL6 inhibitors for inhibition of DLBCL cell growth (Cerchietti et al. 
2010). 
 Overall, there are no good mouse models for HAT gene mutations in B- and T-
cell malignancy. In one report (Rebel et al. 2002), a single mouse reconstituted with 
CBP-null HSCs developed a thymic lymphoma that arose from the CBP-null cells, but 
that mouse has not been further characterized. Based on the inactivation of the wild-type 
EP300 allele in DLBCLs containing certain p300 mutations (Garbati et al. 2010, Haery 
2014), expression of truncated or mutant p300 proteins (from human DLBCLs) in p300-/- 
B-cell precursors may lead to B-cell malignancy in a transgenic mouse model.   
1.8.2 HDAC dysregulation in B- and T-cell lymphoma/leukemia  
Unlike the case with HATs, mutations in genes encoding HDACs have not been found in 
any B- and T-cell malignancies. However, HDACs have been reported to have altered 
(usually increased) expression in a variety of B- and T-cell malignancies, including 
DLBCL, FL, and chronic lymphocytic leukemia (CLL) (Table 1.4). For example, 
HDAC1 is overexpressed in some T-cell lymphomas (Choi et al. 2001, Halkidou et al. 
2004, Zhang et al. 2005, Wilson et al. 2006, Marquard et al. 2009), while HDAC6 has 
been reported to be both overexpressed (Zhang et al. 2004, Marquard et al. 2009) and 
underexpressed (Gloghini et al. 2009) in DLBCL.  
 At this point, two of the most relevant questions are whether altered expression of 
a specific HDAC contributes to the growth or survival of the tumor cells (and how it does 
so) and whether altered HDAC expression can be prognostic for therapy. In a smattering 
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of cases, there are data addressing these questions, but the overall picture is still not clear. 
Inhibition of HDAC8 induces apoptosis in T cell-derived lymphoma and leukemic cells, 
but not in solid tumors (Lee et al. 2006). High HDAC4 expression is associated with a 
poor response to prednisone in ALL, and siRNA-mediated inhibition of HDAC4 has been 
shown to sensitize a T-ALL cell line to etoposide-induced cell death (Gruhn et al. 2013). 
Moreover, the interaction of HDAC4 with the leukemic PLZF-RARα fusion protein 
contributes to oncogenesis because it is required for the repression of differentiation-
associated genes (Chauchereau et al. 2004). 
 In childhood acute lymphoblastic leukemia (ALL), high HDAC3 expression has 
been associated with a better prognosis, whereas overexpression of HDAC7 and 9 have 
been associated with a poorer prognosis (Moreno et al. 2010). A study of over 200 adult 
CLL B-cell tissue samples reported that overexpression of HDAC7 and 10 and 
underexpression of HDAC6 and SIRT3 are correlated with a poor prognosis (Van 
Damme et al. 2012). HDAC6 overexpression correlates with a more favorable outcome in 
DLBCL, but with a negative outcome in peripheral T-cell lymphoma (Marquard et al. 
2009). Although HDAC1, 2 and 3 are all overexpressed in Hodgkin’s lymphoma tissue 
samples, only high HDAC1 expression is correlated with a worse outcome (Adams et al. 
2010). 
 As with HATs, there are no good mouse models for the role of HDACs in cancer. 
Based on most evidence, it is unlikely that overexpression of any HDAC would, by itself, 
be oncogenic. Thus, one method for evaluating the molecular mechanisms by which 
increased HDAC expression contributes to oncogenesis might be to create transgenic 
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mice with B and/or T cell-specific expression of a relevant HDAC (e.g., HDAC6) and 
cross such mice to other common transgenic mouse tumor models (e.g., Eµ-MYC mice). 
One could then determine whether increased HDAC expression leads to enhanced tumor 
development or if such mice develop chemo- or HDACi-resistant tumors.  
1.9 HAT and HDAC inhibitors in the treatment of B- and T-cell cancers 
Given that mutations and dysregulation of HATs and HDACs occur in many B- and T-
cell cancers, as well as their global effects on protein activity and gene expression, these 
enzymes have been investigated for therapeutic targeting. The types of compounds that 
have been found to inhibit HAT and HDAC activity are discussed below, along with 
examples of such molecules being used in the treatment of lymphoid cancer cells. 
Overall, HDACi have been more useful in such settings than HATi, and HDACi are 
being used in the clinic to treat lymphoid cell cancers. 
1.9.1 HAT inhibitors (HATi) 
Several types of compounds have been characterized as HAT inhibitors, including a 
variety of synthetic compounds and natural products and their derivatives. In general, 
such compounds are pan-HAT inhibitors or inhibitors of GCN5 or CBP/p300 (Dekker 
and Haisma 2009, Dekker et al. 2014). 
There are few reports of HATi as inhibitors of B- or T-cell cancers, however there 
are currently no FDA approved HATi for the treatment of human cancer. Anacardic acid, 
found in cashew nuts, is a potent inhibitor of p300, PCAF, and TIP60 (Balasubramanyam 
et al. 2003, Sun et al. 2006). Anacardic acid and derivatives have been shown to inhibit 
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Jurkat T-cell leukemia cells at micromolar concentrations (Eliseeva et al. 2007). Of note, 
Jurkat cells have been shown to express two TIP60 variants, including one with a deleted 
HAT domain (Hlubek et al. 2001). The natural products gallic acid and curcumin have 
both been shown to act as HAT inhibitors (Balasubramanyam et al. 2004, Choi et al. 
2009), and can induce proliferation arrest and apoptosis in lymphoma cells (Uddin et al. 
2009, Kim et al. 2011). However, gallic acid and curcumin are not especially potent 
inhibitors of lymphoma cell growth and both have many protein targets (Verma et al. 
2013, Aggarwal et al. 2015); thus, it is not clear that their effects on lymphoma cell 
growth are due to their anti-HAT activity. The synthetic compound C646 is a specific 
p300 inhibitor, however, it was not especially effective against leukemia cell lines in a 
screen of the National Cancer Institute (NCI) 60-cell line panel (Yan et al. 2013). 
1.9.2 HDAC inhibitors (HDACi)  
Given that increased HDAC expression and activity is found is many lymphoid 
malignancies (see above), it is perhaps not surprising that HDACs should emerge as 
targets for therapy. In contrast to HATi, HDACi have been extensively studied for anti-
cancer activity. Indeed, since 2001, a number of HDACi have been used in the clinic for 
the treatment of various cancers, including B- and T-cell cancers (Zain and O'Connor 
2010). Alone or in combination with other anti-cancer agents, a variety of HDACi have 
been shown to induce apoptosis in many different types of B- and T-cell lymphoma and 
leukemia cell lines (Table 1.5). Following from those studies, several HDACi have been 
tested clinically for the treatment of such human cancers, including cutaneous T-cell 
lymphoma (CTCL), DLBCL, multiple myeloma (MM), FL, Hodgkin’s lymphoma (HL), 
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and several others (Table 1.6), and as of April 2015, there are at least 12 ongoing clinical 
trials testing HDACi alone or in combination with other cancer therapeutics for the 
treatment of several B- and T-cell malignancies (Table 1.7). 
 HDACi fall into five main classes, based in part on their chemical structures and 
in part on their specificity. These include the following: 1) hydroxyamic acids, 2) cyclic 
tetrapeptides, 3) benzamides, 4) ketones, and 5) aliphatic acids. In addition, HDACi can 
have broad-based pan-HDAC inhibitory activity, have class specificity, or even isozyme 
specificity. Currently, four HDACi have received FDA approval for clinical treatment of 
human cancers. The first two FDA-approved inhibitors are the pan-HDACi vorinostat 
(aka suberoylanilide hydroxamic acid [SAHA]), which is available as an oral medication, 
and the class I HDACi romidepsin (a bacterial cyclic peptide), which is administered 
intravenously. HDACi treatment is especially effective in the treatment of CTCL, with 
favorable response rates (from a number of trials) of approximately 70% when using 
romidepsin (Table 6). Although it is not known why CTLC responds well to HDACi 
treatment, increased expression of HDAC2 and histone H4 acetylation have been 
correlated with aggressive CTCL (Marquard et al. 2009). The HDACi belinostat was 
approved in 2014 for relapsed and refractory peripheral T-cell lymphomas (Lee et al. 
2015). Finally, the HDACi panobinostat, another hydroxamate, has been approved by the 
FDA for refractory multiple myeloma (San-Miguel et al. 2014). Because of the role of 
HDACs in normal immune cell function, one problem with using HDACi treatment for 
anti-cancer therapy is the concomitant suppression of host immune responses required for 
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anti-tumor therapy (see also HATs and HDACs in development of Regulatory T cells 
section above) (Kelly-Sell et al. 2012).  
 In the simplest scenario, HDACi treatment increases the level of acetylation of 
histones on chromatin, thereby increasing gene expression, and HDACi also increase the 
acetylation of non-histone proteins. For lymphoid cell TFs, increased acetylation can 
either increase or decrease their activity (Table 1.2). Because of the myriad effects of 
acetylation/deacetylation on gene expression and protein activity, it is almost certain that 
the effects of HDACi on tumor cell growth and survival are not through single or even a 
small number of targets. Moreover, the effects of HDACi would be expected to vary 
among tumor cell types, within a given tumor type, and, due to tumor cell heterogeneity, 
even within a given tumor.  
 Consistent with those hypotheses, treatment of CTCL cell lines with vorinostat 
showed that HDACi treatment leads to hyperacetylation of all core histones, which is 
associated with changes in the expression of genes involved in regulation of the G1/S and 
G2/M transitions, apoptosis, anti-proliferation, and MAPK signaling (Richon et al. 2000). 
Overall, gene expression profiling showed that up to 22% of genes are altered by HDACi 
as early as four hours post treatment in several cell types (Van Lint et al. 1996, Peart et 
al. 2003, Halsall et al. 2012). Nevertheless, there does appear to be a common set of 
genes that change expression in response to HDACi treatment, and these genes include 
several cyclins, the cell-cycle inhibitor p21, p53, BAX, BCL2, MYC, PKCδ, ICAM-1, 
IL-6 receptor, IL-2, IL-8, IL-10, VEGF, NOTCH, GADD45α and GADD45β, TGFβ 
receptor, CTP synthase, and TYMS (reviewed by (de Ruijter et al. 2003, Bolden et al. 
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2006, Zain and O'Connor 2010)). At least in part, HDACi induce cell-cycle arrest by 
causing accumulation of hyperacetylated p53, which then induces expression of p21, 
leading to inhibition of cyclins D and A, which are required for cell-cycle progression 
(reviewed by (Bolden et al. 2006, Zain and O'Connor 2010)). However, because CTCL 
tumors typically grow quite slowly in patients, it is unclear how the reported effects of 
HDACi on cell-cycle progression in rapidly growing cell lines in vitro reflect its effects 
on CTCL tumors in vivo.  
 HDACi treatment of tumor cells has been frequently linked to the modulation of 
BCL2 family expression to favor a pro-apoptotic expression pattern (reviewed by 
(Bolden et al. 2006, Zain and O'Connor 2010, Hagelkruys et al. 2011)). In many cases, 
HDACi-induced apoptosis occurs via increased expression of pro-apoptotic BCL2 family 
members BIM, BAX, PUMA, and NOXA (reviewed by (Xu 2003, Bolden et al. 2006, 
Chen et al. 2009)). Moreover, resistance to HDACi-induced apoptosis can be achieved in 
DLBCL cells lines by artificial or induced expression of anti-apoptotic protein BCL-XL 
(Thompson et al. 2013). Increased activity of BCL2, thioredoxin, and CHK1 has also 
been associated with the development of HDACi resistance in lymphoma (Lee et al. 
2012). 
 There is considerable interest in identifying markers that can predict 
responsiveness to HDACi therapy (Stimson and La Thangue 2009). Markers that have 
been reported to predict better response to HDACi treatment include high levels of 
shuttling protein HR23B (Khan et al. 2010) and several induced mRNAs, including 
cyclin D1 (Ellis and Pili 2010) for CTCL and CDKN1A (Mensah et al. 2015) for 
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DLBCL. Interestingly, it has been reported that DLBCLs with mutations in p300 or CBP 
are more responsive to HDACi treatment (Andersen et al. 2012, Mirati Therapeutics 
2014, ASCO Post 2014), suggesting that decreased HAT activity makes HDACi 
treatment more successful and that combined treatment with HATi and HDACi could be 
a useful strategy. 
  One note of caution in the use of HDACi is the finding that loss of HDAC1/2 
activity by gene KO in mouse T cells has been reported to lead to T-cell malignancy, and 
these malignant cells show increased expression of the oncoprotein MYC and aneuploidy 
(Dovey et al. 2013). 
1.10 Conclusions and perspectives 
The role of acetylation in regulating chromatin structure, gene expression, and protein 
activity will undoubtedly continue to receive much attention. Given the complex 
signaling and gene expression changes that occur in B- and T-cell development, there is 
much more to be learned about the role of regulated acetylation in these processes.  
Although the use of HATi for therapy is at an early stage, HDACi treatment is likely to 
continue for the treatment of B- and T-cell malignancies and certain immune diseases. 
Thus, a deeper understanding of the proteins, genes, and pathways affected by 
deregulated acetylation will be crucial to applying HDACi in the clinic. Given the wide 
range of transcriptional regulators affected by acetylation, there are clearly many targets 
affected by HDACi treatment and these targets no doubt vary among different cancers. 
Thus, HDACi may be most effective when combined with therapeutics that target 
specific pathways in individual cancers. The use of HDACi in combination with other 
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therapeutics is a strategy that is being used in many ongoing clinical trials (Table 1.7), 
and the ability to prescribe appropriate combined HDACi-targeted drug regimens will 
improve as better ways are developed to molecularly profile pathways that are driving 
individual cancers.  
1.11 Thesis rationale 
As discussed above, it will be important to understand the role of epigenetic modifiers in 
human lymphoma, given that modifications of TF activity and chromatin structure by 
HATs and HDACs have been shown to play an important role in the development and 
maintenance of lymphoid malignancies. For example, the roles of MYC and NF-κB in 
various lymphoid cancers have been extensively characterized (Lim et al. 2012, 
Sewastianik et al. 2014) and both proteins can be regulated by acetylation (Table 1.2). In 
the case of NF-κB, the differential dependency of distinct DLBCL molecular subtypes on 
chronically induced nuclear NF-κB activity has identified opportunities for targeted 
therapies. Currently, however, the gene expression profiles of NF-κB target genes within 
even the NF-κB-dependent ABC subtype is still relatively heterogeneous, suggesting that 
this subtype may include other minor subtypes (Alizadeh et al. 2000, Davis et al. 2001). 
  Recent genome-wide approaches have identified the HATs p300/CBP as 
frequently mutated in DLBCL (reviewed in Haery et al. 2015). p300 is a known 
transcriptional coactivator of NF-κB and MYC, but until now, the functional 
consequences of tumor-specific p300 mutations on NF-κB and MYC activity have not 
been extensively characterized. This thesis characterizes biochemical, cellular, molecular 
and biological activities of C-terminally truncated, HAT-deficient p300 mutants (p300ΔC 
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proteins) that are expressed in two human DLBCL cell lines, RC-K8 and SUDHL2 
(Figure 1.3). p300ΔC proteins interact with REL in both of these cell lines, but are weak 
coactivators for REL-dependent transactivation. Thus, the effect of p300ΔC proteins on 
NF-κB signaling is analyzed. It is shown that p300ΔC protein expression is associated 
with reduced expression of several NF-κB target genes and with increased expression of 
MYC target genes in RC-K8 cells. p300ΔC protein expression is also associated with an 
altered histone acetylation pattern in DLBCL cell lines.  
 Because attenuated NF-κB signaling has been shown to enhance oncogenicity in 
some NF-κB-dependent contexts, the ability of HAT-deficient p300ΔC proteins to 
enhance REL’s ability to transform primary chicken lymphoid cells was investigated. It is 
shown that expression of p300ΔC proteins neither independently transforms nor enhances 
the transforming ability of REL in primary chicken lymphoid cells. It is also shown that 
expression of p300ΔC is associated with large-scale alterations in gene expression in the 
DLBCL cell line RC-K8. Specifically, knockdown of p300ΔC increases an NF-κB-driven 
gene expression profile, which we propose is normally blunted by p300ΔC to ensure 
optimal growth and proliferation in RC-K8 and SUDHL2 cells. Conversely, knockdown 
of p300ΔC suggests that expression of p300ΔC in the RC-K8 cell line normally enhances 
the transcriptional output of the oncogenic transcription factor MYC by stabilizing the 
MYC protein. Overall, the research presented in this thesis suggests that HAT-
inactivating mutations in p300 represent a distinct class of oncogenic mutation, herein 
termed cancer modifiers, which cooperate with and enhance the oncogenic activity of 
known oncoproteins and driver mutations.   
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Table 1.1 Roles of HATs and HDACs in B- and T-cell Development and Function 
Molecule Role in early hematopoiesis Role in B cell Role in T cell 
HATs 
GCN5 ND 
Regulates transcription of IgM H-
chain. Activates IRF4 (Required 
for B-cell differentiation) 
ND 
PCAF ND 
HSC maintenance (via TRAPP), 
acetylates E2A (major role in B-
cell differentiation) 
Positively regulates FOXP3 
expression 
CBP HSC maintenance Development of peripheral B cells ND 
p300 HSC maintenance Development of peripheral B cells 
Regulates CCR9 expression during 
thymocyte migration. Acetylates 
FOXP3, which is required for 
survival of Tregs 
TIP60 HSC maintenance ND 
Acetylates FOXP3, and is important 
for survival of Tregs 
MOZ HSC maintenance 
Enhances HOXA9 expression, 
activates PU.1   
HBO1 ND ND 
Regulates CD4/CD8 expression 
patterns in thymocytes. Activates 
CD8 expression via global H3K14 
acetylation 
MOF 
HSC 
maintenance 
and expression 
of 
hematopoietic 
regulators 
ND ND 
HDACs 
HDAC1 
HSC 
maintenance. 
ERK1/2 
repression via 
SMAD1/5 
ND 
No effect on T-cell development, but 
leads to upregulation of HDAC2. 
Represses cytokine production (IL-
4, IL-5, IL-10) in activated T cells 
and during T effector cell 
differentiation. Negatively regulates 
FOXP3 expression. 
HDAC2 HSC maintenance ND ND 
HDAC3 
Repopulation 
of B and T 
cells and HSC 
self-renewal 
ND 
Deacetylates FOXP3, which reduces 
Treg development and suppressive 
function 
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Molecule Role in early hematopoiesis Role in B cell Role in T cell 
HDAC4 ND 
Deacetylates BCL6, activating 
genes (lymphocyte activation, 
differentiation, apoptosis) 
ND 
HDAC5  ND 
Phosphorylated by protein kinases 
D1 and D3 and exported as a result 
of BCR signaling. Deacetylates 
BCL6, which activates genes for 
lymphocyte activation, 
differentiation, and apoptosis 
ND  
HDAC7 ND 
Phosphorylated by protein kinases 
D1 and D3 and exported as a result 
of BCR signaling. Deacetylates 
BCL6, which activates genes for 
lymphocyte activation, 
differentiation, and apoptosis 
Represses Nur77 expression during 
TCR negative selection. Regulates 
gene expression during TCR 
positive selection 
HDAC9 ND ND 
Deacetylates FOXP3, which reduces 
Treg development and 
immunosuppressive activity 
HDAC6 ND ND 
Controls IgM and IgG levels upon 
antigen stimulation. T-cell 
migration. Immune synapse 
formation. Deacetylates FOXP3, 
which reduces Treg development 
and immunosuppressive activity 
HDAC11 ND ND Represses IL-10 expression in APCs 
SIRT1 ND ND 
Deacetylates FOXP3, which reduces 
Treg cell development and 
immunosuppressive activity 
 
Roles of HATs and HDACs in hematopoiesis. ND indicates that no data were reported. 	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Table 1.2. B- and T-cell Transcription Factors That Are Regulated by Acetylation 
Transcription 
Factor 
Effect of 
Acetylation Mechanism of Action References 
C/EBPβ Activation Transactivation (Cesena et al. 2008) 
E2A Activation Transactivation, protein 
stability 
(Hyndman et al. 2012, 
Holmlund et al. 2013) 
E47 Activation Transactivation (Hyndman et al. 2012) 
FOXP3 Activation DNA binding, protein stability (van Loosdregt and Coffer 
2014) 
GATA-2 Activation DNA binding (Hayakawa et al. 2004) 
GATA-3 Activation Transactivation (Yamagata et al. 2000) 
IRF2 Activation Transactivation (Masumi et al. 2003) 
JUN Activation Protein-protein interaction (Vries et al. 2001) 
MYB Activation Transactivation (Sano and Ishii 2001) 
MYC Activation Protein stability (Vervoorts et al. 2006) 
NFATc1 Activation DNA binding (Meissner et al. 2011) 
NOTCH1 Activation Protein stability (Guarani et al. 2011) 
NOTCH3 Activation Protein stability (Palermo et al. 2012) 
p53 Activation Protein stability (Feng et al. 2005) 
PAX5 Activation Transactivation (He et al. 2011) 
PU.1 Activation Transactivation (Bai et al. 2005) 
RUNX1 Activation DNA binding/transactivation (Goyama et al. 2014) 
RUNX2 Activation Protein stability (Park et al. 2010) 
RUNX3 Activation Protein stability (Bae and Lee 2006) 
SMAD3 Activation Transactivation (Inoue et al. 2007) 
SP3 Activation Transactivation (Waby et al. 2008) 
STAT3 Activation DNA binding, transactivation; 
protein-protein interactions 
(Zhuang 2013) 
STAT5 Activation Dimerization, transactivation (Kosan et al. 2013) 
TCF4 Activation Protein-protein interaction (Elfert et al. 2013) 
YY1 Activation DNA binding (Yao et al. 2001) 
NF-κB Activation 
 
Inhibition 
DNA binding, IκB binding, 
transactivation 
DNA binding; IκB binding, 
nuclear export 
(Ghizzoni et al. 2011) 
BCL6 Inhibition HDAC recruitment interference (Bereshchenko et al. 2002) 
CIITA Inhibition Protein degradation (Wu et al. 2011) 
ETS-1 Inhibition DNA binding (Dong 2013) 
HIF-1α           Inhibition Protein degradation (Keith et al. 2012) 
Lymphoid transcription factors and the effect of acetylation on protein function.  
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Table 1.3 HAT Gene Mutations in B- and T-cell Malignancies 
HAT 
Percent of B- and T- 
cell lines with HAT 
gene mutations from 
CCLE (Barretina et al. 
2012) 
Percent of HAT gene mutations in 
leukemia/lymphoma from select genome-wide studies 
ATF2 0.6   
CBP 13.3 DLBCL, 19% (443) (Morin et al. 2011, Pasqualucci et al. 2011, 
Pasqualucci et al. 2011, Lohr et al. 2012, Morin et al. 2013, 
Pasqualucci et al. 2014)  
FL, 50% (52) (Morin et al. 2011, Pasqualucci et al. 2014),  
Relapsed ALL, 18% (71) (Mullighan et al. 2011) 
p300 10.5 DLBCL, 11% (546) (Cerchietti et al. 2010, Morin et al. 2011, 
Pasqualucci et al. 2011, Pasqualucci et al. 2011, Lohr et al. 
2012, Pasqualucci et al. 2014)  
FL, 19% (52) (Morin et al. 2011, Pasqualucci et al. 2014) 
TIP60 0 DLBCL, 2% (49) (Lohr et al. 2012) 
MOZ 7.7 DLBCL, 4% (53) (Morin et al. 2013) 
MORF 27.6   
HBO1 0.6   
NCOA1 2.2   
NCOA2 3.9 DLBCL, 2% (53) (Morin et al. 2013) 
NCOA3 39.8 DLBCL, 4% (53) (Morin et al. 2013) 
CLOCK 0 DLBCL, 2% (102) (Lohr et al. 2012, Morin et al. 2013) 
TAF1 3.3 FL, 10% (39) (Pasqualucci et al. 2014)  
DLBCL, 5% (102) (Lohr et al. 2012, Morin et al. 2013) 
 
Percentage of cell lines mutated in CCLE (Cancer Cell Line Encyclopedia) indicates the 
percentage of 181 hematopoietic and lymphoid cell lines that had a mutation in the 
indicated HAT gene. DLBCL and FL genomic studies indicate the percentage of cases 
reported to have mutations in the indicated HAT genes in either DLBCL (diffuse large B-
cell lymphoma) or FL (follicular lymphoma) patient samples and/or cell lines, with the 
total number of samples analyzed shown in parentheses. 
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Table 1.4 Misregulated Expression of HDACs in B- and T-cell Malignancies 
HDAC Disease Expression Referencess 
1 T-ALL Increased (Moreno et al. 2010) 
 B-ALL Increased (Van Damme et al. 2012) 
 ALL Increased (Gruhn et al. 2013) 
 HL Increased (Adams et al. 2010) 
 DLBCL Increased (Marquard et al. 2009) 
 CLL Increased (Wang et al. 2011) 
2 ALL Increased (Moreno et al. 2010, Gruhn et al. 2013) 
 B-ALL Reduced (Van Damme et al. 2012) 
 HL Increased (Adams et al. 2010) 
 DLBCL Increased (Marquard et al. 2009) 
3 ALL Increased (Moreno et al. 2010) 
 CLL Increased (Wang et al. 2011) 
 DLBCL Increased (Gupta et al. 2012) 
 HL Increased (Adams et al. 2010) 
4 T-ALL Increased (Moreno et al. 2010) 
5 B-ALL Increased (Moreno et al. 2010) 
6 ALL Increased (Moreno et al. 2010) 
 B-ALL Increased (Van Damme et al. 2012) 
 CLL Increased (Wang et al. 2011) 
 DLBCL Increased (Marquard et al. 2009) 
7 ALL Increased (Moreno et al. 2010) 
 B-ALL Increased (Van Damme et al. 2012) 
 CLL Increased (Wang et al. 2011) 
8 ALL Increased (Moreno et al. 2010, Gruhn et al. 2013) 
9 CLL Increased (Wang et al. 2011) 
10 CLL Increased (Wang et al. 2011) 
11 B-ALL Reduced (Van Damme et al. 2012) 
 B-ALL Increased (Van Damme et al. 2012) 
SIRT1 CLL Increased (Wang et al. 2011) 
SIRT3 B-ALL Increased (Van Damme et al. 2012) 
SIRT4 B-ALL Decreased (Van Damme et al. 2012) 
SIRT5 B-ALL Decreased (Van Damme et al. 2012) 
SIRT6 B-ALL Increased (Van Damme et al. 2012) 
 CLL Increased (Wang et al. 2011) 
SIRT11 B-ALL Increased (Van Damme et al. 2012) 
 
ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse 
large B-cell lymphoma; HL, Hodgkin’s lymphoma. 
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Table 1.5 HDACi Compounds That Induce Apoptosis in B- and T-cell Cancer Cells2 
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Cell types: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, 
acute promyelocytic leukemia; BL, Burkitt’s lymphoma; CLL, chronic lymphocytic 
leukemia; CML, chronic myelogenous leukemia; CTCL, cutaneous T-cell lymphoma; 
DLBCL, diffuse large B-cell lymphoma; EBV+ BL, Epstein-Barr virus-positive BL; HL, 
Hodgkin’s lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; NHL, non-
Hodgkin’s lymphoma; PTCL, peripheral T-cell lymphoma; SLL, small lymphocytic 
lymphoma. 
Drug type: 17-AAG (Hsp90 inhibitor); ABT-737 (BH3-mimetic); ATRA (all-trans 
retinoic acid); azacitidine (DNA methyltransferase inhibitor); bexarotene (antineoplastic 
agent); bortezomib (proteasome inhibitor); cambinol (sirtuin inhibitor); carboplatin 
(antineoplastic agent); carfilzomib (proteasome inhibitor); cisplatin (alkylating agent); 
cladribine (adenosine deaminase inhibitor); cyclophosphamide (alkylating agent); 
cytarabine (DNA synthesis inhibitor); decitabine (DNA methyltransferase inhibitor); 
dexamethasone (glucocorticoid steroid); docetaxel (anti-mitotic agent); eltrombopag 
(thrombopoeitin receptor agonist); enzastaurin (PKCβ inhibitor); etoposide 
(topoisomerase inhibitor); everolimus (mTOR inhibitor); EX527 (sirtuin inhibitor); 
gemcitabine (nucleoside analog); GX15-070 (BH3-mimetic); idarubicin (topoisomerase 
II inhibitor); imatinib (tyrosine kinase inhibitor); ifosfamide (alkylating agent); 
isotretinoin (retinoic acid analog); lenalidomide (tumor necrosis factor [TNF] inhibitor); 
melphalan (alkylating agent); NPI-0052 (proteasome inhibitor); pazopanib (tyrosine 
kinase inhibitor); pemetrexed (folate antimetabolites); pioglitazone (thiazolidinedione); 
prednisone (glucocorticoid prodrug); rituximab (anti-CD20 antibody); sargramostin 
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(recombinant GM-CSF); sirtinol (sirtuin inhibitor); sorafenib (tyrosine kinase inhibitor); 
temozolomide (alkylating agent); TRAIL (TNF-related apoptosis-inducing ligand); 
vincristine (mitotic inhibitor).  
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Table 1.6 Summary of Published Clinical Trials of FDA-approved HDACi in 
Lymphoma, Leukemia, and Myeloma 3 
Trial 
phase 
Combination 
drug Cancer type 
No. of 
patients CR PR SD 
% 
Response References 
HDACi: Vorinostat 
I  
DLBCL, HL, MM, T-cell 
lymphoma, MCL, SLL, 
ML 
35 1 4 3 23 (O'Connor et al. 2006) 
I  
FL, MCL, DLBCL, 
CTCL 10 3 1 3 70 (Watanabe et al. 2010) 
I Idarubicin Relapsed or refractory leukemia 41 3 10  32 (Kadia et al. 2010) 
I  Advanced MM 13  1 9 77 (Richardson et al. 2008) 
I Bortezomib Relapsed or refractory MM 21  9  43 (Badros et al. 2009) 
I  
Advanced leukemias, 
myelodysplastic 
syndromes (MDS) 
41 4 3  17 
(Garcia-Manero et al. 
2008) 
I  Advanced CTCL 74  22  30 (Mann et al. 2007) 
I  
HL, NHL, DLBCL, SLL, 
MCL, CTCL, PTCL, 
Myeloma, AML, MDS 
23 1 1 4 26 (Kelly et al. 2005) 
II Idarubicin, Cytarabine AML, MDS 75 57 7  85 
(Garcia-Manero et al. 
2012) 
II Gemtuzumab ozogamicin AML 31 6 1  23 (Walter et al. 2012) 
II  
Relapsed or refractory 
HD 25  1 7 32 
(Kirschbaum et al. 
2012) 
II  
NHL, MCL, relapsed or 
refractory FL, MZL 35 5 5 1 31 
(Kirschbaum et al. 
2011) 
II  Refractory CTCL 33  8 1 27 (Duvic et al. 2007) 
IIb  Advanced CTCL 6  5 1 100 (Duvic et al. 2009) 
IIb  Refractory CTCL 74  22  30 (Olsen et al. 2007) 
 Bortezomib 
Relapsed or refractory 
MM 6  5 1 100 (Mazumder et al. 2010) 
    TOTAL 543 80 105 30    
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Trial 
phase 
Combination 
drug Cancer type 
No. of 
patients CR PR SD 
% 
Response References 
HDACi: Romidepsin 
I  CTCL 4 1 3  100 (Piekarz et al. 2001) 
II  PTCL 130 33 14 33 62 (Coiffier et al. 2012) 
II 
Low-dose 
beam 
radiation 
CTCL 5  4  80 (Akilov et al. 2012) 
II  PTCL 45 8 9 5 49 (Piekarz et al. 2011) 
II  Refractory CTCL 96 6 27 45 81 (Whittaker et al. 2010) 
II  CTCL 71 4 20 26 70 (Piekarz et al. 2009) 
  TOTAL 351 52 77 109   
HDACi: Panobinostat 
I  CTCL 10 2 4 1  (Ellis et al. 2008) 
I 
Ifosfamide, 
Carboplatin, 
Etoposide 
Relapsed or 
refractory cHL 21    86 (Oki et al. 2014) 
I Everolimus Relapsed or refractory lymphoma 30 3 7  33 (Oki et al. 2013) 
Ib Bortezomib Relapsed or refractory MM 62 2 34  61 (San-Miguel et al. 2013) 
Ia/II  Refractory HL 13  13   (Dickinson et al. 2009) 
I/II Melphalan Relapsed or refractory MM 40  3 23  (Berenson et al. 2014) 
II  Relapsed or refractory MM 38  2 9 5 (Wolf et al. 2012) 
II Bortezomib, Dexamethasone 
Relapsed or 
refractory myeloma 55 1 28 8 35 (Richardson et al. 2013) 
II  Refractory CTCL 139 2 22 29 17 (Duvic et al. 2013) 
II  Relapsed or refractory HL 129 5 30 71 27 (Younes et al. 2012) 
II 
Melphalan, 
Thalidomide, 
Prednisone 
Relapsed or 
refractory MM 31 2 10 11 39 (Offidani et al. 2012) 
III Bortezomib, Dexamethasone 
Relapsed or 
refractory MM 387 42 216 65 67 (San-Miguel et al. 2014) 
  TOTAL 955 59 369 217   
HDACi: Belinostat 
I  NHL, HL, MM, CLL 16   5  (Gimsing et al. 2008) 
II  Relapsed or refractory CTCL 29 3 1 10 4 (Foss et al. 2015) 
II  Recurrent PTCL 24 2 4 4 6 (Foss et al. 2015) 
III  Relapsed or refractory CTCL 120 11 15  26 (Lee et al. 2015) 
  TOTAL 189 16 20 19   
3Adapted from (Thompson 2013) 
CR, complete response; PR, partial response; SD, stable disease.  
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Table 1.7 Ongoing Clinical Trials using HDACi for Treatment of Lymphoma, 
Leukemia, and Myeloma 
Trial title HDACi Combination target Phase 
WEE1 Inhibitor MK-1775 and Belinostat in Treating 
Patients With Relapsed or Refractory Myeloid 
Malignancies or Untreated Acute Myeloid Leukemia 
Belinostat WEE1 I 
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in 
Patients W/Relapsed Aggressive B-Cell NHL Belinostat Radiotherapy II 
Panobinostat and Everolimus in Treating Patients With 
Recurrent Multiple Myeloma, Non-Hodgkin 
Lymphoma, or Hodgkin Lymphoma 
Panobinostat mTOR I, II 
Panobinostat in Treating Patients With Relapsed or 
Refractory Non-Hodgkin Lymphoma Panobinostat 
 
II 
Romidepsin in Treating Patients With Lymphoma, 
Chronic Lymphocytic Leukemia, or Solid Tumors With 
Liver Dysfunction 
Romidepsin 
 
I 
Alisertib and Romidepsin in Treating Patients With 
Relapsed or Refractory B-Cell or T-Cell Lymphomas Romidepsin Aurora Kinase I 
Rituximab, Romidepsin, and Lenalidomide in Treating 
Patients With Recurrent or Refractory B-cell Non-
Hodgkin Lymphoma 
Romidepsin 
CD20, immuno-
modulation, 
proliferation, 
angiogenesis 
I, II 
Romidepsin and Lenalidomide in Treating Patients 
With Previously Untreated Peripheral T-Cell 
Lymphoma 
Romidepsin 
Immuno-
modulation, 
proliferation, 
angiogenesis 
II 
Alisertib in Combination With Vorinostat in Treating 
Patients With Relapsed or Recurrent Hodgkin 
Lymphoma, B-Cell Non-Hodgkin Lymphoma, or 
Peripheral T-Cell Lymphoma 
Vorinostat Aurora Kinase I 
Vorinostat and Combination Chemotherapy With 
Rituximab in Treating Patients With HIV-Related 
Diffuse Large B-Cell Non-Hodgkin Lymphoma or 
Other Aggressive B-Cell Lymphomas 
Vorinostat CD20 I, II 
Bortezomib and Vorinostat as Maintenance Therapy 
After Autologous Stem Cell Transplant in Treating 
Patients With Non-Hodgkin Lymphoma 
Vorinostat Proteasome II 
Cytarabine and Daunorubicin Hydrochloride or 
Idarubicin and Cytarabine With or Without Vorinostat 
in Treating Younger Patients With Previously 
Untreated Acute Myeloid Leukemia 
Vorinostat DNA synthesis, Topoisomerase II III 
Summary of ongoing clinical trials using HDACi taken from the National Cancer 
Institute at the National Institute of Health (www.cancer.gov/clinicaltrials). HDACi lists 
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the specific HDACi being tested and combination target describes the target of the other 
(non-HDACi) drug used in the study.  
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Figure 1.1 The general structures of human HATs and HDACs 
Schematic representations are drawn approximately to scale. The catalytically active 
domains and other conserved domains are shown: acetyltransferase domain (KAT), 
bromodomain (Br), cysteine/histidine domain (CH), kinase-inducible domain interacting 
(KIX) domain, PH-D finger (PHD), helix-loop-helix domain (HLH), LXXLL motif (LX), 
PAS domain (PAS). All human HATs are listed with gene alias in parentheses. The size 
of each HAT is shown as number of amino acids. The structure of a representative HAT 
(indicated by asterisk) is shown for each family. All HDACs are listed with their 
predominant subcellular localizations; those that shuttle between the nucleus and 
cytoplasm are indicated by nuc/cyt. The approximate positions of the catalytic domains 
are indicated by green boxes for both the HATs and the HDACs. 
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Figure 1.2 CBP/p300 mutations reported in CCLE in B- and T-cell cancer cell lines 
Schematic diagram of the CBP/p300 proteins with conserved domains indicated in the 
shaded regions as follows: cysteine/histidine domain (CH), KIX domain, bromodomain 
(Br), acetyltransferase domain (KAT). Symbol shapes designate types of mutations as 
follows: missense (circle); nonsense (triangle); and frameshift, splice site, or deletion 
(square). Symbol color indicates the disease type: DLBCL (red); Hodgkin’s lymphoma 
(blue); T-cell leukemia (acute lymphoblastic or anaplastic large cell) (green); plasma cell 
myeloma (yellow); acute lymphoblastic B-cell leukemia (purple); B-cell lymphoma 
unspecified (black); and Burkitt’s lymphoma (white). CBP mutations are (in order, left to 
right) Q170*, M395T, L470fs, A620V, Q790*, P901L, P928A, P975L, S1108L, K1203 
splice, E1238*, T1332I, R1360*, S1432P, D1435E, F1440L, R1446L, Q1491K, 
S1680del, and S1687 p300 mutations are Q160*, M165I, V279I, S281T, L415P, M514V, 
R728W, E1011*, E1160V, A1268V, R1391 splice, H1415P, G1506V, L1520V, K1546fs, 
R1627W, S1650F, R1773W, Q1904P, A2259T, P2358L, P2367L.* indicates a nonsense 
(stop codon) mutation at that position. 
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Figure 1.3 Structures of wild-type and truncated p300 proteins 
Schematic representations of wild-type p300 protein and two C-terminally truncated p300 
proteins expressed in DLBCL cell lines. The catalytically active domains and other 
conserved domains are shown: acetyltransferase domain (KAT), bromodomain (Br), 
cysteine/histidine domain (CH), kinase-inducible domain interacting (KIX) domain, PH-
D finger (PHD), helix-loop-helix domain (HLH), LXXLL motif (LX), PAS domain 
(PAS). The number of amino acids (aa) in each protein is indicated to the right of each 
structure. The name of each p300 mutant (p300ΔC-1087 and -820) indicates a C-terminal 
truncation (ΔC) after the last p300 aa in each protein. The DLBCL cell line in which the 
mutant was identified is listed below each mutant. The details of each C-terminal 
truncation are written to the right of the structures. The 25 non-p300 aa at the C terminus 
of p300ΔC-1087 are encoded by sequences that are normally found on chromosome 6 
and these non-p300 aa are indicated in gray. Structures are drawn to scale. Both C-
terminal truncation mutants lack the corresponding functional domains of the wild-type 
p300 protein (top). 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Recombinant DNA techniques 
DNA manipulations were generally performed as previously described (Sambrook et al, 
1989). For most plasmid restriction digestions, approximately 1 µg of plasmid DNA was 
digested in 1X reaction buffer for 1 h with 1 µl of the appropriate restriction 
endonuclease (New England Biolabs [NEB], Ipswitch, MA). For subclonings, digested 
vector DNA was incubated with 0.1 µg/µl calf intestinal phosphatase (NEB) for 45 min at 
37°C to prevent re-ligation of the vector plasmid.  
2.2 Preparation of bacterial competent cells 
Preparation of Escherichia coli (E. coli) strain DH5α for the propagation of plasmid 
DNA was described previously (Thompson 2013). 
2.3 Plasmid construction 
The constructions and sources of plasmids used in this study are described in Table 2.1. 
Plasmids obtained from other institutions are indicated. 
2.4 DNA ligation and transformation 
DNA was isolated using gel electrophoresis in 1% low-melt agarose (FMC Bioproducts, 
Rockland, ME). Ligations were performed with in-gel fragments or with DNA fragments 
extracted from agarose gel using the UltraClean 15 DNA Purification kit (MO BIO 
Laboratories, Carlsbad, CA). Ligation reactions were performed using an insert:vector 
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DNA ratio of approximately 10:1 in T4 ligase buffer (50 mM Tris-HCl [pH 8.0], 10 mM 
MgCl2, 10 mM dithiothreitol [DTT], 1 mM ATP, 25 mg/ml bovine serum albumin 
[BSA]), supplemented with 1 mM ATP and 400 units of T4 DNA ligase (NEB) in a total 
volume of 40 µl. The ligation reaction was incubated overnight at 18°C before being used 
to transform competent DH5α E. coli cells. 
 Transformations using ligation productions were performed by first heating the 
ligation reaction to 72°C for 10 min to melt any solidified agarose and then incubating 
the ligation reaction at 42°C to prevent re-solidification of the agarose while the 
transformation reaction was assembled. This melting step was omitted for 
transformations performed using plasmid DNA that was not contained in agarose. The 
entire ligation reaction or a portion of plasmid DNA was then mixed with 60 µl 
competent DH5α E. coli cells and 170 µl TCM buffer (10 mM Tris [pH 7.5], 10 mM 
CaCl2, 10 mM MgCl2. 
2.5 Small-scale plasmid preparations 
Small-scale preparations of plasmid DNA were performed using the TENS method (Zhou 
et al., 1990), and have been described previously (Thompson 2013).  
2.6 Large-scale plasmid preparations using the cesium chloride gradient/ultra-
centrifugation method 
Large-scale plasmid DNA preparations were performed by cesium chloride gradient 
centrifugation by standard methods, as described previously (Thompson 2013). 
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2.7 PCR and PCR-based site-directed mutagenesis 
To perform site directed mutagenesis, a primer containing a point mutation was used to 
amplify the gene. 
 PCRs contained 10 – 50 ng of template DNA, 1.25 µM forward primer, 1.25 µM 
reverse primer, 0.2 µM dNTPs and 2 units Vent polymerase (NEB) in 50 µl 1x 
Thermopol buffer (NEB). The PCR was then subjected to the following cycling 
conditions: 94°C for 5 min, 25 cycles of 94°C denaturation (30 sec), 50-65°C annealing 
(optimized for each primer pair, 30 sec), and 72°C extension (1 min / 800 bp product 
sequence), followed by a single final elongation step of 72°C for 10 min.  
 PCR products were then purified by phenol/chloroform extraction followed by 
ethanol precipitation, restriction enzyme digestion, and subcloning into the appropriate 
vector. 
2.8 Isolation of genomic DNA 
Approximately 108 cells were pelleted by centrifugation and rinsed twice with 10 ml PBS 
before being resuspended in 1 ml digestion buffer (100 mM NaCl, 10 mM Tris-HCl [pH 
8.0], 25 mM EDTA, 0.5% SDS, 0.1 mg/ml proteinase K). Samples were then incubated 
overnight at 55°C with shaking, and purified by two extractions in equal volumes of 
phenol followed by a single extraction in an equal volume of chloroform. The DNA was 
then precipitated from the sample by addition of a half volume of 7.5 M ammonium 
acetate and two volumes of 100% ethanol followed by incubation at -20°C for 20 min. 
Precipitated DNA was collected by centrifugation at 4°C for 15 min and pelleted DNA 
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was then washed with 70% ethanol and air dried at room temperature. Dried pellets were 
resuspended in TE buffer to a final DNA concentration of 1 mg/ml. 
2.9 PCR-based sequencing of SUDHL2 genomic DNA 
Two hundred ng of genomic DNA from SUDHL2 cells was subjected to PCR using 
forward and reverse primers specific for sequences surrounding exon 14 of EP300. The 
primers used were 5’- agcataggcaggccctaga and 5’- tatgcttgggggagtatggt. Sequencing of 
the amplified fragment was performed by Eurofins MWG Operon (Huntsville, AL). 
2.10 Cell culture 
The mammalian cell lines and corresponding culture media used in this study are listed in 
Table 2.3. 
 Cell lines were maintained in either Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen) or RPMI medium (Life Technologies, Grand Island, NY) 
supplemented with 10 – 20% fetal bovine serum (FBS; Biologos, Montgomery, IL) as 
indicated in Table 2.3. Culture medium was supplemented with 50 units/ml of penicillin 
and 50 µg/ml of streptomycin. Cells in culture were maintained in a cell culture incubator 
at 37°C and 5% CO2. 
 Cell lines were passaged by standard methods described previously (Thompson 
2013). 
2.11 Freezing and thawing cells 
Cells were frozen and thawed using standard methods described previously (Thompson 
2013). 
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2.12 Polyethylenimine-based cell transfection 
Transfections of 293, 293T, Bosc23, or COS1 cells for reporter assays, virus generation, 
or overexpression studies were performed using polyethylenimine (PEI) (Polysciences 
Inc., Warrington, PA). The day before transfection, cells targeted for transfection were 
seeded in a 60-mm dish at a density such that they were 40-60% confluent on the day of 
transfection. DNA was incubated with PEI at a ratio of 1:3 or 1:6 in 300 ul DMEM for 15 
min at room temperature. Following incubation, 4.7 ml of pre-warmed DMEM/10% FBS 
was added to the DNA:PEI mixture and the entire 5 ml sample was then used to replace 
the culture media of the target cells. After incubation for 24 h, the medium was replaced 
with 5 ml DMEM/10% FBS and cells were incubated for an additional 48 h before being 
harvested for the appropriate assay. 
2.13 Luciferase reporter assay 
Luciferase reporter assays were performed using the Luciferase Assay System (Promega, 
Madison, WI) as described previously (Garbati 2010). 293 cells in 35-mm plates were 
transfected with 0.5 µg of reporter plasmid pGL2-3x-κB-luciferase and 0.5 µg of 
normalization plasmid pRSV-βgal. Cells were co-transfected with 0.5 µg of pcDNA-REL 
or pcDNA3.1 vector alone, along with 0.5 µg of pCMVβ-p300, pCMVβ-p300ΔC, or 
vector alone. In titration experiments, cells were transfected with 0.5 µg of pcDNA-REL, 
and increasing amounts of pCMVβ-p300, pCMVβ-p300ΔC-1087, or pCMVβ-p300ΔC-
820. For all luciferase reporter assay experiments, total DNA per transfection was kept 
constant by including varying amounts of pcDNA3.1 vector. Luciferase and β-
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galactosidase activities were determined, and values were normalized to the relevant 
vector control (1.0). 
 Statistical analyses were performed using a paired one-tailed t-test and p < 0.05 
was considered significant. 
2.14 Retroviral stock preparation and target cell infection 
Virus stocks were prepared and used for infection as described previously (Thompson 
2013). For generation of virus stocks directing target gene expression using pMSCV-
based plasmids, 293T or Bosc23 cells were transfected in 60-mm dishes with 10 ug 
retroviral expression plasmid and 10 ug of the retroviral packaging plasmid (pCL10A1) 
using the PEI method. Twenty-four and 48 h after fluid changing the transfected cells, the 
virus-containing media was harvested and replaced with DMEM with 10% FBS, and any 
cells remaining in the harvested media were removed by centrifugation for 5 min at 1,000 
rpm. Virus-containing media was then used to immediately infect target cells. 
 One million target cells were infected in a 14-ml round bottom tube by mixing the 
cells with 2 ml of harvested virus and 8 µg/ml polybrene and then centrifuging the 
sample at 2,000 rpm for 2 h at room temperature. The virus and polybrene-containing 
media was then removed and the target cells were resuspended in 2 ml of the appropriate 
cell culture media for the given cell line and cells were incubated in a tissue culture 
incubator under standard conditions. Forty-eight h after infection, retrovirally transduced 
cells were selected by the addition of puromycin at a final concentration of 1 µg/ml, 
which was maintained in the media for approximately two weeks with regular fluid 
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changes. Retroviral vector-induced changes in protein expression were then determined 
by Western blotting. 
2.15 Proliferation assay 
One hundred thousand SUDHL2 cells, retrovirally transduced to express p300 shRNA or 
control shRNA, were plated in 16-mm wells in 0.5 ml RPMI containing 10% FBS. On 
each of 5 days after plating, cells from three wells of each cell type were counted using a 
hemocytometer. 
2.16 Soft agar colony formation assay 
Soft agar colony formation assays were performed as described previously (Garbati et al. 
2011). Equal numbers (2000 and 5000) of SUDHL2 cells expressing the indicated 
shRNA were placed in soft agar containing RPMI with 20% FBS and 0.3% Bacto Agar 
(Difco, Franklin Lakes, NJ), and plates were incubated at 37°C in a humid incubator with 
5% CO2. Macroscopic colonies were counted 14 days after plating. 
2.17 Chicken spleen cell transformation assay 
The transformation of primary chicken spleen cells was analyzed by the liquid outgrowth 
assay as described previously (Starczynowski et al. 2003, Gilmore and Gélinas 2015). 
Briefly, spleens were removed from 19 day-old virus-free chickens (Charles River 
Spafas, North Franklin, CT) and were used to prepare single-cell suspensions. Cells were 
electroporated with 20 µg of defective gene-expression virus plasmid and 10 µg of 
replication-competent Rev-A virus plasmid (pSW253). Cells were maintained at 40.5 ºC 
and 5% CO2 in DMEM containing 20% FBS, with fluid changing every 4-5 days for 
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approximately 30 days. Cultures were scored as transformed when the media became 
obviously acidified (i.e., turned yellow).  
2.18 Whole cell extract preparation 
Whole cell extracts were prepared under non-denaturing conditions using mechanical 
lysis in AT buffer (20 mM HEPES (pH 7.0), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
20% v/v glycerol, 1% v/v Triton X-100, 20 mM NaF, 1 mM Na4P2O7-10H2O, 1 mM 
DTT, 1 mM Na3VO4, 10 µl/ml aprotinin,1 mM phenylmethylsulfolnyl fluoride (PMSF), 
1 µg/ml pepstatin A, 1 µg/ml leupeptin). Cells in culture were collected by trypsin-
mediated cleavage or scraping and washed twice with 10 ml PBS before being transferred 
to a 1.5 ml microcentrifuge tube. Approximately 100 µl ice-cold AT buffer was added for 
every 2 mil cells in the cell pellet and the cells were resuspended. The cell solution was 
homogenized by passage through a 27.5-gauge needle at least 5 times. NaCl was then 
added to each sample to a final concentration of 150 mM and debris was cleared by 
centrifugation in a microcentrifuge for 30 min at top speed and 4°C. The supernatant was 
collected and samples were maintained on ice during use or were stored at -80°C. 
2.19 Protein concentration determination 
Protein concentration of cell extracts was determined using the Bio-Rad Protein Assay 
Dye Reagent (Bio-Rad). The dye was diluted to a concentration of 1x with water and 190 
µl was added to each of several wells in a 96-well microplate with a transparent bottom. 
A solution of 1 mg/ml BSA was used to generate a standard curve containing 0-10 µg 
BSA and approximately 0.5-5 µl of each sample was diluted into the dye reagent such 
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that the intensity of the sample-containing dye was within the range of the standard 
curve. The absorbance of each sample at 595 nm was determined using a Bio-Rad Model 
550 Microplate Reader (Bio-Rad) and the protein concentrations of the samples were 
extrapolated using the absorbance readings of the BSA-generated standard curve. 
2.20 GST-tagged protein purification and pulldown assay 
GST pulldown assays followed by Western blotting were performed as described 
previously (Garbati 2010). Briefly, DH5α E. coli cells were transformed with pGEX-KG 
bacterial expression vectors. A single colony was used to inoculate 5 ml LB 
supplemented with 100 µg/ml Amp and the culture was grown at 37°C overnight. The 5 
ml culture was used to inoculate 50 ml LB supplemented with 100 µg/ml Amp, which 
was then incubated for 1 h at 37°C. After 1 h, IPTG was added to a final concentration of 
0.1 mM to induce pGEX-directed protein expression and the culture was incubated for an 
additional 2-3 h at 37°C. The bacteria were then collected by centrifugation in an HB-4 
rotor of a Sorvall RC-5 centrifuge for 10 min at 5,000 rpm and 4°C. The cells were then 
washed twice with 10 ml PBS and then resuspended in 2 ml ice-cold PBS containing 
protease inhibitors (1% aprotinin, 2 µg/ml leupeptin, and 1 mM PMSF) and transferred to 
a 15 ml conical tube stored on ice. Samples were incubated in an ice bath and lysed with 
a probe sonicator (Sonic Dismembrator 550, Fisher Scientific Inc., Pittsburgh, PA) at 
level 3.5 intensity and 4 cycles of 30 sec sonication followed by 2 min rest. Samples were 
then transferred to microcentrifuge tubes and supplemented with approximately 200 µl 
10% Triton-X 100 to a final concentration of 1% followed by a 10 min incubation on ice. 
Debris was then collected by centrifugation in a Hermle Z180M microcentrifuge for 15 
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min at 13,000 rpm and 4°C. The supernatant was then collected and combined with 50 µl 
of a 50% slurry of glutathione agarose beads and the samples were incubated on a nutator 
overnight at 4°C. The next day, the beads were washed 5 times with 1 ml cold PBS. After 
rinsing, 5% of the beads were saved for quantitation of the amount of protein used in the 
pull-down assay on a Coomassie blue-stained SDS-polyacrylamide gel. 
  To continue with a pull-down assay, 300 µg of cell extract containing the target 
protein for pulldown was added to the remaining 95% of the beads. The samples were 
then brought to a total volume of 1 ml using PBS, which was supplemented with protease 
inhibitors. The samples were then incubated on the nutator at 4°C for 3 h, after which the 
beads were pelleted by gentle centrifugation at 1,000 rpm for 1 min at 4°C. Four percent 
(40 µl) of the supernatant was saved to analyze the unbound fraction of protein that was 
not pulled down by the beads, and the remaining supernatant was discarded. The beads 
were then washed four times with 1 ml cold PBS. To elute the bound proteins, 20-40 µl 
of 2X SDS sample buffer was added to the rinsed and collected beads, the samples were 
vortexed briefly, and proteins were eluted by boiling for 10 min. One percent of the 
amount of cell extract used for each pull-down (30 µg) was included on the gel as an 
input lane. The membrane was then subjected to anti-p300 or anti-REL Western blotting. 
2.21 Protein co-immunoprecipitation (Co-IP) 
For co-immunoprecipitation of overexpressed proteins, 293 cells in 100-mm dishes were 
co-transfected with 10 µg pcDNA-Flag-REL and 10 µg pCMVβ-p300ΔC-820. Two days 
later, nuclear extracts were prepared using a Nuclear Complex Co-IP Kit (Active Motif, 
Carlsbad, CA) according to the manufacturer’s instructions. Nuclear extracts containing 
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300 µg of protein were incubated with anti-p300 antiserum or rabbit pre-immune serum 
for 3 h at 4°C. 100 µl of a 50% slurry of Protein A Sepharose CL-4B (GE Healthcare Life 
Sciences, Pittsburgh, PA) was added and the sample was incubated for an additional 1 h 
at 4°C. The beads were then washed in PBS and proteins were eluted by heating at 95°C 
in SDS sample buffer. Proteins were electrophoresed on a 7.5% SDS-polyacrylamide gel 
and transferred to a nitrocellulose membrane as described above. One percent of the 
amount of nuclear extract used for one immunoprecipitation (3 µg) was included on the 
gel as an input lane. The membranes were then subjected to anti-REL Western blotting.  
 Co-immunoprecipitation of endogenous REL and p300ΔC-820 in SUDHL2 cells 
was performed using the Nuclear Complex Co-IP Kit as described by the manufacturer 
(cat. no. 54001, Active Motif). Three micrograms of normal rabbit IgG (sc-2027, Santa 
Cruz Biotechnology) or anti-p300 antiserum (sc-584, Santa Cruz Biotechnology) was 
incubated with 250 µg of nuclear extract in IP Low Buffer (Active Motif) for 3 h at 4°C. 
50 µl of a 50% slurry of Protein A Sepharose CL-4B (GE Healthcare Life Sciences) was 
added, and samples were incubated with rocking for an additional 3 h. Beads were then 
washed with IP Low Buffer and proteins were eluted by heating at 95°C in SDS sample 
buffer. Proteins were electrophoresed on a 6% SDS-polyacrylamide gel and transferred to 
a nitrocellulose membrane as described above. Ten percent of the amount of nuclear 
extract used for one immunoprecipitation (25 µg) was included on the gel as an input 
lane. The membranes were then subjected to anti-REL or anti-p300 Western blotting. 
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2.22 SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate proteins 
under denaturing conditions, and was performed using standard methods previously 
described (Garbati 2010, Thompson 2013). 
2.23 Western blotting 
Western blotting was performed to detect the relative expression level of proteins using 
antibodies directed against such proteins. Proteins were separated by SDS-PAGE as 
described above. Proteins contained in the gel were then transferred to a nitrocellulose 
membrane (Osmonics, Westborough, MA) using a wet transfer apparatus. For the 
efficient transfer of proteins less than 200 kDa in size, the transfer was performed in a 
standard transfer buffer (20 mM Tris, 150 mM glycine, 20% methanol). For the efficient 
transfer of proteins greater than 200 kDa in size, a modified transfer buffer (20 mM Tris, 
150 mM glycine, 10% methanol, 0.05% w/v SDS) was used (Garbati 2010). Transfers 
were performed at 4°C and 260 mA for 2.5 h followed by 100 mA overnight, a procedure 
that was required for nearly complete transfer of high molecular weight proteins to the 
nitrocellulose filter. After transfer, the membrane was then blocked with a solution of 5% 
milk (Lab Scientific, Livingston, NJ) in TBS-T (10 mM Tris-HCl [pH 7.4], 150 mM 
NaCl, 0.1% v/v Tween 20) for 1 h at room temperature with gentle rocking. The 
membrane was then incubated with a solution of primary antibody in TBS-T for 1 h at 
room temperature or overnight at 4°C with gentle rocking. After incubation with primary 
antibody, membranes were washed with 50 ml TBS-T for three rounds of 10 min with 
gentle shaking and then incubated with a solution of secondary antibody conjugated to 
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horseradish peroxidase in TBS-T for 1 h at room temperature with gentle shaking. After 
incubation with secondary antibody, membranes were washed (same as above) followed 
by two additional 5 min washes with 50 ml TBS (10 mM Tris-HCl [pH 7.4], 150 mM 
NaCl). After the final wash, 1 ml of a solution of SuperSignal West Dura Extended 
Duration Substrate (Thermo Scientific, Rockford, IL) was added to the membrane and 
incubated for 5 min at room temperature. Luminescence on the membranes was then 
visualized by exposure to Blue Basic Autorad Film (Bioexpress, Kaysville, UT), which 
was developed on the Kodak M35 X-OMAT Processor (Kodak Diagnostic Imaging, 
Rochester, NY). 
2.24 Antibodies 
Antibodies used in this study are listed in Table 2.5. 
2.25 Chromatin-immunoprecipitation (ChIP) 
Approximately 108 RC-K8 cells were fixed with 3% formaldehyde for 20 min at room 
temperature. Cells were then rinsed three times with ice-cold PBS and nuclear lysate was 
prepared as described above. Cross-linked nuclear extracts were then kept in an ice bath 
while sonicated with a Branson digital sonicator at 35% amplitude for 15 cycles of 15 s 
sonication followed by 45 s rest. After sonication, cell debris was precipitated by addition 
of 10% Triton-X and incubation on ice for 10 min followed by centrifugation in a 
microcentrifuge at 4°C for 15 min. The protein concentration of the supernatant was then 
quantified and a volume containing 350 µg of protein was incubated at 4°C overnight 
with 300 µg of either rabbit anti-p300 antiserum (Santa Cruz Biotechnology, sc584) or 
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pre-immune serum in a total volume of 0.5 ml with gentle agitation. The next day, 50 µl 
of a 50% slurry of Protein A sepharose beads was added and the samples were incubated 
for 3 h at 4°C with gentle agitation. Beads were washed 6 times with 700 µl RIPA buffer 
(50 mM Tris-HCl [pH 7.2], 150 mM NaCl, 1% deoxycholic acid, 1% Triton X-100, 0.1% 
SDS) and then once with TE supplemented with 50 mM NaCl. Bead-conjugated 
complexes were eluted in 250 µl TE with 2% SDS by incubation at 65°C for 15 min with 
gentle mixing by vortex every 2 min.  
 Crosslink reversal and DNA purification were performed as described previously 
(Lee et al. 2006, Haery et al. 2014). Briefly, eluates were supplemented with 1 µl 10 
mg/ml proteinase K and 1 µl 10 mg/ml RNase A and were then incubated for 1 h at 42°C. 
Following reversal of crosslinks, DNA was purified by two extractions with equal 
volumes of phenol and then one extraction with an equal volume of chloroform. DNA 
was precipitated by the addition of 20 µg glycogen, 20 µl 3 M sodium acetate, and 660 µl 
100% ethanol followed by incubation at 20°C for 2 h. DNA was pelleted by 
centrifugation in a microcentrifuge for 20 min at 4°C, the pellet was rinsed with 70% 
ethanol and spun for an additional 5 min before the supernatant was decanted and the 
pellet was air dried for approximately 1 h. The recovered dried DNA pellet was 
resuspended in 20 ul TE.  
 Recovered DNA was then subjected to qPCR using primers to amplify the 
TNFAIP3 (A20) promoter. PCRs were performed in the ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems, Foster City, CA) using 40 cycles of 94°C for 15 
s and 60°C for 1 min.  The primers used were 5’-CAGCCCGACCCAGAGAGTCAC and 
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5’-TTCGTGGCGGGCCAAG (Amir-Zilberstein et al. 2007). Cycle threshold (Ct) values 
for p300 were normalized to the pre-immune serum control values (1.0). Error bars 
represent standard error. 
2.26 Electrophoretic Mobility Shift Assay (EMSA) 
Whole cell extracts were prepared as described previously (Haery et al. 2014) and 
analyzed by EMSA as described previously (Yeo et al. 2015). The indicated amounts of 
whole-cell extracts were incubated with radiolabeled κB-site probe (Yeo et al. 2015) or 
LSF-site probe (kindly provided by Ulla Hansen, Boston University) (Huang et al. 1990). 
Samples were electrophoresed on non-denaturing 5% polyacrylamide gels, and protein-
DNA complexes were detected by autoradiography. 
2.27 RNA isolation, cDNA generation, and real-time qualitative PCR 
Total cellular RNA was isolated using TRIzol Reagent (Invitrogen, Grand Island, NY) 
according to the manufacturer’s protocol. The mRNA was reverse transcribed into cDNA 
using M-MLV reverse transcriptase (Promega) and random primers (Promega). One 
thirtieth of the synthesized cDNA was combined with gene-specific primers and Power 
SYBR Green PCR Master Mix (Applied Biosystems). PCRs were performed as described 
above. Ct values were obtained for each sample and normalized to Ct values for GAPDH 
cDNA amplification (ΔCt) and then to Ct values from control shRNA-expressing RC-K8 
cells (ΔΔCt) using methods described previously (Livak and Schmittgen 2001). The fold 
change in mRNA was normalized to the fold change in GAPDH mRNA expression (1.0) 
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between p300 and control knockdown RC-K8 cells. Primers used to perform qPCR are 
listed in Table 2.2. 
2.28 Histone extraction and quantification of histone acetylation by mass 
spectrometry 
Cell lines were maintained in healthy conditions for several passages before histones 
were purified using the Active Motif Histone Purification Kit (cat no. 40025) according 
to the manufacturer’s instructions. Concentrations were determined using Nanodrop and 
then 5 µg of each sample was chemically propionylated using 1.5 µl propionic anhydride, 
and ammonium hydroxide was used to quickly adjust the pH to approximately 8.0 
(Garcia et al. 2007). Samples were then incubated at 51°C for 1 h followed by trypsin 
digestion overnight at 37°C. The fraction of acetylated to unmodified at a given histone 
H3 site was performed as described previously (Kuo and Andrews 2013). 
2.29 Statistical analyses 
For luciferase reporter assays, p-values were determined using a paired one-tailed 
Student’s t-test for values obtained from at least 2 biological replicates, and significance 
was attributed to p-values < 0.05. Luciferase values were obtained by taking the mean 
and standard error of luciferase activity for at least two biological replicates. Values 
within each biological replicate were the mean of two or three technical replicates. A 
one-tailed t-test (rather than a two-tailed t-test) was used because 1) p300 is a known 
transcriptional coactivator and thus, transcriptional output is expected to increase relative 
to REL alone, and 2) none of the individual technical replicates indicated that p300 
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mutants had an inhibitory effect on REL-dependent transactivation. Thus, our analysis 
was restricted to a one-tailed t-test based on the hypothesis that p300 mutants enhanced 
REL-dependent transactivation. 
 For qPCR analysis, each sample was assayed with three technical replicates that 
were then averaged to obtain the Ct value for that sample. Values for NF-κB target genes 
in Chapter 3 were obtained by taking the mean and standard error of two (A20 gene) or 
four (all other genes) biological replicates. Validation of NF-κB or MYC target gene 
expression in Chapter 4 was done with six technical replicates of the same mRNA that 
was used for microarray studies. p-values were calculated with a two-sample, equal 
variance, two-tailed Students t-test, and significance was attributed to p-values<0.05. 
 A Pearson’s correlation coefficient was used to determine if there was any 
correlation between the level of histone acetylation at a particular lysine residue and the 
expression level of full-length p300 protein. This analysis was done to determine if there 
was any linear relationship between the histone acetylation at various lysine residues and 
full-length p300 protein across multiple B-lymphoma cell lines. For the six cell lines 
analyzed (all cell lines except Karpas422), the degree of acetylation at a particular histone 
was related to the expression of p300 protein, and an ‘r’ value was calculated for the 
Pearson product moment correlation coefficient. 
 
2.30 Microarray analysis 
Endogenous p300ΔC-1087 was stably knocked down in RC-K8 cells by expression of 
virally transduced shRNA, as described above. Ectopic p300ΔC-1087 was stably 
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overexpressed in BJAB cells by expression of virally transduced sequences. After 
approximately 4 weeks, mRNA was isolated using the TRIzol method, as described 
above, and then further purified using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA). 
Microarray analyses of RNA samples were then performed by the Boston University 
Microarray Core Facility.  
 Processing and statistical analysis of raw microarray data was done by the Boston 
University (BU) Microarray Core Resource facility. Affymetrix GeneChip Human Gene 
2.0 ST CEL files were normalized to produce gene-level expression values using the 
implementation of the Robust Multiarray Average (RMA) (Irizarry et al. 2003) in the affy 
package (version 1.36.1) (Gautier et al. 2004) included within in the Bioconductor 
software suite (version 2.12) (Gentleman et al. 2004) and an Entrez Gene-specific 
probeset mapping (version 16.0.0) from the Molecular and Behavioral Neuroscience 
Institute (Brainarray) at the University of Michigan (Dai et al. 2005) 
(brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF). The expression of 
each gene in each of the four samples was obtained by collapsing the expression values 
from the gene-specific probe-sets into a single average value. The sequences of the 
EP300-specific probes used on the microarray (see Figure 4.3) were as follows:  
probe 1 CCCGGGCCGAAGAAGAGATTTCCTG; probe 2  GCCAAGCGGCCTAAACTCTCATCT; 
probe 3 GCAGGCTTGACTTCTCCCAACATG; probe 4 TTGCTATGGACAAAAAGGCAGTTCC; 
probe 5 GCTGATCCAGAGAAGCGCAAGCTCA; probe 6 GGAGCACCCGTTGGACTTGGAAATC;  
probe 7 GTAGGAGTTCAAACGCCGAGTCTTC; probe 8 TGGGTCCTATGCCAACAGCAGCTCA; 
probe 9 CCAGTTTCCATGAATCCAGGGCCTA; probe 10 TCCAGCGGTCAAGCTCCAGTGTCTC; 
probe 11 CTGCCCGGTGAACTCTCCTATAATG; probe 12 CCAGCAGATACTCAGCCGGAGGATA; 
	  	  
72 
probe 13 TTGGAGGCACTTTACCGTCAGGATC; probe 14 GAGCCCTGGCAGTATGTCGATGATA; 
probe 15 AGTTGTGCACAATACCTCGTGATGC; probe 16 AGATCCAAGGGGAGAGCGTTTCTTT; 
probe 17 GTGTCCTTCACCATGAGATCATCTG; probe 18 GGCTGTTTAAAGAAAAGTGCACGAA; 
probe 19 GACCTGTGCTTCTTTGGCATGCATG; probe 20 TCCTAAATGCTTGAGGACTGCAGTC; 
probe 21 CATTGCCATCCTCCTGACCAGAAGA; probe 22 CTGGCCCAATGTTCTGGAAGAAAGC; 
probe 23 CCCGGGATGCCCAATGTATCTAACG; probe 24 CTGCCTCCCATTGTTGATCCTGATC; 
probe 25 CAGATGGCCCACGTGCAAATTTTTC. 
 Array quality was assessed by computing Relative Log Expression (RLE) and 
Normalized Unscaled Standard Error (NUSE) using the affyPLM Bioconductor package 
(version 1.34.0) (Brettschneider et al. 2008). Pairwise differential expression was 
assessed using the moderated (empirical Bayesian) t-test implemented in the limma 
package (version 3.14.4) (i.e., creating simple linear models with lmFit, followed by 
empirical Bayesian adjustment with eBayes). Correction for multiple hypothesis testing 
was accomplished using the Benjamini-Hochberg false discovery rate (FDR) (Benjamini 
and Hochberg 1995). All statistical analyses were performed using the R environment for 
statistical computing (version 2.15.1). 
 A pairwise “modified” t-test (Smyth 2004) was used to obtain a p-value for the 
fold-change of each gene following p300ΔC-1087 knockdown. This analysis is a 
Bayesian analysis that does not test each gene independently, but rather leverages 
information from all genes on the array to increase the statistical power over a standard 
two-sample Student t-test. The number of genes identified as having changed expression 
at each p-value threshold had a relatively high FDR (FDR > 5%), so Benjamini-Hochberg 
FDR-correction (Benjamini and Hochberg 1995, Benjamini et al. 2001) was used to 
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obtain FDR-corrected p-values (‘q’ values). The FDR q value was also recomputed after 
removing probe-sets that were not expressed above the array-wise median value of at 
least one array because probe-sets with low overall expression are more strongly affected 
by random technical variation and more likely to produce false positive results. 
2.31 Ingenuity Pathway Analysis (IPA) 
IPA (www.ingenuity.com) was used to examine the set of differentially expressed genes 
in RC-K8 cells with p300ΔC-1087 knockdown, and to predict upstream regulator 
molecules whose activity could explain the observed gene expression changes. A bias-
corrected z-score (rather than a z-score) was used to infer the activation state of putative 
upstream regulators because our dataset of 560 differentially expressed genes exhibited a 
bias (i.e., there were more downregulated genes (350) than upregulated genes (210)). The 
regulators were then sorted by bias-corrected z-scores. All significantly predicted 
upstream regulators are shown. A p-value of overlap is shown for each predicted 
upstream regulator, which was determined by IPA using a Fisher’s exact test, and this p-
value indicates whether there is a statistically significant overlap between the microarray 
results and the genes that are known to be regulated by a given regulator based on the 
database of literature assembled by IPA. A positive z-score (greater than 2.0) indicates 
that a given upstream regulator was activated by knockdown of p300ΔC-1087, whereas a 
negative z-score (less than 2.0) indicates that a given upstream regulator was inhibited by 
knockdown of p300ΔC.  
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2.32 Gene Set Enrichment Analysis (GSEA) 
GSEA (Subramanian et al. 2005) was used to determine if there were biological 
processes that showed enrichment in the set of differentially expressed genes in RC-K8 
cells with p300ΔC-1087 knockdown. Specifically, GSEA (version 2.0.13) was used to 
identify biological terms, pathways and processes that were coordinately up- or down-
regulated within each pairwise comparison. GSEA of RC-K8 cell microarray data was 
performed by the BU Microarray Core Resource facility. For this analysis, the Entrez 
Gene identifiers of the genes interrogated by the array were ranked according to the 
moderated t statistic computed for the p300 knockdown compared to control. These 
ranked lists were then used to perform pre-ranked GSEA analyses (default parameters 
with random seed 1234) using the Entrez Gene versions of transcription factor motif gene 
sets obtained from the Molecular Signatures Database (MSigDB), version 4.0 
(Subramanian et al. 2007). We used MSigDB gene sets defined by either NF-κB (5 gene 
sets) or MYC (5 gene sets) binding motifs in the gene promoter (Xie et al. 2005). 
Specifically, the lists comprised genes with NF-κB binding sites or MYC binding sites as 
defined in the TRANSFAC database (version 7.4, www.gene-regulation.com), each of 
which is annotated by a TRANSFAC record. A normalized enrichment score (NES) was 
used to represent enriched gene sets (i.e., a positive NES indicates gene sets enriched 
towards the top of the ranked list, and thus, gene sets enhanced by p300ΔC-1087 
knockdown in RC-K8 cells, and vice versa). For GSEA of expression data obtained from 
the Cancer Cell Line Encyclopedia (CCLE), the Hallmark and the Oncogenic Signatures 
gene sets were obtained from MSigDB, version 5.0. A normalized enrichment score 
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(NES) was used to represent enriched gene sets (i.e., a positive NES indicates gene sets 
enriched towards the top of the ranked list, and thus, gene sets enhanced in the cohort of 
cell lines with p300 truncating mutations, and a negative NES indicates gene sets 
enhanced in the wild-type p300/CBP cohort). Each enrichment score was also associated 
with an FDR q-value, to which we applied a cutoff of 0.25, which represents a 25% false 
discovery rate, as is recommended by GSEA.  
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Table 2.1 Plasmids Used in This Study 
Mammalian expression vectors 
pCMVβ-p53 CMV promoter-driven expression vector containing wild-type 
p53. From Ulla Hansen (BU), and originally from Zhi-Xiong Xiao 
(BU Medical School) 
pCMVβ-p300-
HA 
CMV promoter-driven expression vector containing C-terminally 
HA-tagged human p300 (Garbati 2010) 
pCMVβ- 
p300ΔC-820 
CMV promoter-driven expression vector containing p300ΔC-820. 
The NdeI-HindIII fragment from pCMVβ- p300-HA was replaced 
with an NdeI-HindIII digested PCR product generated with 
primers: p300-for-exon 9 and p300ΔC-HindIII-Sud2-Rev with 
template pCMVβ-p300-HA 
pcDNA-Flag-
REL 
pcDNA3.1 expression vector containing FLAG-tagged REL 
(Garbati 2010)  
pcDNA3.1 CMV promotor-driven expression vector (Invitrogen) 
pcDNA3.1- 
p300ΔC-820 
HindIII-p300ΔC-820-HindIII PCR fragment was ligated with 
HindIII-digested pcDNA3.1. Primers: p300-HindIII-For and 
p300ΔC-HindIII-Sud2-Rev with template pCMVβ-p300ΔC-820 
pcDNA3.1- 
p300ΔC-1087 
HindIII-p300ΔC-1087-HindIII PCR fragment was ligated with 
HindIII-digested pcDNA3.1. Primers: p300-HindIII-ATG-For and 
Non-p300-H3-R with template pCMVβ-p300ΔC-1087 
SL1180-REL SL1180 containing REL cDNA (Starczynowski 2006) 
 
Bacterial expression vectors 
pGEX-KG Expression plasmid containing GST domain upstream of an 
MCS 
pGEX-2T Expression plasmid containing GST domain upstream of an 
MCS 
pGEX-2T-REL REL C-terminal transactivation sequence (aa 323-587) fused 
to GST (Garbati 2010, Garbati et al. 2011) 
pGEX-2T-p300-5’ 
Bam 
p300 aa 1 – 595 fused to GST (gift of Andrew Kung, 
Columbia University Medical Center) 
pGEX-2T-p300-CH1 p300 aa 302 – 528 fused to GST (gift of Andrew Kung, 
Columbia University Medical Center) 
pGEX-2T-p300-C493 p300 aa 302 – 493 fused to GST (gift of Andrew Kung, 
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  Columbia University Medical Center) 
pGEX-2T-p300-
N340 
p300 aa 340 – 528 fused to GST (gift of Andrew Kung, 
Columbia University Medical Center) 
pGEX-KG-p53 EcoRI-p53- PCR fragment was ligated with EcoRI and HindIII 
digested pGEX-KG 
 
Retroviral vectors 
pCL10a1 Retrovirus packaging vector containing the viral envelope 
protein, gp70, and the 10A1 envelope protein isolated from mice 
infected with amphotropic MuLV. (Novus Biologicals, Littleton 
CO) (Garbati et al. 2011) 
pSW253 Rev-A helper virus for packaging of spleen necrosis virus (SNV) 
vectors (Starczynowski 2006) 
pSiren-p300 pSIREN containing shRNA sequences directed against 5’ 
sequences of EP300 [5′-ACCAGATGCCTCGAATAA-3′ 
(Sankar et al. 2008)]; inserted sequences were designed using the 
shRNA Sequence Designer (Clontech) with BamHI and EcoRI 
overhangs and subcloned into pSIREN-RetroQ digested with 
BamHI and EcoRI. (Garbati et al. 2011) 
pSiren-control pSIREN containing non-targeting shRNA sequences [5’-
GCAAGCTGCCCGTGCCCTG-3’ (Scherr et al. 2003)]; inserted 
sequences were designed using the shRNA Sequence Designer 
(Clontech) with BamHI and EcoRI overhangs and subcloned into 
pSIREN-RetroQ digested with BamHI and EcoRI. (Garbati et al. 
2011) 
pMH-cREL-Neo SNV vector containing human REL and Neo (Starczynowski 
2006) 
pMH-p300ΔC-820 PmeI fragment containing p300ΔC-820 (digested from pcDNA-
p300ΔC-820) was ligated with RsrII-NcoI digested/Klenow-
treated pMH105-Neo (no 5’ gene) 
pMH-REL-
p300ΔC-820 
XbaI-SpeI fragment containing REL (digested from SL1180) was 
ligated with a partial XbaI-digested pMH-p300ΔC-820, in order 
to insert REL at the 5’ gene position 
pMH-p300ΔC-
1087 
PmeI fragment containing p300ΔC-1087 (digested from pcDNA-
p300ΔC-1087) was ligated with RsrII-NcoI digested/Klenow-
treated pMH105-Neo (no 5’ gene) 
pMH-cREL-
p300ΔC-1087 
XbaI-SpeI fragment containing REL (digested from SL1180) was 
ligated with a partial XbaI-digested pMH-p300ΔC-1087, in order 
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to insert REL at the 5’ gene position 
pMH-cREL-Bcl2 SNV vector containing REL and chicken Bcl2 (Starczynowski 
2006) 
 
Reporter constructs 
RSV-βgal Contains the Rous sarcoma virus (RSV) LTR upstream of the β-
galactosidase gene (gift of Douglas Faller, BU Medical School)  
pGL2-3X-κB-Luc pGL2-based reporter plasmid has a minimal c-fos promoter 
element and three copies of the major histocompatibility complex 
(MHC) class I κB-site element (TGGGGATTCCCCA) placed 
upstream of the luciferase gene ((Mitchell and Sugden 1995, 
Garbati 2010) 
pG13-Luc Luciferase reporter construct encodes luciferase downstream of 13 
copies of the p53 consensus binding site from the p21 gene 
promoter. (from Bert Vogelstein, via Addgene) 
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Table 2.2 Primers Used in This Study 
Primers with restriction sites, used for subcloning 
p300ΔC-HindIII-Sud2-Rev 5’- GTGAAGCTTGTAAGGGACAGTGAATGTGGCTC 
p300-HindIII-ATG-For 5’- CTCTAAGCTTATGGCCGAGAATGTGGTGGAAC 
Non-p300-gene-Rev 5’-CCCAAGCTTCAAAGCCACAGAAATTGCATCTC 
(Garbati et al. 2011) 
EcoRI-5-p53 5’- GCGCGAATTCATATGGAGGAGCCGCAGTCAGAT 
HindIII-3-p53 5’- GCATTTCGAATCTCAGTCTGAGTCAGG 
CCCTTCTG 
 
Primers against endogenous sequences, used for genotyping or RNAi 
EP300 exon 14 5’- AGCATAGGCAGGCCCTAGA  
5’- TATGCTTGGGGGAGTATGGT 
PCR, then 
sequencing 
EP300 exon 29 in gDNA 5’- TGGCCTCTTCTAGGCAAAAA 
5’- CCATGCCCAGCTAATTTTGT 
PCR, then 
sequencing 
EP300 exon 29-30 in 
cDNA 
5’- ATTTCTGGCCCAATGTTCTG 
5’- TCTCCATTTTGTGGTCATGG 
PCR, then 
sequencing 
EP300 exon 30 in gDNA 5’- AACTCAGCATTCGCCAGTCT 
5’- GTGTCTCCACATGGTGCTTG 
PCR, then 
sequencing 
p300 shRNA hairpin 
target 
5’- ACCAGATGCCTCGAATAA RNAi 
Control shRNA hairpin 
target 
5’- GCAAGCTGCCCGTGCCCTG RNAi 
 
Primers used for qPCR 
A1 5’- TACAGGCTGGCTCAGGACTAT 
5’- CGCAACATTTTGTAGCACTCTG 
A20 5’- CGCTCAAGGAAACAGACACA 
5’- CTTCAGGGTCACCAAGGGTA 
A20 Promoter 5’- CAGCCCGACCCAGAGAGTCAC 
5’- CTTGGCCCGCCACGAA 
AIMP2 5’- AGGTAAAGCCCTATCACGGG 
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5’- ACAGGTTAGACTCTTCCTGCAC 
Birc3 5’- AAGCTACCTCTCAGCCTACTTT 
5’- CCACTGTTTTCTGTACCCGGA 
CAD 5’- AGTGGTGTTTCAAACCGGCAT 
5’- CAGAGGATAGGTGAGCACTAAGA 
CCR7 5’- TGAGGTCACGGACGATTACAT 
5’- GTAGGCCCACGAAACAAATGAT 
CD274 5’- TGGCATTTGCTGAACGCATTT 
5’- TGCAGCCAGGTCTAATTGTTTT 
CD80 5’- AAACTCGCATCTACTGGCAAA 
5’- GGTTCTTGTACTCGGGCCATA 
CDK4 5’- ATGGCTACCTCTCGATATGAGC 
5’- CATTGGGGACTCTCACACTCT 
FASN 5’- AAGGACCTGTCTAGGTTTGATGC 
5’- TGGCTTCATAGGTGACTTCCA 
GBP2 5’- CTATCTGCAATTACGCAGCCT 
5’- TGTTCTGGCTTCTTGGGATGA 
GAPDH 5’- TGGTATCGTGGAAGGACTCATGAC 
5’- ATGCCAGTGAGCTTCCCGTTCAGC 
HIP1 5’- ACACGCCAGAACGTGCATA 
5’- CACTGCGTTGCTAGACAGAG 
IFNG1 5’- TCGGTAACTGACTTGAATGTCCA 
5’- TCGCTTCCCTGTTTTAGCTGC 
IL1A 5’- TGGTAGTAGCAACCAACGGGA 
5’- ACTTTGATTGAGGGCGTCATTC 
IRF1 5’- CTGTGCGAGTGTACCGGATG 
5’- ATCCCCACATGACTTCCTCTT 
LDHA 5’- ATGGCAACTCTAAAGGATCAGC 
5’- CCAACCCCAACAACTGTAATCT 
LTA 5’- CATCTACTTCGTCTACTCCCAGG 
5’- CCCCGTGGTACATCGAGTG 
MYBL1 5’- AGGCAAGCAGTGTAGAGAAAGA 
5’- CGATTTCCCAACCGCTTATGT 
NFKBIA (IκB) 5’- CTCCGAGACTTTCGAGGAAATAC 
5’- GCCATTGTAGTTGGTAGCCTTCA 
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NME1 5’- AAGGAGATCGGCTTGTGGTTT 
5’- CTGAGCACAGCTCGTGTAATC 
ODC1 5’- TTTACTGCCAAGGACATTCTGG 
5’- GGAGAGCTTTTAACCACCTCAG 
PFAS 5’- CCCAGTCCTTCACTTCTATGTTC 
5’- GTAGCACAGTTCAGTCTCGAC 
PGK1 5’- TGGACGTTAAAGGGAAGCGG 
5’- GCTCATAAGGACTACCGACTTGG 
SRM 5’- GTGGTGGCCTATGCCTACTG 
5’- CTCCTGGAAGTTCGTGCTCG 
TNF 5’- GAGGCCAAGCCCTGGTATG 
5’- CGGGCCGATTGATCTCAGC 
TMOD2 5’- GCACTCCCCTTTCAAAAAGAGC 
5’- GCACTCTCAGGATCTAGGTCAT 
TNFSF4 5’- CCAGGCCAAGATTCGAGAGG 
5’- CCGATGTGATACCTGAAGAGCA 
TRAF1 5’- TCCTGTGGAAGATCACCAATGT 
5’- GCAGGCACAACTTGTAGCC 
 qPCR primers were generally obtained from PrimerBank, located at: 
pga.mgh.harvard.edu/primerbank 
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Table 2.3 Vertebrate Cell Lines Used in This Study 
Cell line Description Culture media 
293 (aka A293) Human embryonic kidney cell line DMEM-10 
293T Human embryonic kidney cell line 
expressing the SV40 large T antigen 
DMEM-10 
Bosc23 Human kidney cells derived from the 
293T line 
DMEM-10 
BJAB GCB DLBCL, EVB(-) DMEM-20 
DF1 Chicken fibroblast cell line DMEM-10 
Farage GCB-DLBCL RPMI-10 
Karpas422 GCB-DLBCL RPMI-20 
Pfeiffer GCB-DLBCL RPMI-10 
Ramos Burkitt’s lymphoma RPMI-10 
RC-K8 ABC-DLBCL DMEM-10 
SUDHL-2 ABC-DLBCL RPMI-10 
SUDHL-6 GCB-DLBCL RPMI-10 
SUDHL-8 GCB-DLBCL RPMI-20 
Saos2 Human bone osteosarcoma, p53 is 
entirely deleted. Used for p53 reporter 
assays 
DMEM-10 
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Table 2.4 Description of DLBCL Cell Lines Used in This Study 
Official name: RC-K8 
Origin Established from the peritoneal effusion of a 55-year-old man with 
lymphoma, described at the time as true histiocytic lymphoma, in 
1984 (terminal, refractory stage) 
Subtype ABC-DLBCL 
Classification EBV negative, pulmonary metastasis developed in RC-K8 cell-
transplanted hamsters; BCL6 translocation. 
(http://www.dsmz.de/human_and_animal_cell_lines/info). 
t(11;14)(q23;q32) chromosomal translocation, and several others 
(Kubonishi et al. 1986) 
Mutations 
affecting NF-
κB signaling 
These cells have constitutively active nuclear NF-κB and are 
characterized by high expression of NF-κB target genes (Kalaitzidis 
et al. 2002) 
NF-κB 
activating 
mutations 
Inactivating mutations in the IκBα gene, resulting in the absence of 
detectable IκBα protein in RC-K8 cells (Kalaitzidis et al. 2002). 
Biallelic inactivating mutations (G(+1)A, ΔT2227) in the A20 
ubiquitin modifying protein (Compagno et al. 2009) 
NF-κB 
inactivating 
mutations 
Chromosomal translocation within the REL locus, resulting in the 
expression of REL-NRG protein (Lu et al. 1991, Kalaitzidis and 
Gilmore 2002)  
Truncating mutation in the HAT coactivator p300 (Garbati et al. 
2010).  
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Official name: SU-DHL-2 
Origin Established from the peritoneal effusion of a 73-year-old woman with 
lymphoma, described at the time as true histiocytic lymphoma, in 
1984 (terminal, refractory stage). 
Subtype ABC-DLBCL 
Classification EBV negative 
NF-κB 
activating 
mutations 
Biallelic inactivating mutations (R183X, S459X) in the A20 ubiquitin 
modifying protein (Compagno et al. 2009) 
NF-κB 
inactivating 
mutations 
Truncating mutation in the HAT coactivator p300 (hemizygous 
mutation, Q821X) (Pasqualucci et al. 2011) 
 
Official name: OCI-LY10 
Origin Established from the lymph node of a patient from specimens taken at 
diagnosis; EBV-negative (Tweeddale et al. 1987) 
Subtype BCL6 rearrangement (Lossos et al. 2003); Shares high SNP identity 
with the KARPAS-422 cell line (ABC-DLBCL); MYC copy number 
loss (Barretina et al. 2012) 
NF-κB 
inactivating 
mutations 
Truncating mutation in the HAT coactivators CBP (E1238*, P901L) 
and p300 (Q160X) 
 
 
Classification and NF-κB mutations describe known characteristics of the indicated cell 
line, based on literature. 	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Table 2.5 Antibodies Used in This Study 
Protein Catalog # Type/Antigen 
Dilution 
(Application) Host Source 
A20 550859 mAb 1:200 (WB) Mouse BD 
Pharmingen 
Acetylated 
H3K14 
7627 mAb 1:1000 (WB) Rabbit CST 
Acetylated
-Lysine 
9814 mAb/ε-amine group 
of lysine residue 
1:1000 (WB) Rabbit CST 
CBP sc7300 mAb/C-terminus 1:200 (WB) Mouse SCB 
Histone H3 9715 pAb/C-terminus 1:1000 (WB) Rabbit CST 
IκBα 4814 mAb/N-terminus 1:1000 (WB) Mouse CST 
REL 265 pAb/C-terminus 1:10,000 (WB); 
1:50 (IF) 
Rabbit Dr. Nancy 
Rice 
p300 sc584 pAb/N-terminus 1:200 (WB);  
1:50 (IF);  
0.3 ug/ml (IP); 
0.6 ug/ml (ChIP) 
Rabbit SCB 
p-ERK 9101 pAb 1:1000 (WB) Rabbit CST 
p53 sc126 mAb/N-terminus 1:1000 (WB) Mouse SCB 
β-tubulin sc9104 pAb/C-terminus 1:500 (WB) Rabbit SCB 
Rabbit IgG 7074 pAb/HRP-
conjugated 
1:2000 (WB) Goat CST 
Mouse IgG 7076 pAb/HRP-
conjugated 
1:2000 (WB) Horse CST 
Rabbit IgG 9887 FITC-conjugated 1:80 (IF) Goat Sigma 
MYC sc40 mAb/C-terminus 1:1000 (WB) Mouse SCB 
 
CST, Cell Signaling Technology; IF, immunofluorescence; mAb, monoclonal antibody; 
pAb, polyclonal antibody; SCB, Santa Cruz Biotechnology; WB, Western blotting 
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CHAPTER 3 
CHARACTERIZATION OF P300 MUTANTS 
EXPRESSED IN HUMAN DLBCL CELL LINES1 
3.1 Introduction 
We have previously shown that, due to a 3’ alteration in one copy of the EP300 gene, the 
DLBCL cell line RC-K8 expresses a C-terminally truncated HAT-deficient p300 protein 
(herein called p300ΔC-1087, Figure 1.3) (Garbati et al. 2010, Garbati et al. 2011). Even 
though the other copy of the EP300 locus appears intact, RC-K8 cells express low to 
undetectable levels of wild-type p300 mRNA and protein (Garbati et al. 2010, Garbati et 
al. 2011). We previously reported that the RC-K8 p300ΔC-1087 could not act as a 
coactivator for the REL transcription factor (Garbati et al. 2011). Of note, knockdown of 
p300ΔC-1087 expression reduces the proliferation and soft agar colony-forming ability 
of RC-K8 cells (Garbati et al. 2011), and re-expression of wild-type p300 is tolerated in 
RC-K8 cells, but sensitizes them to treatment with small-molecule BCL6 inhibitors 
(Cerchietti et al. 2010). Other studies have demonstrated that expression of a HAT 
domain mutant of p300 results in increased proliferation of hematopoietic stem and 
progenitor cells, whereas complete loss of p300 does not (Kimbrel et al. 2009). Such 
findings suggest that p300 HAT activity normally limits B-cell proliferation, and that 
expression of p300 proteins with an inactive catalytic domain contributes to B-cell 
growth, survival, and tumorigenesis.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Adapted from Haery et al. 2014 
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In this chapter, the expression and activity of a HAT-deficient p300 protein 
(p300ΔC-820) from a second DLBCL cell line (SUDHL2) is characterized. In addition, it 
is shown that the p300ΔC-1087 protein expressed in RC-K8 cells can directly affect the 
activity of genes containing upstream NF-κB/REL binding sites. Finally, it is shown that 
B-lymphoma cell lines expressing C-terminally truncated p300 proteins have reduced 
histone acetylation at certain lysine residues.   
3.2 Alterations in the p300 protein are not seen in eight additional B-lymphoma cell 
lines 
Prior to large-scale studies on the DLBCL genome, we surveyed several B-lymphoma 
cell lines for truncating p300 mutations. We performed anti-p300 Western blotting on 
eight B-lymphoma cell lines and looked for the absence of the expression of full-length 
p300 as a marker for expression of truncated p300. None of the eight cell lines appeared 
to have mutations that caused loss of full-length p300 protein (Figure 3.1). Because wild-
type p300 has been shown to play a role in repression of MYC gene expression (Sankar et 
al. 2008), we also wanted to determine whether the loss of wild-type p300 in RC-K8 cells 
was correlated with high MYC protein expression, relative to other B-lymphoma cell 
lines. Therefore, we performed anti-MYC Western blotting on the RC-K8 cell line 
(which contains a truncated p300 protein) and the eight additional cell lines that express 
full-length p300, and did not find an obvious correlation between the levels of p300 and 
MYC protein expression (Figure 3.1). Namely, the B-lymphoma cell lines surveyed 
exhibited a broad range of MYC protein expression, and there were not especially high 
levels of MYC protein in RC-K8 cells, which lack full-length wild-type p300.   
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3.3 The SUDHL2 DLBCL cell line expresses a C-terminally truncated p300 protein 
After the release of multiple large-scale DLBCL genomic studies, we searched these 
publications for reported mutations in the EP300 gene to further pursue our interest in 
characterizing the function of mutant HATs in DLBCL. Pasqualucci et al. (2011) 
reported that several human DLBCL cell lines, including BJAB, Farage, SUDHL2 and 
SUDHL8, express no detectable full-length p300 protein. Because of our ongoing interest 
in p300 mutations in DLBCL (Garbati et al. 2010, Garbati et al. 2011), we were 
interested in further characterizing p300 status in these four cell lines. In particular, the 
reported absence of full-length p300 in BJAB and Farage cells is in contrast to our 
previous findings (Garbati et al. 2010) and those of others (Eckner et al. 1996, Cotter and 
Robertson 2000, Li et al. 2000, Wang et al. 2000). Therefore, we reassessed p300 
expression in these four DLBCL cell lines by Western blotting of whole-cell extracts, and 
included multiple independent cell lines in our analyses (including the ones used by 
Pasqualucci et al. 2011). As a further control, we analyzed RC-K8 cells, which we have 
previously shown express little or no full-length p300 (Garbati et al. 2010, Garbati et al. 
2011). As shown in Figure 3.2a, multiple isolates of BJAB, Farage, and SUDHL8 cells 
express easily detectable levels of full-length p300. In contrast, RC-K8 and SUDHL2 
cells do not express detectable levels of full-length p300. 
 Although full-length p300 is not expressed in RC-K8 cells, these cells do express 
a C-terminally truncated p300 protein (p300ΔC-1087) (Garbati et al. 2010, Garbati et al. 
2011). Due to the absence of full-length p300 in SUDHL2 cells (Figure 3.2a) and the 
reported nonsense mutation at EP300 codon 821 in these cells (Pasqualucci et al. 2011), 
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we next determined whether SUDHL2 cells express a C-terminally truncated form of 
p300. Western blotting using an antibody against N-terminal sequences of p300 showed 
that SUDHL2 cells express a smaller form of p300 under conditions where there is no 
detectable full-length p300 (Figure 3.2b). Consistent with the size expected for the 
reported codon 821 nonsense mutation (Pasqualucci et al. 2011), the single anti-p300-
reactive protein in SUDHL2 cell lysates migrated at approximately 90 kDa (herein called 
p300ΔC-820). 
 Pasqualucci et al. (2011) reported that SUDHL2 cells are hemizygous for the 
EP300 gene and contain only the codon 821 mutant allele. To confirm that SUDHL2 
cells lack wild-type EP300 sequences, we PCR-amplified and then sequenced EP300 
genomic DNA flanking codon 821 in exon 14. Our results confirmed that the amplified 
DNA only contained the C2856T mutation (CAG to TAG) at codon 821 in exon 14 
(Figure 3.2c), demonstrating that there is no wild-type EP300 locus in SUDHL2 cells. 
 Quantitation of p300 levels demonstrated that the truncated p300 proteins in RC-
K8 and SUDHL2 cells are expressed at low levels compared to full-length p300 in four 
other B-lymphoma cell lines (Figure 3.2b, relative p300 values). In contrast, the levels of 
the p300-related HAT CBP were similar in all six cell lines, and certainly did not vary 
depending on whether a given cell line expressed full-length or truncated p300 
(Figure 3.2d). These results show that neither overexpression of mutant p300 nor 
compensatory changes in CBP expression occurs in B-lymphoma cell lines expressing 
truncated p300 mutants. Instead, the expression of a truncated p300 appears to be 
associated with reduced expression of full-length p300. 
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3.4 Characterization of the p300ΔC-820 protein from SUDHL2 cells 
To further characterize the p300ΔC-820 protein, we created a CMV promoter-based 
plasmid expression vector for p300ΔC-820 by mutating codon 821 to a stop codon in a 
full-length p300 cDNA, based on the nonsense mutation in SUDHL2 genomic DNA. 
When transfected into 293T cells, the synthetic p300ΔC-820 cDNA directed the 
expression of a protein that nearly co-migrated with p300ΔC-820 from SUDHL2 cells 
(Figure 3.3a). The subtle difference in migration patterns of p300ΔC-820 SUDHL2 and 
293T cells may reflect cell-specific (i.e., lymphoid vs. non-lymphoid) differences in the 
proteins, perhaps due to post-translational modification. 
 We next analyzed the subcellular localization of ectopically expressed p300ΔC-
820 in transfected fibroblasts. As shown in Figure 3.3b, overexpressed wild-type p300, 
p300ΔC-1087, and p300ΔC-820 predominantly localized to discrete punctate regions of 
the nucleus (“speckles”) in transfected fibroblasts, which can indicate sites of active 
transcription (Spector and Lamond 2011). This speckled localization of p300ΔC-820 is 
similar to the staining seen with wild-type p300 and p300ΔC-1087 (from RC-K8 cells), 
but is distinct from the overall nuclear DNA staining seen with DAPI.  
 We have previously shown that wild-type p300 can enhance the ability of 
transcription factor REL to activate a multimeric κB-site reporter gene, whereas p300ΔC-
1087 cannot (Garbati et al. 2011). In more extensive studies, we now find that high levels 
of p300ΔC-820 and p300ΔC-1087 can weakly enhance transactivation by REL. 
Consistent with previous results (Garbati et al. 2011), wild-type p300 enhanced the 
ability of REL to activate the κB-site reporter in 293 cells by approximately 2.5-fold 
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(Figure 3.3c). In contrast, p300ΔC-820 and p300ΔC-1087 enhanced REL-dependent 
transactivation, on average, by only 1.6- and 1.4-fold, respectively (Figure 3.3c). To 
further assess the ability of these C-terminally truncated mutants to enhance REL-
dependent transactivation, we co-transfected a constant amount of REL plasmid with 
increasing amounts of either p300ΔC-820 or p300ΔC-1087 expression plasmids and 
measured transcriptional activation of the κB-site reporter. Like wild-type p300, both 
p300ΔC-820 and p300ΔC-1087 enhanced REL-dependent transactivation in a generally 
dose-dependent manner (Figure 3.3d). However, both p300 mutants enhanced 
transcription to a lesser extent than an equimolar amount of wild-type p300 (e.g., 500 ng 
of p300ΔC-820 plasmid enhanced REL-dependent transactivation by 1.5-fold, whereas 
500 ng of wild-type p300 plasmid resulted in a 2.4-fold enhancement). Together, these 
results demonstrate that both p300ΔC-820 and p300ΔC-1087 can enter the nucleus and 
function as relatively weak coactivators for REL-dependent transactivation.  
3.5 p300ΔC-820 interacts with REL transactivation domain sequences in vitro and in 
vivo 
We have previously shown that p300ΔC-1087 retains the ability to interact with 
transcription factor REL in vitro and in RC-K8 cells, and that this interaction primarily 
occurs via the C-terminal transactivation domain (TAD) of REL (Garbati et al. 2010). To 
determine whether p300ΔC-820 also has the ability to interact with REL, a pull-down 
assay was performed using a GST-REL-TAD fusion protein and whole-cell extracts from 
SUDHL2 cells. Anti-p300 Western blotting showed that GST-REL-TAD specifically 
pulled down p300ΔC-820 (Figure 3.4a). As a control, GST-REL-TAD was incubated 
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with whole-cell extracts from 293 cells, where it was able to pull down endogenous wild-
type p300 protein (Figure 3.4a). Moreover, a GST-p300 fusion protein containing the 
CH1 protein interaction domain (aa 300-528, retained in p300ΔC-820) could pull-down 
REL from SUDHL2 whole-cell extracts (Figure 3.4b). This ability to pull-down REL was 
lost when a smaller CH1 region was used (aa 340-528) (Figure 3.4b), indicating that the 
entire CH1 domain of p300 is required for efficient binding to REL. 
 To determine whether p300ΔC-820 retains the ability to interact with REL in 
vivo, we performed an anti-p300 immunoprecipitation from 293 cells co-transfected with 
expression plasmids for p300ΔC-820 and REL. Anti-REL Western blotting of an anti-
p300 immunoprecipitate demonstrated that REL can interact with p300ΔC-820, at least 
when overexpressed in a non-lymphoid cell type (Figure 3.4c). Of note, the elevated 
expression level of overexpressed p300ΔC-820 likely contributed to protein-protein 
interactions in 293 cells. Therefore, to determine whether endogenous p300ΔC-820 and 
REL interact in SUDHL2 cells, we performed an anti-p300 immunoprecipitation on 
nuclear extracts. Anti-REL Western blotting of the anti-p300 immunoprecipitate 
demonstrated that REL is also present, indicating that REL and p300ΔC-820 interact in 
SUDHL2 cells (Figure 3.4d). 
3.6 Knockdown of p300ΔC-820 reduces the growth of SUDHL2 cells 
To determine whether p300ΔC-820 contributes to the growth of SUDHL2 cells (which 
contain no wild-type EP300 allele), we first knocked down expression of p300ΔC-820 in 
these cells using a retroviral vector containing a short hairpin RNA (shRNA) that has 
been previously shown to knock down expression of wild-type p300 (Sankar et al. 2008) 
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and p300ΔC-1087 (Garbati et al. 2011). Western blotting followed by densitometry 
showed that p300ΔC-820 expression was reduced by approximately 67% in a pool of 
SUDHL2 cells expressing p300 shRNA as compared to SUDHL2 cells expressing a 
control, non-targeting shRNA (Figure 3.5a).  
 We next compared the proliferation of SUDHL2 cells expressing p300 shRNA 
and control shRNA by counting cells over the course of four days. Knockdown of 
p300ΔC-820 reduced the proliferation of SUDHL2 in liquid medium (Figure 3.5b). There 
are two reasons why we believe that the reduced proliferation of the p300ΔC-820 
knockdown SUDHL2 cells is not due to a higher rate of cell death: 1) the p300ΔC-820 
knockdown cells were selected for puromycin resistance (and therefore had to grow out 
over several passages) and 2) visual inspection of these cells did not reveal a high degree 
of cell death. Thus, we believe that knockdown of p300ΔC-820 causes cells to proliferate 
more slowly. In addition, SUDHL2 cells with knockdown of p300ΔC-820 formed 
approximately 8-fold fewer colonies in soft agar than control SUDHL2 cells 
(Figure 3.5c). The reduced growth of p300ΔC-820 knockdown cells in both liquid media 
and soft agar suggests that p300ΔC-820 contributes to molecular pathways that are 
required for the optimal in vitro growth of SUDHL2 cells. 
3.7 p300ΔC-1087 suppresses the expression of NF-κB-regulated genes encoding A20 
and IκBα 
Previous results have shown that several REL/NF-κB target genes are highly expressed in 
RC-K8 cells (Kalaitzidis et al. 2002). Because REL and p300ΔC-1087 interact in RC-K8 
cells (Garbati et al. 2010), we sought to determine whether knockdown of p300ΔC-1087 
	  	  
94 
would affect expression of some known REL-regulated genes in RC-K8 cells. Therefore, 
qPCR was performed to compare mRNA levels of seven such genes (A20, BCL2A1, 
CCR7, NFKBIA [encoding IκBα], LTA, TNF, TRAF1) in RC-K8 cells expressing p300 
shRNA to control cells (Figure 3.6a). First, we confirmed by Western blotting that 
p300ΔC-1087 expression was reduced in RC-K8 cells expressing p300 shRNA as 
compared to RC-K8 cells expressing a control, non-targeting shRNA (Figure 3.6b, top 
panel). As shown in Figure 3.6a, expression of A20, CCR7, NFKBIA, and TRAF1 
mRNAs was significantly increased (1.2- to 1.5-fold; p  <  0.05) in p300 knockdown cells, 
relative to control RC-K8 cells. Expression of A1 LTA, and TNFα were not significantly 
increased in RC-K8 cells expressing p300 shRNA. While the changes in individual 
mRNA levels are relatively minor, the cumulative effect of broad gene deregulation may 
contribute to the more dramatic growth phenotype seen upon knockdown of p300ΔC-
1087 (Garbati et al. 2011). 
 Extracts from RC-K8 cells with knockdown of p300ΔC-1087 were next subjected 
to anti-A20 and anti-IκBα Western blotting to determine whether the increases in mRNA 
seen in these cells resulted in increases in protein levels. As shown in Figure 3.6b, A20 
and IκBα protein levels were increased in RC-K8 cells expressing p300 shRNA. β-
tubulin expression was not affected by p300ΔC-1087 knockdown. These results also 
show that the observed changes in A20 and IκBα protein expression are more substantial 
than the corresponding changes in mRNA (Figure 3.6b compared to Figure 3.6a). 
Regarding this discrepancy, we note that RC-K8 cells contain protein-destabilizing 
mutations in the A20 gene (Compagno et al. 2009) and multiple mutations in the IκBα 
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gene, thus, increased expression of A20 and IκBα protein upon p300ΔC-1087 
knockdown may also be due to post-transcriptional or post-translational processes that 
stabilize or otherwise increase A20 and IκBα protein levels.  
 We then sought to determine whether the p300ΔC-1087 protein is located at the 
A20 promoter in RC-K8 cells. Therefore, we performed a ChIP assay in which p300ΔC-
1087 was immunoprecipitated from RC-K8 cell nuclei and, after reversing crosslinks, 
qPCR was performed using primers surrounding the κB sites of the A20 promoter. As 
shown in Figure 3.6c, A20 promoter sequences were enriched by approximately four-fold 
(as compared to the IgG control) in an anti-p300ΔC-1087 immonoprecipitate from RC-
K8 cells.  
 The expression of p300ΔC-1087 is thus associated with a reduction in A20 and 
IκBα expression at both the mRNA and protein levels. Furthermore, p300ΔC-1087 can be 
detected by ChIP at the A20 promoter, suggesting that p300ΔC-1087 has a proximal 
inhibitory effect on expression of mRNA from the A20 promoter. This analysis was 
performed using RC-K8 cells, rather than SUDHL2 cells, because SUDHL2 cells express 
a mutant form of A20 protein that is unstable and difficult to detect (Compagno et al. 
2009).  
3.8 Wild-type p300 expression may contribute to overall histone H3 acetylation in B-
cell lymphoma  
Because DLBCL cell lines expressing C-terminally truncated, HAT-deficient p300 
proteins do not express detectable amounts of wild-type p300, we next asked whether 
there was any reduction in overall histone acetylation in cell lines lacking wild-type p300 
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among a small panel of B-lymphoma cell lines. To answer this question, we entered into 
a collaboration with the laboratory of Dr. Andrew Andrews (Fox Chase Cancer Center).  
We isolated histones from six B-lymphoma cell lines that express varying levels of wild-
type p300, from RC-K8 and SUDHL2 (which express no detectable wild-type p300 
protein), and from Karpas422 cells (which express detectable wild-type p300 but no 
detectable CBP (Morin et al. 2011)), and then Dr. Andrews’ laboratory used a mass 
spectrometry-based approach to quantify the degree of acetylation of six lysine residues 
on histone H3 that can be acetylated by p300 (Das et al. 2009, Henry et al. 2013). The 
value obtained for each lysine residue represents the fraction of that residue that was 
acetylated relative to the total amount of each residue that was acetylated plus 
unmodified (Figure 3.7, Table 3.1). Acetylation of H3K9, K56, and K64 was low and 
sometimes undetectable in all nine cell lines. In contrast, acetylation of H3K14, K18, and 
K23 was within a detectable range and varied among the different cell lines. Cell lines 
with reduced wild-type p300 or CBP (i.e., RC-K8, SUDHL2, and Karpas422, indicated 
by red diamonds) had average or below average levels of H3K14 and H3K18 acetylation 
(mean and 95% CIs were H3K14 (0.058  ±  0.091) and H3K18 (0.012  ±  0.014), as 
compared to the broad range of H3K14 and H3K18 acetylation values found in cell lines 
with detectable levels of full-length p300 and CBP (H3K14, mean 0.252  ±  0.141, H3K18, 
mean 0.030  ±  0.010) (i.e., Farage, Pfeiffer, BJAB, Ramos, SUDHL6, and SUDHL8, 
indicated by blue circles) (Figure 3.7, Table 3.1). In contrast, cell lines lacking detectable 
wild-type p300 or CBP (i.e., SUDHL2, RC-K8, and Karpas422) did not have below 
average levels of H3K23 acetylation (mean 0.231  ±  0.039), relative to the broad range of 
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acetylation values exhibited by cell lines with detectable levels of full-length p300 and 
CBP (mean 0.158  ±  0.061). In addition, we calculated a Pearson’s correlation coefficient 
for the relationship between histone acetylation at each lysine residue and the level of 
wild-type p300 expressed (Figure 3.2b). Karpas422 was not included in this analysis 
because HAT activity in this cell line is confounded by lack of CBP expression. The only 
lysine residue to show a strong correlation between wild-type p300 level and acetylation 
was H3K14 (r = 0.92) suggesting that truncating mutations in p300 may be associated 
with global reduction of H3K14 acetylation. 
3.9 Chapter 3 Summary 
In this chapter, molecular properties of the HAT-deficient p300ΔC-820 protein from the 
human DLBCL cell line SUDHL2 are characterized. This is only the second truncated 
p300 mutant that has been functionally characterized in a human DLBCL cell line, the 
first being the p300ΔC-1087 protein from the RC-K8 cell line (Garbati et al. 2010, 
Garbati et al. 2011). We show that p300ΔC-820 is the only form of p300 protein 
expressed in SUDHL2 cells and that p300ΔC-820 contributes to SUDHL2 cell growth, as 
knockdown of p300ΔC-820 expression reduced the liquid media and soft agar growth of 
SUDHL2 cells. Like wild-type p300, p300ΔC-820 localizes to the nucleus and can 
interact with NF-κB family member REL, but p300ΔC-820 has a reduced ability to 
enhance REL-dependent transactivation in reporter assays. As such, p300ΔC mutants 
have the potential to attenuate expression of transcription factor-specific target genes by 
preventing the interaction of transcription factors with other functionally intact 
coactivators. Indeed, knockdown of p300ΔC-1087 in RC-K8 cells resulted in increased 
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expression of NF-κB target genes A20, CCR7, NFKBIA, TRAF1 and TNFα, as well as an 
increase in A20 and IκBα protein expression. Finally, the RC-K8 and SUDHL2 cell lines, 
which have reduced expression of wild-type p300, had generally reduced levels of 
acetylation of histone H3 K14 and K18 among a panel of B-lymphoma cell lines. 	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Table 3.1 Fraction of Acetylated Lysine Residues Relative to Total Acetylated Plus 
Unmodified Residues in Histone H32 
Cell line 
Ratio of acetylated to acetylated plus unmodified peptides 
K9 K14 K18 K23 K56 K64 
BJAB 0.0004 0.1800 0.0273 0.1883 0.0000 0.0000 
Farage 0.0038 0.2819 0.0333 0.1693 0.0012 0.0000 
Karpas422 0.0024 0.0027 0.0035 0.1922 0.0001 0.0000 
Pfeiffer 0.0071 0.0175 0.0175 0.2020 0.0369 0.0000 
Ramos 0.0042 0.4967 0.0215 0.2148 0.0001 0.0000 
RC-K8 0.0001 0.1507 0.0057 0.2417 0.0000 0.0000 
SUDHL2 0.0124 0.0214 0.0265 0.2596 0.0001 0.0000 
SUDHL6 0.0124 0.3977 0.0305 0.0061 0.0000 0.0000 
SUDHL8 0.0035 0.1372 0.0515 0.1663 0.0001 0.0000 
 
Fraction of acetylated lysine residue as determined by mass spectrometry for B-
lymphoma cell lines. Values are plotted in Figure 3.7 	    
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Analyses performed by Ryan Henry and Andrew Andrews, Fox Chase Cancer Center 
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Figure 3.1 Expression of p300 and MYC in a panel of human B-lymphoma cell lines 
Extracts from the indicated human B-lymphoma cell lines were analyzed by Western 
blotting for p300, MYC, and β-tubulin (as a loading control). In a given panel, all lanes 
contain equal amounts of cellular protein, except for the first lane in the top panel, which 
contains twice the amount of protein in order to detect the low levels of p300ΔC in RC-
K8 cells. 
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Figure 3.2 Expression of p300 proteins in DLBCL cell lines, and SUDHL2 cells do 
not have a wild-type EP300 sequence at codon 821 
(a) Anti-p300 Western blotting was performed on whole-cell extracts from the indicated 
DLBCL cell lines. The sources of the cell lines are described in Chapter 2 and in the 
indicated references in the figure. Thirty-five µg of total protein from whole-cell extracts 
was loaded for all samples except for RC-K8 (50 µg). (b) SUDHL2 cells express a C-
terminally truncated p300 protein (p300ΔC-820). Whole-cell extracts from the six 
indicated cell lines were analyzed by Western blotting for relative expression of p300. 
The amount of total cell protein loaded is indicated. Western blots were performed with 
N-terminal anti-p300 antiserum. p300 expression was quantified by densitometric 
analysis and is relative to full-length p300 in Ramos cells (100). Relative p300 expression 
for the SUDHL2 and RC-K8 cell lines was determined by analyzing the bands 
corresponding to p300ΔC-820 and p300ΔC-1087, respectively. Full-length p300 in 
SUDHL2 and RC-K8 cell lines was undetectable (0). (c) Genomic DNA corresponding to 
exon 14 of EP300 in SUDHL cells was amplified by PCR and sequenced. Sequencing 
was performed in the forward (top strand) and reverse (bottom strand) direction. 
Chromatograms and corresponding nucleotides are shown in the forward (top strand) and 
reverse (bottom strand) direction. The reported C2856T nonsense mutation at codon 821 
(Pasqualucci et al. 2011) is highlighted. (d) Whole-cell extracts from the six indicated 
DLBCL cell lines were analyzed by Western blotting for expression of CB Twenty-five 
µg of whole-cell extract was used for each sample. Western blotting was performed with 
anti-CBP and anti-β-tubulin (as a loading control) antisera.  
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Figure 3.2 Expression of p300 proteins in DLBCL cell lines, and SUDHL2 cells do 
not have a wild-type EP300 sequence at codon 821 
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Figure 3.3 p300ΔC-820 localizes to the nucleus, but only weakly enhances REL 
transactivation 
(a) Anti-p300 Western blotting was performed on extracts from control 293T cells, 
p300ΔC-820-transfected 293T cells, and SUDHL2 cells. Twenty-five µg of control 293T 
and SUDHL2 total protein and 30 ng of p300ΔC-820-transfected 293T total protein were 
loaded. Extracts from both p300ΔC-820-transfected 293T cells and normal SUDHL2 
were loaded together in the last lane. (b) DF-1 chicken fibroblasts were transfected with 
3 µg of pCMVβ-p300, pCMVβ- p300ΔC-1087, or pCMVβ- p300ΔC-820 as indicated. 
Indirect immunofluorescence was performed using a primary anti-p300 antiserum and an 
FITC-conjugated anti-rabbit secondary antibody (top row). Nuclei were visualized by 
DAPI staining (bottom row). (c) 293 cells were co-transfected with 0.5 µg of pcDNA-
REL along with 0.5 µg of pCMVβ-p300, pCMVβ-p300ΔC-1087, or pCMVβ-p300ΔC-
820 as indicated. Western blotting shows relative p300 and REL expression in transfected 
cells (bottom panel). Luciferase and β-galactosidase activities were determined, and 
values were normalized to control transfections (1.0, top panel). Error bars represent 
standard error of the mean. (d) 293 cells were co-transfected with 0.5 µg of pcDNA-REL 
and the indicated amounts of pCMVβ-p300, pCMVβ-p300ΔC-820, or pCMVβ-p300ΔC-
1087. Luciferase and β-galactosidase activities were determined, and values were 
normalized to REL-alone control transfections as indicated (1.0, white bar). Total DNA 
within each experiment was kept constant by the addition of empty pcDNA3.1 vector. 
Asterisks represent p-value  <  0.05 for the difference between the indicated value and the 
control value (1.0) in a one-tailed t-test. For all reporter assays, values are the average of 
at least two biological replicates. Error bars represent standard error of the mean. 
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Figure 3.3 p300ΔC-820 localizes to the nucleus, but only weakly enhances REL 
transactivation 
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Figure 3.4 p300ΔC-820 interacts with REL in vitro and in vivo 
(a) A GST-REL-TAD (aa 324-587) pulldown was performed on whole-cell extracts from 
SUDHL2 (p300ΔC-820, top panel) or A293 cells (wild-type 300, middle panel). Bound 
proteins were subjected to anti-p300 Western blotting to detect p300ΔC-820 or WT p300, 
as indicated. (b) GST-p300 pulldown of endogenous REL from SUDHL2 whole-cell 
extracts. Bound proteins were subjected to anti-REL Western blotting. The structure of 
wild-type p300 is shown and structures of GST-p300 mutants used are indicated. (c) 
Nuclear extracts of 293 cells co-transfected with p300ΔC-820 and REL were 
immunoprecipitated with normal rabbit IgG or anti-p300 antiserum. Immunoprecipitates 
were subjected to anti-REL or anti-p300 Western blotting, as indicated. One percent 
(3 µg) of the nuclear extract used for immunoprecipitation was included as an input for 
the anti-REL blot and 10% (30 µg) of the nuclear extract was used as input for the anti-
p300 blot. (d) Nuclear extracts of SUDHL2 cells were immunoprecipitation with normal 
rabbit IgG or anti-p300 antiserum. Immunoprecipitates were subjected to anti-REL or 
anti-p300 Western blotting, as indicated. Ten percent (25 µg) of the nuclear extract used 
for immunoprecipitate was included as an input for the anti-REL blot and 30% (75 µg) of 
the nuclear extract was used as input for the anti-p300 blot. Coomassie Blue staining was 
performed on 5% of GST or GST-fusion protein used in the pulldowns (a, b lower 
panels). 
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Figure 3.4 p300ΔC-820 interacts with REL in vitro and in vivo 
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Figure 3.5 Knockdown of p300ΔC reduces proliferation of SUDHL2 cells 
(a) Anti-p300 Western blotting was performed on whole-cell extracts from SUDHL2 
cells expressing p300 shRNA or control shRNA. Anti-β-tubulin Western blotting is a 
loading control. (b) 105 SUDHL2 cells expressing p300 shRNA or control shRNA were 
plated in 500 µl RPMI/10% FBS in 16-mm wells. On each day, three wells of each cell 
type were counted. Three technical replicates of the experiment were performed and one 
representative result in shown. (c) Soft agar colony assays were performed using 
SUDHL2 cells expressing p300 shRNA or control shRNA. Results are averages of three 
technical replicates each performed with triplicate plates containing 2000 or 5000 cells. 
Colony numbers are normalized to the number of colonies formed by SUDHL2 cells 
expressing control shRNA (100). Error bars represent standard deviation.  	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Figure 3.5 Knockdown of p300ΔC reduces proliferation of SUDHL2 cells 
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Figure 3.6 Knockdown of p300ΔC increases A20 and IκBα expression in RC-K8 
cells 
(a) cDNA prepared by reverse transcription of total RNA from RC-K8 cells expressing 
p300 shRNA or a control shRNA was subjected to real-time qPCR using gene-specific 
primers. mRNA expression values from RC-K8 cells expressing p300 shRNA were 
compared to values from RC-K8 cells expressing control shRNA to determine the fold 
change in expression. Error bars represent standard error of the mean. Asterisks indicate 
significant p-values (< 0.05) for the difference in mRNA levels relative to control cells 
(=1.0) using a two-tailed t-test. Independent knockdowns (biological replicates) were 
performed in for each gene: A20 (n = 2); all other genes (n = 4). Ct values were obtained 
in triplicate for each gene in each independent knockdown. Ct values for all genes 
(excluding GAPDH) ranged from 20.3 to 27.4 (b) Anti-p300, anti-A20, and anti-IκBα 
Western blotting was performed on whole-cell extracts from RC-K8 cells expressing 
p300 shRNA or control shRNA. Anti-β-tubulin Western blotting is a loading control. (c) 
RC-K8 cells were subjected to crosslinking with formaldehyde and extracts from isolated 
nuclei were then immunoprecipitated using normal rabbit IgG or anti-p300 antiserum. 
The crosslinks were reversed and DNA in immunoprecipitates was subjected to qPCR 
using primers spanning the A20 promoter region. Relative A20 promoter PCR product 
was normalized to the IgG control (1.0). Error bars represent the standard error of the 
mean. 
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Figure 3.6 Knockdown of p300ΔC increases A20 and IκBα expression in RC-K8 
cells 
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Figure 3.7 Total histone H3 lysine acetylation profile in DLBCL cell lines3 
Total histones were extracted from the indicated cell lines, and were treated with trypsin. 
Trypsinized histone samples were then subjected to mass-spec analysis. (a) For each H3 
lysine residue, the amount of the acetylated lysine residue was measured relative to total 
amount of acetylated plus unmodified residue. Cell lines indicated by red diamonds 
express undetectable levels of wild-type p300 (RC-K8, SUDHL2) or wild-type CBP 
(Karpas422) by Western blotting. Cell lines indicated by blue circles express detectable 
levels of p300 and CBP by Western blotting. A box plot of the fraction of acetylated 
lysine residue out of total acetylated plus unmodified H3 was plotted for each lysine 
residue. For cell lines indicated by red diamonds, the mean values and 95% CIs for H3 
lysine acetylation were as follows: H3K14 (0.058  ±  0.091), H3K18 (0.012  ±  0.014), and 
H3K23 (0.231  ±  0.039). For cell lines indicated by blue circles, the means and 95% CIs 
were H3K14 (0.252  ±  0.141), H3K18 (0.030  ±  0.010), and H3K23 (0.158  ±  0.061). (b) 
Total histones were extracted from the indicated cell lines. For each H3 lysine residue, 
the amount of the acetylated lysine residue is reported relative to total amount of 
acetylated plus unmodified residue. To generate the relative fraction of acetylated H3, a 
single common maximum value and single common minimum value were applied to all 
lysine residues analyzed, and absolute values (Table 3.1) within each residue were 
distributed proportionally across this normalized range. The relative fraction of acetylated 
H3 for all cell lines is shown as a box plot for each lysine residue (bottom and top of the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Analyses performed by Ryan Henry and Andrew Andrews, Fox Chase Cancer Center 
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box represent the first and third quartiles, respectively; bottom and top of error bars 
represent the minimum and maximum of all the values, respectively) . Cell lines 
indicated by red diamonds express undetectable levels of wild-type p300 (RC-K8, 
SUDHL2) or wild-type CBP (Karpas422) by Western blotting. Cell lines indicated by 
blue circles express detectable levels of full-length p300 and CBP by Western blotting.  
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CHAPTER 4 
KNOCKDOWN OF P300ΔC AFFECTS THE ACTIVITY AND GENE 
EXPRESSION PROGRAMS OF NF-κB AND MYC IN TWO HUMAN DIFFUSE 
LARGE B-CELL LYMPHOMA CELL LINES 
4.1 Introduction 
Large-scale genomic studies have shown that the p300/CBP histone acetyltransferases 
(HATs) are mutated in approximately 15% of diffuse large B-cell lymphoma (DLBCL) 
cell lines and patient tumor tissue, as well as many other cancer types including breast, 
colon, and lung, and that the majority of these mutations reduce or inactivate HAT 
activity (reviewed in Haery et al. 2015). Given the prevalence of the p300/CBP mutations 
in DLBCL and other cancers, it is almost certain that they contribute to the cancer 
phenotype. Our laboratory has previously characterized two C-terminally truncated, 
HAT-deficient p300 mutants (p300ΔC proteins) in the human DLBCL cell lines RC-K8 
and SUDHL2 (mutants p300ΔC-1087 and p300ΔC-820, respectively), and shown that 
expression of these mutant p300 proteins is required for the optimal growth of these two 
DLBCL cell lines (Garbati et al. 2010, Garbati et al. 2011, Haery et al. 2014). That is, 
knockdown of p300ΔC protein expression reduces the growth of both RC-K8 and 
SUDHL2 cells in culture (Garbati et al. 2011, Haery et al. 2014) (see also Chapter 3).  
Given that there are dozens of lymphoid transcription factors (Table 1.2) and 
thousands of genomic regulatory regions that are subjected to dynamic patterns of 
acetylation/deacetylation (Roh et al. 2005), it is likely that p300/CBP mutant proteins in 
DLBCL have myriad effects on gene expression, acting both at genomic and non-
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genomic levels. When other tissue types are considered, the potential consequences of 
p300/CBP mutations are even further expanded, and the effects of cancer-related HAT 
gene mutations are almost certainly highly context-dependent.  
Therefore, in this chapter, the effects of p300 mutations in DLBCL are 
investigated by large-scale gene expression analysis of the RC-K8 cell line. To determine 
the function of p300ΔC-1087 in vivo, cDNA microarray and qPCR analyses were 
performed to compare mRNA expression patterns in RC-K8 cells with p300ΔC-1087 
knocked down versus control RC-K8 cells. The differential mRNA expression patterns 
were then analyzed using Ingenuity Pathway Analysis (IPA) software. IPA identified NF-
κB and MYC as upstream regulators of the differential gene expression pattern in RC-K8 
cells, and thus, identified NF-κB and MYC as being affected by the expression of 
p300ΔC-1087. Consistent with this finding, knockdown of p300ΔC resulted in reduced 
MYC protein levels and increased NF-κB DNA-binding activity in both SUDHL2 and 
RC-K8 cells. Following from those findings, we also determined whether we could use 
Gene Set Enrichment Analysis (GSEA) to identify NF-κB and MYC target gene sets 
from the Molecular Signatures Database (MSigDB) as being significantly enriched in our 
differentially expressed list of genes. MSigDB contains gene sets involved in many well-
defined pathways and oncogenic processes, and thus, we wanted to examine gene 
expression data from other cancer cell lines and other cancer tissue types to determine 
whether any of these pathways or oncogenic processes were affected by the expression of 
p300ΔC proteins. Indeed, GSEA was able to identify significant enrichment of the 
MSigDB NF-κB and MYC target gene sets in our RC-K8 microarray data. Therefore, we 
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next used GSEA to identify other MSigDB gene sets that were significantly enriched in a 
cohort of cell lines predicted to have C-terminally truncating p300 mutations, as 
compared to a cohort of cell lines with wild-type p300 and CBP. This analysis identified 
gene sets involved in the UV response, p53 signaling, and MYC signaling as being 
significantly upregulated in the cohort of cell lines with wild-type p300/CBP (as 
compared to the mutant p300 cohort). Overall, these analyses demonstrate that NF-κB 
and MYC, as well as their dependent pathways, are affected by the expression of p300ΔC 
in RC-K8 and SUDHL2 DLBCL cells, and further suggest that GSEA is a useful tool for 
identifying pathways and processes affected by p300 mutation using cancer cell line 
mRNA expression data. 
4.2 p300ΔC mutations do not affect the protein’s half-life 
Consistent with our previous results (Garbati et al. 2010, Haery et al. 2014), in Figure 
4.1a we show that the RC-K8 and SUDHL2 DLBCL cell lines each express a truncated 
form of p300, but no full-length p300 protein. In contrast, the BJAB DLBCL cell line 
expresses only full-length p300 protein.  
We have previously shown that the p300ΔC proteins from RC-K8 and SUDHL2 
cells retain many of the properties of wild-type p300, such as being able to bind to NF-κB 
transcription factor REL and to localize to discrete nuclear “speckles” (Garbati et al. 
2011, Haery et al. 2014). We next sought to determine whether the p300ΔC proteins have 
alterations in protein stability as compared to wild-type p300. To determine the normal 
rate of turnover of p300ΔC proteins, we treated RC-K8 and SUDHL2 cells with 
cycloheximide to block protein synthesis for 0, 4, 6, and 8 h, and then performed anti-
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p300 Western blotting (Figure 4.1b). As a control, we measured the half-life of wild-type 
p300 in BJAB cells (Figure 4.1b). Densitometric analysis of Western blotting results 
showed that the protein half-lives of the p300ΔC-1087 (RC-K8) and p300ΔC-820 
(SUDHL2) mutants are approximately 4.5 h, which is similar to the half-life of wild-type 
p300 from BJAB cells (Figure 4.1c). Our experimentally determined half-life of wild-
type p300 is similar to the value (4.75 h) reported previously by others (Jain et al. 2012). 
Thus, the C-terminal truncations of p300 in RC-K8 and SUDHL2 cells do not appear to 
change p300’s stability, and therefore, one might expect that the dynamics of the 
interactions of p300ΔC proteins with proteins in cells would not be substantially affected 
by differences in molecular processes influenced by protein turnover. 
4.3 Knockdown of p300ΔC-1087 affects the expression of many genes in RC-K8 cells 
We have previously shown that p300ΔC mutants in RC-K8 and SUDHL2 cell lines retain 
the ability to interact with transcription factor REL, but are weak transcriptional 
coactivators for REL as compared to wild-type p300 (Garbati et al. 2010, Garbati et al. 
2011, Haery et al. 2014). Moreover, expression of the p300ΔC-1087 protein in the RC-
K8 cell line is correlated with reduced expression of select NF-κB target genes (Haery et 
al. 2014) (see also Chapter 3).  
To more extensively characterize the influence of p300ΔC on gene expression in 
DLBCL cells, we knocked down the expression of p300ΔC-1087 in RC-K8 cells and 
then used cDNA microarrays to compare gene expression patterns of p300ΔC-1087 
knockdown cells to control RC-K8 cells. To accomplish this, RC-K8 cells were first 
infected with a retroviral vector directing the expression of either p300 shRNA or a 
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control shRNA, and stably transduced pools of cells were generated by selection with 
puromycin (as the retroviral vector contains the gene for puromycin resistance). Two 
independent pairs of retroviral transductions were performed, and p300ΔC-1087 
knockdown was confirmed by Western blotting (Figure 4.2a). In both experiments, 
p300ΔC-1087 expression levels were reduced by approximately 90% (based on 
densitometric analysis), whereas the level of the control β-tubulin protein was not 
affected by knockdown of p300ΔC-1087 (Figure 4.2a).  
As a control for the effect of p300ΔC-1087 knockdown on overall gene 
expression in the cDNA samples that were to be used for the microarray analysis, qPCR 
was used to measure the expression of mRNA for four REL/NF-κB target genes that we 
have previously shown to increase following p300ΔC-1087 knockdown (Haery et al. 
2014). We confirmed that the levels of mRNA of the REL/NF-κB target genes A20, 
CCR7, IKBα, and TRAF1 were increased in both samples that were isolated from RC-K8 
cells in which p300ΔC-1087 was knocked down (Figure 4.2b).  
Microarray analyses using an Affymetrix human Gene 2.0 ST array were then 
performed on mRNA isolated from each of the two independent RNA samples from both 
control and p300ΔC-1087 knockdown RC-K8 cells. To confirm that the knockdown of 
p300ΔC-1087 was detectable in our microarray, we examined the individual probe-level 
expression of the p300 probe-set in these samples, predicting that the expression levels of 
probes targeting the 3’ terminus (i.e., the region encoding C-terminal residues) of p300 
would be underrepresented because one EP300 allele in RC-K8 cells harbors the 
truncating mutation and mRNA from the other wild-type EP300 allele is expressed at low 
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levels (Garbati et al. 2010), As expected, the levels of individual probes targeting 
sequences encoding the C-terminal residues of p300 (which are missing in p300ΔC-1087) 
were low-to-undetectable in both control RC-K8 and p300ΔC-1087 knockdown RC-K8 
cells (Figure 4.3). This result also confirmed that wild-type p300 mRNA is expressed at 
extremely low levels in RC-K8 cells. Furthermore, expression of p300 sequences 
detected by probes directed against sequences encoding the N-terminal region of p300 
(which are retained in p300ΔC-1087) were reduced in RC-K8 cells expressing p300ΔC-
1087 shRNA as compared to control RC-K8 cell samples (Figure 4.3). Taken together, 
these results confirmed that p300ΔC-1087 mRNA expression was reduced in RC-K8 
cells stably transduced with p300 shRNA as compared to RC-K8 cells transduced with a 
control shRNA. 
As a further control, we sought to confirm that we could detect expression of the 
mRNA for full-length p300 in the BJAB cell line, which we have previously shown 
expresses wild-type p300 (Haery et al. 2014). Therefore, we also examined individual 
p300-directed probe expression in control BJAB cells and in BJAB cells overexpressing 
p300ΔC-1087 (generated by retroviral transduction). Results showed that easily 
detectable expression levels were obtained with probes spanning the entire p300 mRNA 
in control BJAB cells, confirming that these cells express full-length p300 mRNA 
(Figure 4.3). Furthermore, only signals from N-terminal probes were increased in BJAB 
cells ectopically expressing p300ΔC-1087, confirming that mRNA expression signals 
from probes corresponding to sequences encoding C-terminal p300 residues arise from 
expression of endogenous full-length p300 mRNA in BJAB cells (Figure 4.3). 
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Specifically, probes targeting the N-terminal region of p300 (probes 2 – 13) were 
expressed at an average level of approximately 1,020 units in BJAB cells overexpressing 
p300ΔC-1087 compared to approximately 340 units for these same probes in control 
BJAB cells (Figure 4.3). On the other hand, probes targeting the C-terminal region of 
p300 (probes 14 – 25) had an average expression of approximately 340 units in both 
control BJAB cells and in BJAB cells overexpressing p300ΔC-1087 (Figure 4.3), 
indicating that overexpression of p300ΔC-1087 did not change the levels of mRNA 
expression from the C-terminal sequences (which are not in p300ΔC-1087). 
Nevertheless, we noted that the 5’ probes in BJAB cells overexpressing p300ΔC-1087 
did not give uniformly high values on the microarray. Therefore, as a final control for the 
integrity of the microarray, we examined the nucleotide sequences of two specific 5’ (N-
terminal) p300 probes that had particularly low expression (probe 5) and particularly high 
expression (probe 10).  The sequences of probes 5 and 10 both corresponded exactly to 
sequences at the expected positions of p300 mRNA. Moreover, the sequences of probes 5 
and 10 had similar GC-content (56% and 60%, respectively), suggesting that the 
observed differences in probe-specific expression levels are due to other intrinsic 
properties of the sequences, such as the efficiency of hybridization under the conditions 
used. 
After having performed the above control analyses on both our generated cDNA 
and our microarray probes, we sought to characterize the effects of p300ΔC-1087 
knockdown on global gene expression in RC-K8 cells. Therefore, we analyzed 
microarrays performed on the four samples (two control and two p300ΔC-1087 
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knockdown) from RC-K8 cells. Then, the change in mRNA expression for each gene was 
obtained by comparing the expression values in the p300ΔC-1087 knockdown (n = 2) to 
the values in control shRNA cells (n = 2). The numbers of differentially expressed genes 
based on the microarray results are shown for various p-value and FDR-corrected p-value 
(‘q’) thresholds (Table 4.1). The number of differentially expressed genes expected by 
chance for various p-values are summarized in Table 4.1. Taking the FDR analysis into 
consideration, our analyses identified 560 genes that showed statistically significant 
differential expression following p300ΔC-1087 knockdown, at a q threshold of 0.05 
(FDR = 5%). Of these 560 affected genes in RC-K8 p300ΔC-1087 knockdown cells, 210 
were upregulated and 350 were downregulated, and the minimum expression change 
observed was 1.5-fold. It should be noted that we did not anticipate large differences in 
the expression of individual genes in p300ΔC-1087 knockdown versus control cells, 
given that p300 is not a direct activator of transcription (i.e., it is a modifier of 
transcription factor activity) and given that we have previously shown that p300ΔC-1087 
has only partially reduced transcriptional enhancing ability as compared to wild-type 
p300 for REL-dependent gene activation (Garbati et al. 2011, Haery et al. 2014). 
4.4 Knockdown of p300ΔC-1087 in RC-K8 cells differentially affects NF-κB- and 
MYC-dependent gene networks  
To determine whether knockdown of p300ΔC-1087 in RC-K8 cells affects the expression 
patterns of specific gene networks, we applied Ingenuity Pathway Analysis (IPA) 
software to identify upstream regulators that were associated with the 560 genes whose 
expression change was considered statistically significant (q < 0.05). A summary of the 
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15 predicted upstream regulators that passed our filtering criteria (z-score of ≥ 2.0 or ≤ -
2.0, p-value of overlap < 0.01) is listed in Table 4.2. These 15 regulators comprised 10 
upstream regulators with positive z-scores (i.e., regulators activated by p300ΔC-1087 
knockdown, and thus, regulators whose activity is inhibited by p300ΔC-1087 expression) 
and 5 upstream regulators with negative z-scores (i.e., regulators inhibited by p300ΔC-
1087 knockdown, and thus, normally enhanced by p300ΔC-1087 expression) (Table 4.2). 
Some of the 15 upstream regulators are either regulators of specific transcription factors 
(e.g., TNF, IL1β) or transcription factors themselves (e.g., NF-κB, TP53, MYC) that are 
known to interact with p300 (reviewed in Haery et al. 2015).  
 Of interest to us, both NF-κB and the potent NF-κB upstream activator TNF are 
among the upstream regulators with positive z-scores, which is consistent with our 
finding that p300ΔC-1087 knockdown increased expression of select NF-κB target genes 
(see Figures 3.6a and 4.2b, and Haery et al., 2014). Specifically, the IPA indicated that 
NF-κB and TNF signaling are increased by knockdown of p300ΔC-1087, with NF-κB 
and TNF exhibiting positive bias-corrected z-scores of 3.400 and 3.783, respectively 
(Table 4.2). Or, in other words, the IPA suggests that p300ΔC-1087 normally acts to 
reduce NF-κB and TNF signaling in control RC-K8 cells. 
 Given our interest in the deregulation of NF-κB signaling and lymphomagenesis, 
we inspected the NF-κB target gene list for mRNAs that were significantly differentially 
expressed in our microarrays. Overall, there were 26 NF-κB target genes with statistically 
significant (q < 0.05) changes in gene expression (19 increased; 7 decreased) that were 
used to identify the NF-κB complex as an upstream regulator of the observed RC-K8 
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expression pattern. Of these 26 genes, expression changes in approximately two-thirds 
(17) of the genes (Table 4.3, genes 1 -17) were consistent with a program of NF-κB 
activation following knockdown of p300ΔC-1087 (i.e., there were 17 NF-κB-activated 
genes that were upregulated upon p300ΔC-1087 knockdown). These genes are listed in 
Table 4.3, and the effect of their fold-change on NF-κB activity is denoted as “activated” 
(i.e., their fold change in expression indicates that NF-κB is activated by p300ΔC-1087 
knockdown). We note that some inconsistent gene effects are expected, as individual 
genes can be regulated by multiple regulators, and that these effects can vary across cell 
types or disease states. These NF-κB target genes and their associated fold changes and 
statistical parameters following p300ΔC-1087 knockdown are listed in Table 4.3. As 
described below, these genes and the NF-κB pathway were analyzed in more detail. 
 The IPA also showed that MYC signaling was significantly inhibited (z-score = -
3.929, p-value = 6.90E-05) by p300ΔC-1087 knockdown (Table 4.2), i.e., MYC target 
genes showed overall altered expression following p300ΔC-1087 knockdown. 
Furthermore, the MYC coactivator BRD4 (Delmore et al. 2011) is also among those 
regulators that were inhibited (z-score = -2.018, p-value = 6.26E-04) by knockdown of 
p300ΔC-1087. Specifically, IPA identified 41 MYC targets with statistically significant 
(q < 0.05) expression changes following knockdown of p300ΔC-1087. These MYC 
targets are summarized with corresponding statistics in Table 4.4. Based on the known 
function of these genes and their corresponding fold changes in the microarray, 
approximately two-thirds (28) of the 41 differentially regulated MYC target genes were 
consistent with a program of MYC inhibition following p300ΔC-1087 knockdown (i.e., 
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two-thirds of the genes were either MYC-activated genes that showed downregulation 
upon p300ΔC-1087 knockdown, or MYC-inhibited genes that showed upregulation upon 
p300ΔC-1087 knockdown). These genes are listed in Table 4.4 (genes 1-28), and the 
effect of their fold-change on MYC activity is denoted as “inhibited.” Overall, the 
analysis of the MYC gene program by IPA suggests that p300ΔC-1087 normally acts to 
increase MYC signaling in RC-K8 cells. 
 MYC functions as both a transcriptional repressor and activator, whereas NF-κB 
is generally a transcriptional activator. Thus, among the 28 MYC-dependent genes whose 
expression was significantly correlated with an “inhibited” MYC profile following 
p300ΔC-1087 knockdown, there were 16 genes whose mRNA levels decreased (genes 
normally activated by MYC, genes 1-16) and 12 genes whose mRNA levels increased 
(genes normally repressed by MYC, genes 17-28) (see Table 4.4). In contrast, all 17 of 
the NF-κB-dependent genes with expression changes consistent with an “activated” NF-
κB program following p300ΔC-1087 knockdown showed increased expression (i.e., are 
genes activated by NF-κB) (see Table 4.3). Moreover, two genes (ODC1 and CD274) are 
found on both the MYC and NF-κB lists.  Given the direction of their changes (ODC1 
down-regulated 3.2-fold; CD274 up-regulated 2.0-fold), one might predict that in RC-K8 
cells ODC1 is normally activated by MYC, whereas CD274 is primarily activated by NF-
κB.  
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4.5 Knockdown of p300ΔC-1087 enhances NF-κB activity in RC-K8 and SUDHL-2 
cells 
To validate the dampening effect of p300ΔC-1087 on REL/NF-κB target gene expression 
in RC-K8 cells, we selected 11 NF-κB pathway genes that had a statistically significant 
(q < 0.05) expression increases of at least 1.8-fold following knockdown of p300ΔC-
1087 (Table 4.3), and measured their expression levels by qPCR. The qPCR results 
confirmed that the expression of all 11 genes was significantly upregulated (p < 0.05) by 
knockdown of p300ΔC-1087 in RC-K8 cells (Figure 4.4a). 
 To investigate the mechanism by which p300ΔC-1087 might dampen NF-κB 
target gene expression, we first compared the expression levels of REL and RELA/p65 
proteins in RC-K8 and SUDHL2 cells with p300ΔC protein knocked down to control 
cells (for p300ΔC protein knockdown in these cells, see Figures 4.2a and 3.5a, 
respectively). As shown in Figure 4.4b, the levels of REL and RELA/p65 proteins were 
not affected by knockdown of p300ΔC in either RC-K8 or SUDHL2 cells, as judged by 
Western blotting of whole-cell extracts from RC-K8 and SUDHL2 cells. As a control, we 
show that the levels of β-tubulin were also not affected (Figure 4.4b). Because NF-κB 
DNA-binding activity is generally regulated by post-translational mechanisms (e.g., 
interaction with an IκB inhibitor or nuclear translocation), we next determined whether 
the DNA-binding activity of NF-κB was affected by knockdown of p300ΔC proteins in 
the RC-K8 and SUDHL2 cell lines. That is, we compared the κB site DNA-binding 
activity in cell extracts from p300ΔC knockdown and control cells in an electrophoretic 
mobility shift assay (EMSA). As shown in Figure 4.4c (top panel), knockdown of 
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p300ΔC in both RC-K8 and SUDHL2 cells led to increased κB site DNA-binding 
activity. We have previously shown that the κB site DNA-binding activity consists 
primarily of complexes containing REL in RC-K8 cells (Kalaitzidis et al. 2002) and 
containing p65 and REL in SUDHL2 cells (Alan Yeo, personal communication). The 
different κB site DNA-binding complexes in these two cell types likely accounts for the 
different mobilities of the DNA-protein complexes in the EMSA (Figure 4.4c, top panel). 
In contrast, the DNA-binding activity of transcription factor LSF, which was not among 
the predicted upstream regulators affecting gene expression patterns in RC-K8 cells 
following p300ΔC knockdown (Table 4.2), was not noticeably affected by knockdown of 
p300ΔC (Figure 4.4c, bottom panel). Taken together, these results suggest that NF-κB 
DNA-binding activity and target gene expression are both specifically reduced in the 
presence of p300ΔC expression in the RC-K8 and SUDHL2 DLBCL cell lines. 
 As discussed further in Chapter 5, there are only three DLBCL cell lines reported 
to harbor p300-truncating mutations (RC-K8, SUDHL2, OCLY10) (Garbati et al. 2010, 
Garbati et al. 2011, Barretina et al. 2012, Haery et al. 2014). These three cell lines are all 
classified as being part of the ABC-like/high NF-κB activity DLBCL molecular subtype. 
Thus, to date, p300 truncating mutations, which we have shown can reduce NF-κB DNA-
binding activity and target gene expression, are exclusively found in the DLBCL subtype 
defined by constitutively active NF-κB. 
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4.6 Knockdown of p300ΔC-1087 expression is associated with a decreased MYC-
expression profile in RC-K8 cells 
To validate our prediction that p300ΔC-1087 knockdown is associated with decreased 
MYC target gene expression in RC-K8 cells, we selected 10 MYC-dependent genes that 
had statistically significant (q < 0.05) decreased expression—based on the microarray 
analysis—of at least 1.8-fold following p300ΔC-1087 knockdown (Table 4.4), and 
measured their expression levels by qPCR. Results showed that the mRNA levels of 9 of 
the 10 genes were significantly (p < 0.05) decreased in RC-K8 cells following p300ΔC-
1087 knockdown (Figure 4.5a). Expression of one of the 10 genes (CAD) was not 
significantly changed (Figure 4.5a, white bar). Overall, these results suggest that 
p300ΔC-1087 expression is normally associated with enhanced MYC activity in RC-K8 
cells. 
 Because MYC DNA-binding activity is primarily regulated at the level of protein 
expression (Levens 2010), we used Western blotting of whole-cell extracts to compare 
the levels of MYC protein in control and p300ΔC knockdown cells for both RC-K8 cells 
and SUDHL2 cells. As shown in Figure 4.5b, the levels of MYC protein were reduced in 
both RC-K8 and SUDHL2 cells following knockdown of p300ΔC protein (to 40% and 
60%, respectively, of MYC levels in the corresponding control cells). Of note, the levels 
of MYC were decreased in both cell types even though the basal levels of MYC were 
different in the two cell types. 
 To determine whether enhanced MYC signaling observed in RC-K8 cells might 
be due to a direct interaction with p300ΔC-1087, we performed a co-
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immunoprecipitation (co-IP) to determine whether MYC and p300ΔC-1087 interacted 
with one another in RC-K8 cells. Specifically, whole-cell extracts from RC-K8 cells were 
first subjected to immunoprecipitation with anti-p300 antiserum and then immune 
complexes were subjected to anti-MYC Western blotting (Figure 4.5c). As a control, 
immune complexes were also subjected to Western blotting for REL (Figure 4.5c), which 
we have previously shown interacts with p300ΔC-1087 in RC-K8 cells (Garbati et al. 
2010, Haery et al. 2014). Co-IP showed that MYC co-immunoprecipitated with p300ΔC-
1087, suggesting that these proteins interact in RC-K8 cells. Consistent with our previous 
results, REL was co-immunoprecipitated with p300ΔC-1087 (Figure 4.5c). 
4.7 Gene set enrichment analysis (GSEA) of p300 mutations 
Due to the prevalence of p300/CBP mutations in DLBCL (Haery et al. 2015), we used 
computational analyses to determine whether the effect of the p300ΔC-1087 mutant on 
gene expression patterns in RC-K8 cells can be generalized to p300 truncation mutants in 
other cancer tissue types. To determine whether GSEA could identify known pathways 
that were deregulated in our microarray data (based on our results above), we first asked 
whether GSEA could identify NF-κB and MYC target genes as significantly enriched in 
our dataset (i.e., a proof-of-concept analysis). 
 We used GSEA to determine whether there was a correlation between the RC-K8 
gene expression profiles and specific gene sets from the Molecular Signatures Database 
(MSigDB), which is a compilation of gene sets derived from several types of biological 
experiments and computational predictions (Subramanian et al. 2005, Subramanian et al. 
2007) (broadinstitute.org/gsea/msigdb). Given that (1) p300 is a transcriptional 
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coactivator that is recruited to DNA by specific TFs and (2) we have evidence that NF-
κB and MYC are two TFs that are affected by p300ΔC-1087 in RC-K8 cells, we wanted 
to determine whether GSEA could report enrichment of NF-κB or MYC binding motif-
defined gene sets in our microarray data. To test this, we first ranked all genes in our 
array by a moderated t-statistic computed for the expression change in p300ΔC-1087 
knockdown compared to the control knockdown (i.e., genes whose expression was 
strongly enhanced by p300ΔC-1087 knockdown were at the top of the list, and genes 
whose expression was strongly reduced were at the bottom. We then used GSEA to 
determine whether our ranking showed significant enrichment, at the top or the bottom of 
the list, for NF-κB or MYC-defined gene sets. We found that all 10 MSigDB gene sets 
that were defined by either NF-κB or MYC binding motifs were significantly enriched at 
the top or bottom, respectively, of our ranked list (Table 4.5, Figure 4.6). All ten gene 
sets were associated with a nominal p-value (which represents the significance of the 
enrichment score) of < 0.05, and eight of the ten were associated with a nominal p-value 
of < 0.01. These enrichment patterns support the hypothesis that the transcriptional 
activities of NF-κB and MYC are reduced and enhanced, respectively, by the expression 
of p300ΔC-1087 in RCK8 cells. Furthermore, these results suggest that analyzing the 
promoter motifs associated with differentially expressed genes could be used to identify 
TFs affected by the expression of p300ΔC mutants in other cells.  
 Given that GSEA was able to identify pathways that we have shown are altered in 
RC-K8 cells with p300ΔC-1087 knockdown, we then used GSEA to examine other 
mRNA expression data associated with p300 mutations across other cancer tissue types. 
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The Cancer Cell Line Encyclopedia (CCLE) contains mutational analyses and mRNA 
expression data for a large number of human cancer cell lines (Barretina et al. 2012). 
Premature nonsense mutations in p300, as occur in SUDHL2 cells (Pasqualucci et al. 
2011), would be expected to result in the expression of a C-terminally truncated p300 
protein. To determine whether there was an enriched gene expression pattern among cell 
lines that harbored p300 nonsense mutations (n = 19 cell lines from various cancer cell 
types, Appendix II), we used GSEA to compare the CCLE gene expression patterns of 
cell lines with p300 nonsense mutations to cell lines that expressed both wild-type p300 
and wild-type CBP (n = 853 cell lines from various cancer cell types, Appendix II). 
Given that the cell lines used for this analysis represent a variety of cancer tissue types, 
we anticipated that this analysis would only be able to reveal broad patterns in gene 
expression, and would not necessarily be able to identify gene sets that strongly correlate 
with a specific tissue type or a specific cancer subtype. Thus, in order to determine 
whether this GSEA-based analysis could identify such broad biological states or 
processes, we compared the CCLE expression patterns to the collection of ‘hallmark gene 
sets” and ‘oncogenic signatures’ from the MSigDB (V5.0). These collections contain 
signatures derived by aggregating many MSigDB gene sets to represent well-defined 
biological states or processes, as well as signatures defined directly from microarray gene 
expression data from cancer gene perturbations. Because we were interested in broadly 
defined gene expression patterns, we sought enrichment signatures composed of greater 
than 200 genes, which is more likely to reflect deregulation of a transcriptional regulator 
(e.g., a transcription factor). This analysis did not identify any gene sets composed of 
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greater than 200 genes that were significantly enriched (FDR < 0.25 and nominal p-value 
< 0.05). The only significantly enriched gene sets were composed of less than 30 genes, 
and thus, we do not believe that they are likely to be associated with a mechanism based 
on the expression of p300, which is a broad transcriptional coactivator. Nevertheless, in 
Table 4.6, we list the three pathways (involved in UV response, p53 signaling, and MYC 
signaling) that are significantly enriched in the control cohort (i.e., the 853 cell lines that 
express wild-type p300/CBP). Of note, while MYC signaling was enhanced in RC-K8 
cells expressing p300ΔC-1087, other p300 truncating mutants may have different types 
of effects on MYC activity, which may depend on the tissue type and/or the structure of 
the truncated p300 protein.  
4.8 p300ΔC proteins do not enhance REL-induced transformation of primary 
chicken spleen cells 
We have previously shown that overexpression of wild-type REL can transform primary 
chicken spleen cells in vitro (Gilmore et al. 2001), and that the transforming activity of 
REL can be enhanced either by mutations in REL that reduce its transactivation activity 
(Starczynowski et al. 2003) or by co-expression of the anti-apoptotic protein Bcl-2 
(Gilmore et al. 2001). Because of the dampening effect of p300ΔC proteins on REL-
dependent transactivation (Garbati et al. 2011, Haery 2014) and the toxicity of REL 
hyperactivity in certain cell types (Schwartz and Witte 1988, Bash et al. 1997), we sought 
to determine whether co-expression of p300ΔC mutants would also enhance REL-
dependent lymphoid cell transformation in normal (non-transformed) primary chicken 
spleen cells. To do this, we created spleen necrosis virus retroviral vectors for the 
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expression of the p300ΔC-1087 or p300ΔC-820 alone or in combination with REL 
(Figure 4.7a), and quantitatively assessed their ability to transform chicken spleen cells 
using a liquid outgrowth assay (Gilmore and Gélinas 2015). As shown in Figure 4.7a, 
p300ΔC-1087 and p300ΔC-820 did not by themselves have transforming activity in this 
assay. Co-expression of p300ΔC-1087 or p300ΔC-820 did not enhance the ability of REL 
to transform these cultures, as compared to a control REL-Neo two-gene virus (Figure 
4.7a). Indeed, the REL-p300ΔC viruses had reduced transforming activity compared to 
the REL-Neo control virus, both in terms of the numbers of plates transformed and the 
numbers of days it took for the plates to become transformed (Figure 4.7a). Consistent 
with our previous results (Gilmore et al. 2001), co-expression of chicken Bcl-2 
accelerated REL-dependent transformation (i.e., reduced the number of days it took the 
cells to become transformed from 14 days in the control to 12 days with the REL-Bcl-2 
virus, Figure 4.7a). As controls, we show that the created vectors can direct expression of 
the appropriately sized proteins in 293T cells (Figure 4.7b) and that the p300ΔC proteins 
located to discrete nuclear “speckles” in these cells (Figure 4.7c). Although the 
transformation assay has only been performed one time and with a limited number of 
assay plates, these preliminary results suggest that p300ΔC proteins cannot enhance 
REL-dependent oncogenic transformation, at least in the context of primary chicken 
immune cells.   
4.9 Chapter 4 Summary 
In this chapter, we have investigated the large-scale effects of C-terminally truncating 
p300 mutations on gene expression using primarily the RC-K8 DLBCL cell line. We 
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found that expression of the p300ΔC-1087 protein in RC-K8 cells generally reduces NF-
κB target gene expression. It is shown that knockdown of p300ΔC in RC-K8 or SUDHL2 
cells did not affect the cellular levels of REL or p65 protein, but was associated with an 
increased in the DNA-binding activity of NF-κB transcription factor REL. We also 
showed that expression of p300ΔC is associated with increased MYC protein levels and 
target gene-inducing activity in RC-K8 cells. Finally, in a preliminary set of experiments, 
we show that the p300ΔC proteins from RC-K8 and SUDHL2 cells cannot enhance REL-
dependent transformation of primary chicken spleen cells, suggesting that the REL-
p300ΔC transcriptional complex is not a hyperactive oncogenic initiating complex. 
Overall, these results suggest that p300ΔC proteins do not contribute to initial oncogenic 
transformation, but are associated with changes in gene expression that contribute to NF-
κB- and MYC-dependent optimal growth of cancerous cells. 
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Table 4.1 Summary of differential gene expression for p300ΔC knockdown vs. 
control RC-K8 cells, based on p-value thresholds. 
p-value 
threshold 
p300ΔC 
vs. control Expected FDR 
q 
threshold 
All genes 
(p300ΔC 
vs. control) 
Expression 
filtered 
(p300ΔC 
vs. control) 
0.05 4592 1205 26% 0.25 4294 5066 
0.01 1786 241 13% 0.1 898 2199 
0.005 1109 120 11% 0.05 0 560* 
0.001 300 24 8% 0.01 0 0 
 
Summary of the number of genes with differential expression below or equal to the 
indicated p-value thresholds (p300ΔC vs. control), as well as the number of genes that are 
expected by chance (Expected) based on the total number of genes in the array (n = 
24,094) at each p-value threshold. The FDR (false discovery rate), which is based on the 
number of genes discovered and the number of genes expected, is shown for each p-value 
threshold. Benjamini-Hochberg FDR correction was applied to p-values to obtain FDR-
corrected p-values (‘q’ values). The number of genes with differential expression at 
various q thresholds is shown (All genes). The FDR q-value was then recomputed after 
removing genes that were not expressed above the array-wise median value of at least 
one array (i.e., genes with low overall expression, see section 2.30), and the recomputed 
number of genes at various thresholds is shown (Expression filtered). Asterisk indicates 
the genes that were considered to be statistically significant (see section 4.3), and were 
further analyzed by IPA (see section 4.4). 	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Table 4.2 Upstream regulators of p300ΔC-dependent gene expression patterns in 
RC-K8 cells.  
Upstream 
Regulator Molecule Type 
Bias-corrected 
z-score 
p-value of 
overlap 
Upstream regulators activated by knockdown of p300ΔC-1087 
TNF Cytokine 3.783 1.14E-04 
TGM2 Enzyme 3.738 3.69E-03 
IL1B Cytokine 3.499 8.35E-03 
NF-κB Transcription factor 3.400 4.36E-04 
TP53 Transcription factor 3.147 1.95E-03 
NUPR1 Transcription factor 3.083 4.37E-05 
PTPRJ Phosphatase 2.874 5.15E-03 
SLC29A1 Transporter 2.282 6.39E-04 
MAP4K4 Kinase 2.201 1.82E-04 
PML Transcription factor 2.109 4.08E-03 
Upstream regulators inhibited by knockdown of p300ΔC-1087 
MYC Transcription factor -3.929 6.90E-05 
PTPN1 Phosphatase -2.286 3.02E-03 
IGF1R Transmembrane receptor -2.175 1.12E-03 
KLF15 Transcription factor -2.042 3.98E-05 
BRD4 Kinase and MYC co-activator -2.018 6.26E-04 
 
Fifteen predicted upstream regulators of the mRNA expression pattern in RC-K8 cells 
with p300ΔC-1087 knockdown compared to control RC-K8 cells (sorted by bias-
corrected z-score). The general functions of the upstream regulator is listed under 
Molecular Type. Bias-corrected z-scores and p-values indicating the overlap between 
each target gene set and the microarray results are shown. The analysis was based on the 
fold changes of genes/molecules (n = 560) that were significantly differentially expressed 
(q < 0.05) in RC-K8 cells with p300ΔC-1087 knockdown compared to control RC-K8 
cells. z-scores above 2.0 are considered valid for pathway activation, and z-scores below 
2.0 are considered value for pathway inhibition.  
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Table 4.3 NF-κB Target Genes 
No. Gene ID 
Fold 
change Ratio 
NF-κB in 
RC-K8 cells 
q 
(filtered) p-value Function 
1 IFNG* 6.0 6.0 Activated 3.9E-02 1.2E-05 Interferon 
2 TNFSF4* 2.5 2.5 Activated 4.0E-02 1.1E-04 Cytokine 
3 HIP1* 2.4 2.4 Activated 3.9E-02 5.4E-05 Endocytosis/trafficking 
4 TMOD2* 2.3 2.3 Activated 4.2E-02 3.5E-04 Actin-regulatory 
5 GBP2* 2.3 2.3 Activated 4.0E-02 1.9E-04 GTPase 
6 MYBL1* 2.2 2.2 Affected 4.0E-02 1.4E-04 Transcription factor 
7 IRF1* 2.1 2.1 Activated 4.0E-02 1.1E-04 Transcription factor 
8 CD274* 2.0 2.0 Activated 4.0E-02 1.8E-04 T-cell suppressing 
activity 
9 CD80* 1.9 1.9 Activated 4.4E-02 9.1E-04 Membrane receptor 
10 BIRC3* 1.9 1.9 Activated 4.4E-02 8.4E-04 Inhibitor of apoptosis 
11 IL1A* 1.8 1.8 Activated 4.5E-02 1.0E-03 Cytokine 
12 ZC3H12A 1.7 1.7 Activated 4.5E-02 9.5E-04 Cell death activator 
13 SOCS1 1.7 1.7 Activated 4.9E-02 1.8E-03 Suppressor cytokine 
signaling 
14 HLA-F 1.7 1.7 Activated 4.5E-02 1.1E-03 MHC heavy chain 
15 GADD45B 1.7 1.7 Activated 4.4E-02 8.4E-04 Inhibitor cell growth 
16 NFKBIZ 1.6 1.6 Activated 4.9E-02 1.8E-03 IL6 activator 
17 E2F7 1.6 1.6 Activated 4.5E-02 1.1E-03 Transcription factor 
18 GADD45A 1.6 1.6 Inhibited 4.5E-02 9.9E-04 Inhibitor cell growth 
19 PEA15 1.6 1.6 Affected 4.8E-02 1.5E-03 Negative apoptotic 
regulator 
20 LTB -1.7 0.6 Inhibited 4.8E-02 1.5E-03 Inflammatory inducer 
21 NOP14 -1.7 0.6 Affected 4.9E-02 1.7E-03 Ribosome biogenesis 
22 PPIF -1.8 0.6 Inhibited 4.9E-02 1.7E-03 Protein biosynthesis 
23 IKBKE -2.0 0.5 Inhibited 4.0E-02 1.8E-04 NF-κB activation 
24 ODC1* -3.2 0.3 Inhibited 4.0E-02 8.8E-05 Protein biosynthesis 
25 CCL17 -4.2 0.2 Inhibited 3.9E-02 4.2E-05 Cytokine 
26 SFTPA1 -4.3 0.2 Affected 4.2E-02 4.1E-04 Pathogen defense 
 
List of differentially expressed NF-κB target genes, q < 0.05. Genes are numbered (No.) 
arbitrarily for referencing in text. Asterisks indicate genes whose expression was 
validated by qPCR (Figure 4.4). Fold change designates the fold change in expression in 
p300ΔC knockdown vs. control RC-K8 cells obtained by microarray. Ratio indicates the 
fold change values as ratios of the gene expression in knockdown cells as compared to 
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control cells obtained by microarray. ‘NF-κB in RC-K8 cells’ indicates how the 
expression of the given gene observed in the microarray (i.e. fold change and ratio 
columns) affects overall NF-κB signaling in RC-K8 cells; this is reported by IPA and 
based on literature reports; ‘activated’ indicates the observed fold change in that gene is 
associated with activated NF-κB signaling; ‘inhibited’ indicates the observed fold change 
in that gene is associated with inhibited NF-κB signaling; and ‘affected’ indicates the 
gene is regulated by NF-κB, but there is no consensus on the directionality of this effect 
based on literature reports. q value reports the expression filtered FDR-corrected p-values 
(‘q’ values) associated with the fold change for each gene. p-value reports the p-value 
associated with the fold change for each gene (based on a modified t-test). ‘Function’ is a 
brief description of the known protein function; MHC, major histocompatibility complex. 	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Table 4.4 MYC Target Genes 
No. Gene ID 
Fold 
change Ratio 
MYC in 
RC-K8 cells 
q 
(filtered) p-value Function 
1 ODC1* -3.2 0.31 Inhibited 4.0E-02 8.8E-05 Protein biosynthesis 
2 FASN* -2.9 0.34 Inhibited 4.2E-02 3.3E-04 Fatty acid synthesis 
3 SRM* -2.5 0.40 Inhibited 4.4E-02 7.3E-04 Spermidine biosynthesis 
4 NME1* -2.3 0.43 Inhibited 4.4E-02 7.2E-04 Kinase 
5 CAD* -2.2 0.45 Inhibited 4.2E-02 2.7E-04 Pyrimidine biosynthesis 
6 PFAS* -2.2 0.45 Inhibited 4.0E-02 2.1E-04 Purine biosynthesis 
7 AIMP2* -2.1 0.48 Inhibited 4.2E-02 2.6E-04 Unknown 
8 LDHA* -2.0 0.50 Inhibited 4.3E-02 5.0E-04 Anaerobic glycolysis 
9 PGK1* -2.0 0.50 Inhibited 4.5E-02 1.1E-03 Kinase 
10 CDK4* -1.8 0.56 Inhibited 4.5E-02 9.7E-04 Cyclin-dependent kinase 
11 MINA -1.8 0.56 Inhibited 4.4E-02 5.9E-04 Cell growth 
12 PNO1 -1.8 0.56 Inhibited 4.4E-02 8.3E-04 Immunity 
13 DNPH1 -1.7 0.59 Inhibited 4.4E-02 8.3E-04 Proliferation 
14 NOLC1 -1.7 0.59 Inhibited 4.5E-02 9.7E-04 Unknown 
15 PHB -1.7 0.59 Inhibited 5.0E-02 2.1E-03 Tumor suppression 
16 DBI -1.5 0.67 Inhibited 5.0E-02 2.2E-03 Lipid metabolism 
17 GADD45A 1.6 1.60 Inhibited 4.5E-02 9.9E-04 Inhibitor cell growth 
18 CD48 1.7 1.70 Inhibited 4.9E-02 1.8E-03 Immune cell activation 
19 HLA-B 1.7 1.70 Inhibited 4.4E-02 7.2E-04 MHC heavy chain 
20 LAMB3 1.8 1.80 Inhibited 4.4E-02 7.6E-04 Basement membrane 
21 CD274 2.0 2.00 Inhibited 4.0E-02 1.8E-04 T-cell suppressing 
activity 
22 DDB2 2.0 2.00 Inhibited 4.2E-02 4.4E-04 DNA damage response 
23 HLA-E 2.0 2.00 Inhibited 4.2E-02 3.9E-04 MHC heavy chain 
24 SERPINE2 2.1 2.10 Inhibited 4.0E-02 1.8E-04 Protease inhibitor 
25 FADS2 2.3 2.30 Inhibited 4.2E-02 2.4E-04 Fatty acid metabolism 
26 GBP2 2.3 2.30 Inhibited 4.0E-02 1.9E-04 GTPase 
27 CTSB 2.5 2.50 Inhibited 4.4E-02 6.1E-04 APP proteolytic 
processing 
28 RRM2B 2.5 2.50 Inhibited 4.0E-02 1.3E-04 DNA synthesis 
29 
ACAT1 -2.1 0.48 Affected 4.0E-02 1.7E-04 
Biosynthesis/metabolis
m 
30 POLR2G -2.1 0.48 Affected 4.2E-02 3.4E-04 Transcription initiation 
31 RUVBL1 -2.1 0.48 Affected 4.2E-02 3.1E-04 ATPase 
32 DHFR -2.0 0.50 Affected 4.6E-02 1.2E-03 Purine synthesis 
33 POLR1B -1.9 0.53 Affected 4.5E-02 1.1E-03 rRNA transcription 
34 MAT2A -1.8 0.56 Affected 4.4E-02 6.7E-04 Biosynthesis 
35 SGK1 1.6 1.60 Affected 4.9E-02 2.0E-03 Kinase 
36 GADD45B 1.7 1.70 Affected 4.4E-02 8.4E-04 Inhibitor cell growth 
37 PLA1A 2.0 2.00 Affected 4.4E-02 8.4E-04 Liposome activity 
38 ITM2B 2.6 2.60 Affected 4.0E-02 1.2E-04 Inhibits amyloid 
deposition 
39 FLNA -1.7 0.59 Activated 4.4E-02 7.7E-04 Actin regulation 
40 ASS1 1.8 1.80 Activated 4.9E-02 1.9E-03 Arginine biosynthesis 
41 GH1 2.0 2.00 Activated 4.9E-02 1.8E-03 Growth hormone 
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List of differentially expressed MYC target genes, q < 0.05. Genes are numbered (No.) 
arbitrarily for referencing in text. Asterisks indicate genes whose expression was 
validated by qPCR. Fold change designates the fold change in expression in p300ΔC 
knockdown vs. control RC-K8 cells obtained by microarray. Ratio indicates the fold 
change values as ratios of the gene expression in knockdown cells as compared to control 
cells obtained by microarray. ‘MYC in RC-K8 cells’ indicates how the expression of the 
given gene observed in the microarray (i.e. fold change and ratio columns) affects overall 
MYC signaling in RC-K8 cells; this is reported by IPA and based on literature reports; 
‘activated’ indicates the observed fold change in that gene is associated with activated 
MYC signaling; ‘inhibited’ indicates the observed fold change in that gene is associated 
with inhibited MYC signaling; and ‘affected’ indicates the gene is regulated by MYC, but 
there is no consensus on the directionality of this effect based on literature reports. The q-
value indicates the expression filtered FDR-corrected p-values (‘q’ values) associated 
with the fold change for each gene. The p-value indicates the p-value associated with the 
fold change for each gene (based on a modified t-test). ‘Function’ is a brief description of 
the known protein function; MHC, major histocompatibility complex; APP, amyloid 
precursor protein. 	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Table 4.5 Gene Set Enrichment Analysis (GSEA) of NF-κB and MYC defined gene 
sets in RC-K8 cells with p300ΔC-1087 knocked down 
Gene Set Name Size NES 
FDR q 
value 
Nominal 
p value 
V$NFKAPPAB_01 
www.broadinstitute.org/gsea/msigdb/cards/V$NFKAPPAB_01 
248 1.59 0.1326 < 0.001 
V$NFKB_Q6_01 
broadinstitute.org/gsea/msigdb/cards/V$NFKB_Q6_01 
229 1.49 0.1634 2.25E-03 
V$NFKB_Q6 
broadinstitute.org/gsea/msigdb/cards/V$NFKB_Q6 
249 1.44 0.1787 < 0.001 
V$NFKB_C 
broadinstitute.org/gsea/msigdb/cards/V$NFKB_C 
256 1.43 0.1880 8.99E-03 
V$NFKAPPAB65_01 
broadinstitute.org/gsea/msigdb/cards/V$NFKAPPAB65_01 
235 1.36 0.2190 1.32E-02 
V$MYCMAX_02 
broadinstitute.org/gsea/msigdb/cards/V$MYCMAX_02 
260 -1.29 0.1762 2.82E-02 
V$MYCMAX_03 
broadinstitute.org/gsea/msigdb/cards/V$MYCMAX_03 
245 -1.46 0.0701 3.58E-03 
V$MYCMAX_B 
broadinstitute.org/gsea/msigdb/cards/V$MYCMAX_B 
259 -1.47 0.0649 1.83E-03 
V$NMYC_01 
broadinstitute.org/gsea/msigdb/cards/V$NMYC_01 
266 -1.49 0.0596 1.80E-03 
V$MYCMAX_01 
broadinstitute.org/gsea/msigdb/cards/V$MYCMAX_01 
247 -2.16 0.0001 < 0.001 
 
Enrichment of NF-κB or MYC target gene sets in RC-K8 cells with p300ΔC-1087 
knocked down relative to control RC-K8 cells. Gene expression values from the 
microarray were ranked according to the moderated t-statistic and ranked lists were used 
to perform pre-ranked GSEA analyses using NF-κB or MYC DNA-binding site defined 
gene sets obtained from the Molecular Signatures Database (MSigDB, C3 Motif Gene 
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Sets, TFT Transcription Factor Targets), version 4.0. Gene set name lists the name 
provided by MSigDB and a link to the gene set; size lists the number of genes in the gene 
set that overlap with the genes in the ranked list; NES lists the normalized enrichment 
score (the enrichment score normalized to gene set size); FDR q-value lists the FDR-
corrected p-value; nominal p value lists the p value computed from the NES and is used 
to compute significance of each gene set, which can be equal to 0 since it is computed by 
permutation. p-values of 0 are reported as p < 0.001 because 1000 permutations were run. 
Rows are sorted by descending NES. 	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Table 4.6 Gene Set Enrichment Analysis (GSEA) of human cancer cell lines 
containing with p300 nonsense mutations as compared to cell lines with wild-type 
p300/CBP 
Gene Set Name Size NES FDR q 
value 
Nominal 
p value 
HALLMARK_UV_RESPONSE_UP       
Genes up-regulated in response to ultraviolet 
(UV) radiation  
26 -1.613 0.1039 0.0091 
HALLMARK_P53_PATHWAY              
Genes involved in p53 pathways and 
networks 
27 -1.581 0.0688 0.0178 
HALLMARK_MYC_TARGETS_V1            
A subgroup of genes regulated by MYC - 
version 1 (v1) 
27 -1.506 0.0827 0.0367 
 
GSEA report results for a comparison of cancer cell lines harboring p300 nonsense 
mutations (n = 19) to cancer cell lines with wild-type p300/CBP (n = 853). Gene sets 
enriched with FDR < 0.25 and nominal p-value < 0.05 are shown. Size designates the 
number of genes in the gene set after filtering out those genes that are not in the 
expression dataset. Normalized enrichment score (NES) indicates the degree to which 
this gene set is overrepresented at the top or bottom of the ranked list of genes in the 
wild-type p300/CBP cohort expression dataset. A negative NES indicates that the 
designated gene set is expressed at relatively lower levels in cancer cell lines with p300 
nonsense mutations (n = 19) as compared to cancer cell lines with wild-type p300/CBP (n 
= 853). 	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Figure 4.1 Half-life of wild-type and mutant p300ΔC proteins in BJAB, RC-K8 and 
SUDHL2 DLBCL cell lines 
(a) Anti-p300 Western blot of 25 µg of whole-cell extracts from BJAB, SUDHL2 and 
RC-K8 cells. The relevant p300 proteins are indicated. (b) Expression of p300 proteins in 
SUDHL2, RC-K8, and BJAB cells treated with cycloheximide (CHX) for the indicated 
times. Anti-p300 Western blotting was performed on 25 µg of whole-cell extract from the 
indicated cell lines. Western blotting was performed with anti-β-tubulin antiserum as a 
control. (c) Expression of the relevant p300 proteins was quantified by densitometric 
analysis and is shown relative to the levels of the p300 protein in control cells that were 
not treated with CHX (0 h; relative value of 100). A representative result of from least 
two independent experiments is shown. 
 
	    
	  	  
143 
Figure 4.1 Half-life of wild-type and mutant p300ΔC proteins in BJAB, RC-K8 and 
SUDHL2 DLBCL cell lines 
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Figure 4.2 p300ΔC knockdown in RC-K8 cells  
(a) Expression of p300ΔC-1087 in RC-K8 cells expressing a control or p300-specific 
shRNA. Anti-p300 Western blotting was performed on 40 µg of whole-cell extract from 
four independent samples of RC-K8 cells stably expressing p300 or control shRNA 
(knockdowns (KD) 1, 2). Western blotting was performed with anti-β-tubulin antiserum 
as a control. (b) mRNA extracts from RC-K8 cells expressing p300 shRNA or control 
shRNA were subjected to real-time qPCR using gene-specific primers as indicated. Gene 
expression values from RC-K8 cells expressing p300 shRNA were compared to values 
from RC-K8 cells expressing control shRNA, and are shown as mRNA fold change 
following p300ΔC-1087 knockdown. Error bars represent the standard error of the mean 
(n = 3 technical replicates). The discrepancy in TRAF1 mRNA expression between 
replicates may be due to variability between independent shRNA knockdowns. 
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Figure 4.2 p300ΔC knockdown in RC-K8 cells  
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Figure 4.3 Microarray probe level analysis of EP300 mRNA levels 
Individual probe expression for the p300 gene obtained from microarray analysis of RC-
K8 and BJAB cells. Expression values from BJAB cell samples is shown in red; (control 
BJAB = dark red, BJAB with p300ΔC-1087 overexpressed = light red). Expression 
values from RC-K8 samples is shown in blue: (control RC-K8 = light blue, RC-K8 with 
p300ΔC-1087 knocked down = light blue). Location of probes spanning the gene are 
shown on the x-axis. Probes 2-13 correspond to sequences that are contained in p300ΔC-
1087; probes 14-25 correspond to p300 sequences that are deleted in p300ΔC-1087. 
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Figure 4.4 Knockdown of p300ΔC expression is correlated with increased NF-κB 
DNA-binding activity in RC-K8 cells 
(a) cDNA from reverse transcribed total RNA from RC-K8 cells expressing p300 shRNA 
or a control shRNA was subjected to real-time qPCR using gene-specific primers. mRNA 
expression values from RC-K8 cells expressing p300 shRNA were compared to values 
from RC-K8 cells expressing control shRNA to determine the fold change in expression. 
Error bars represent standard error of the mean (n =2 replicates of the same mRNA 
analyzed by microarray, each replicate was tested in triplicate). Asterisks represent 
significant fold changes (p<0.05) in a one-tailed students t-test. (b) Anti-p65 or anti-REL 
Western blotting was performed using 25 µg whole-cell extract from RC-K8 or SUDHL2 
cells expressing p300 or control shRNA. Western blotting was performed with anti-β-
tubulin antiserum as a control. (c) EMSA using a κB-site was performed using 25 µg 
whole-cell extract from RC-K8 or SUDHL2 cells expressing p300 or control shRNA. In 
the bottom panel of the EMSA, 5 µg of whole-cell extracts were incubated with an LSF 
binding site probe. 
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Figure 4.4 Knockdown of p300ΔC expression is correlated with increased NF-κB 
DNA-binding activity in RC-K8 cells 
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Figure 4.5 Knockdown of p300ΔC reduces expression of a MYC target-gene profile 
in RC-K8 cells 
(a) Reverse transcribed total RNA from RC-K8 cells expressing p300 shRNA or a control 
shRNA was subjected to real-time qPCR using gene-specific primers. mRNA expression 
values from RC-K8 cells expressing p300 shRNA were compared to values from RC-K8 
cells expressing control shRNA to determine the fold change in expression. Error bars 
represent standard error of the mean (n =2 replicates of the same mRNA analyzed by 
microarray, each replicate was tested in triplicate). Asterisks and gray shading represent 
significant fold changes (p<0.05) in a one-tailed students t-test. (b) Anti-MYC Western 
blotting was performed using 25 µg of whole-cell extract from RC-K8 or SUDHL2 cells 
expressing p300 or control shRNA. Western blotting was performed with anti-β-tubulin 
antiserum as a control. The relative level of MYC in each p300 knockdown was found by 
densitometry and is indicated below each lane as a fraction of MYC expressed in the 
corresponding control knockdown (1.0). (c) Whole-cell extracts of RC-K8 cells were 
immunoprecipitated with normal rabbit IgG or anti-p300 antiserum. Immunoprecipitates 
were subjected to anti-MYC or anti-REL Western blotting, as indicated. Ten percent 
(100 µg) and 1% (10 µg) of whole-cell extract used for immunoprecipitate was included 
as an input for the anti-MYC blot and 10% (100 µg) of whole-cell extract used for 
immunoprecipitate was included as input for the anti-REL blot. 
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Figure 4.5 Knockdown of p300ΔC reduces expression of a MYC target-gene profile 
in RC-K8 cells 
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Figure 4.6 Gene Set Enrichment Plots of NF-κB and MYC gene set enrichment in 
RC-K8 cells with p300ΔC-1087 knockdown 
Enrichment of NF-κB or MYC target gene sets in RC-K8 cells with p300ΔC knocked 
down relative to control RC-K8 cells. Gene expression values from the microarray were 
ranked according to the moderated t-statistic and ranked lists were used to perform pre-
ranked GSEA analyses using NF-κB or MYC DNA-binding site defined gene sets 
obtained from the Molecular Signatures Database (MSigDB, C3 Motif Gene Sets, TFT 
Transcription Factor Targets), version 4.0. Results reported in Table 4.5. Each gene set 
name is indicated at the top of the plot; FDR q-value lists the FDR-corrected p value; 
nominal p value lists the p value computed from the NES and indicates significance of 
each gene set, which can be equal to 0 since it is computed by permutation. p-values of 0 
are reported as p < 0.001 because 1000 permutations were run; NES lists the normalized 
enrichment score (the enrichment score normalized to gene set size). A positive NES 
indicates gene sets that were upregulated in RC-K8 cells with p300ΔC-1087 knocked 
down, relative to control RC-K8 cells. A negative NES indicates gene sets that were 
downregulated in RC-K8 cells with p300ΔC-1087 knocked down, relative to control RC-
K8 cells. Top panel, NF κB gene sets; bottom panel, MYC gene sets. The ranking of 
genes in the ordered list from RC-K8 cells is shown on the x-axis. The black bars (middle 
portion of the plot) represent members of the gene set that appear in the ranked list of 
genes. 
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Figure 4.6 Gene Set Enrichment Plots of NF-κB and MYC gene set enrichment in 
RC-K8 cells with p300ΔC-1087 knockdown 
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Figure 4.7 REL-directed transformation of primary chicken spleen cells is not 
enhanced by co-expression of p300ΔC proteins  
(a) General structures of the retroviral vectors used to infect primary chicken spleen cells 
are shown. Their activities in liquid outgrowth transformation are shown as the number of 
plates transformed over the number of plates infected, and the average time in days until 
the cells were transformed. (b) Expression of p300ΔC (top panel) and REL (lower panel) 
was determined by Western blotting performed on 30 µg of whole-cell extract from 293T 
cells transfected with either pcDNA3.1 expression vectors or spleen necrosis virus 
(SNV)-based retroviral vectors for the expression of the indicated proteins, and non-
transfected control 293T cells. (c) 293T cells were transfected with 2 µg of the indicated 
retroviral vector (listed on left). Indirect immunofluorescence was performed using either 
a primary anti-REL (column 1) or anti-p300 (column 3) antibody, and an FITC-
conjugated anti-rabbit secondary antibody. Nuclei were visualized by DAPI staining 
(columns 2 and 4).  
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Figure 4.7 REL-directed transformation of primary chicken spleen cells is not 
enhanced by co-expression of p300ΔC proteins  
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CHAPTER 5 
DISCUSSION 
5.1 Summary 
The research described in this thesis focuses on two human DLBCL cell lines, RC-K8 
and SUDHL2, which express C-terminally truncated HAT-deficient forms of the 
transcriptional coactivator protein p300, herein termed p300ΔC-1087 and p300ΔC-820, 
respectively. The p300ΔC-820 protein is only the second truncated p300 mutant that has 
been functionally characterized in a human DLBCL cell line; the p300ΔC-1087 protein in 
RC-K8 cells was the first such protein characterized in human DLBCL (Garbati et al. 
2010, Garbati et al. 2011). In chapter 3, molecular and biological properties of the HAT-
deficient p300ΔC-820 protein from SUDHL2 cells are characterized. Like p300ΔC-1087 
in RC-K8 cells (Garbati et al. 2011), p300ΔC-820 is shown to contribute to SUDHL2 cell 
growth, as knockdown of p300ΔC-820 expression compromised the liquid media and soft 
agar growth of SUDHL2 cells. The results in chapter 4 primarily focus on the large-scale 
effects on gene expression of knockdown of p300ΔC-1087 in RC-K8 cells. In particular, 
it is shown that knockdown of p300ΔC-1087 has effects on gene expression patterns 
controlled by two transcription factors (TFs), NF-κB and MYC, that play major roles in 
B-cell lymphomagenesis and cancer development in general.  
5.2 p300 truncations in the DLBCL cell lines used in this research 
Several lines of evidence make it clear that the RC-K8 and SUHDL2 cell lines express C-
terminally truncated forms of p300. First, both cell lines express p300-reactive proteins 
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that are smaller than wild-type p300 on SDS-polyacrylamide gels (Figures 3.2b and 4.1a; 
Haery et al. 2014). Second, these proteins are detected with p300 antiserum that 
recognizes N-terminal sequences, but are not detected by antiserum against C-terminal 
sequences (Garbati et al. 2010, Haery et al. 2014). Third, characterization of genomic and 
cDNA sequences has shown that both cell lines are predicted to encode C-terminally 
truncated proteins. Specifically, the RC-K8 cell line has a genomic alteration after exon 
17 that causes it to express a protein with aa 1-1087 of p300, as well as 25 aa from 
inserted sequences at this region (Garbati et al. 2010, Garbati et al. 2011). Although the 
RC-K8 cell line has one EP300 allele that appears to be wild-type, there is considerably 
reduced mRNA expression from the apparently wild-type allele and no wild-type p300 
protein can be detected (Garbati et al. 2011) (Figure 3.2a, b). The SUDHL2 cell line has a 
nonsense mutation (C2461T) at codon 821. Additionally, SUDHL2 has been reported to 
have only a single EP300 allele (i.e., a hemizygous mutation) (Pasqualucci et al. 2011), 
and DNA sequencing of a PCR product of the EP300 locus from SUDHL2 genomic 
DNA showed that a wild-type sequence cannot be detected at codon 821 (Figure 3.2c). 
Pasqualucci et al. (2011) reported that no wild-type p300 protein was expressed in 
the BJAB, Farage and SUDHL8 cell lines. The results reported herein (see Figure 3.2a) 
contradict that previously published report (Pasqualucci et al. 2011) on the lack of full-
length p300 protein in the BJAB, Farage, and SUDHL8 DLBCL cell lines. That is, we 
were able to show that multiple cell line stocks of these three cell lines, including ones 
used in the conflicting report, express easily detectable levels of full-length p300 protein 
(Figure 3.2a). Furthermore, we detected full-length p300 mRNA in BJAB cells using 
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gene-specific probes that spanned the length of the protein (Figure 4.3). Thus, we believe 
that the lack of full-length p300 protein in these three cell lines reported in Pasqualucci et 
al. (2011) was due to a technical error. Northern blotting data reported by Pasqualucci et 
al. (2011) further support our results, in that the BJAB, Farage, and SUDHL8 cell lines 
express detectable levels of full-length p300 mRNA, whereas SUDHL2 cell do not. 
Moreover, full-length p300 protein expression in BJAB and Farage cells has been 
reported by several others (Eckner et al. 1996, Cotter and Robertson 2000, Li et al. 2000, 
Wang et al. 2000, Cerchietti et al. 2010). 
5.3 Evidence for the contribution of mutant p300 proteins to B-cell 
lymphomagenesis 
A variety of evidence suggests that HAT-deficient p300 mutant proteins can play an 
active role in B-cell lymphomagenesis. First, expression of the HAT-deficient p300 
proteins is preferentially retained in both the RC-K8 and SUDHL2 cell lines, whereas the 
wild-type allele is silenced or absent, respectively (Garbati et al. 2010, Haery et al. 2014) 
(Figure 3.2d); if the lack of p300 protein activity promoted the growth of these cells, one 
would expect that the mutant protein would not be expressed after extended passage in 
vitro. Second, knockdown of p300ΔC mutant protein expression reduces the growth of 
both the RC-K8 and SUDHL2 DLBCL cell lines (Garbati et al. 2011, Haery et al. 2014). 
Third, HAT-deficient p300 mutants localize to sites of active transcription in cell nuclei, 
interact with the lymphomagenic TF REL, and affect transcription of REL and MYC 
target genes (Garbati et al. 2010, Garbati et al. 2011, Haery et al. 2014) (Chapters 3 and 
4).  
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Other evidence also supports a role for HAT-deficient p300 proteins in lymphoid 
cell growth. Expression of a HAT-deficient mutant of p300 increases the proliferation of 
hematopoietic stem cells in which the wild-type p300 locus has been disrupted, whereas 
re-expression of wild-type p300 does not increase their proliferation (Kimbrel et al. 
2009). As shown in chapter 3, DLBCL cell lines that express HAT-defective p300 
mutants have generally lower levels of histone H3 acetylation at K14 and K18 (Haery et 
al. 2014). Low levels of H3K14 and H3K18 acetylation have been associated with 
proliferation in other cell types (Barber et al. 2012), and CBP/p300 catalyze nearly all 
H3K18 acetylation in mice (Jin et al. 2011). Similar to the effects of mutations on HAT 
activity in DLBCL, the HBZ protein of the oncogenic Human T-cell Leukemia Virus 
type 1 (HTLV-1) binds to and inactivates the HAT domains of CBP and p300, and 
consequently reduces cellular levels of H3K18 acetylation (Clerc et al. 2008, Wurm et al. 
2012). Inhibition of CBP/p300 HAT activity may therefore also be important for 
HTLV1-induced T-cell leukemia. Overall, the expression of HAT domain-deficient p300 
proteins appears to be different from the complete absence of p300 protein, a point that is 
discussed in greater detail below (section 5.10). 
5.4 Effects of the C-terminal truncations found in RC-K8 and SUDHL2 cells on the 
activity of p300 
Despite the substantial C-terminal truncations in the p300ΔC proteins from RC-K8 and 
SUDHL2 cells, these mutant proteins retain certain properties that are indistinguishable 
from wild-type p300. First, p300ΔC-820 and p300ΔC-1087 both localize to subnuclear 
“speckles’ (Garbati et al. 2011, Haery et al. 2014), which have been identified as sites of 
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active transcription to which wild-type p300 can also localize (Spector 1993, von Mikecz 
et al. 2000). Second, in co-immunoprecipitation experiments, both proteins can interact 
with NF-κB family member REL (Figure 3.4c, d and Garbati et al. 2010), an interaction 
that occurs through the CH1 domain that is retained in both p300ΔC proteins (Figure 
3.4b). Third, the half-lives of both p300ΔC proteins (~4.5 h) are similar to that of wild-
type p300 (Figure 4.1c) (Jain et al. 2012).  
 Other activities of these p300ΔC proteins are clearly altered. First, they lack the 
HAT domain and are therefore catalytically inactive. Likely due to the absence of the 
HAT domain, both p300ΔC proteins have a reduced ability to enhance REL-dependent 
transactivation in reporter assays (Garbati et al. 2011, Haery et al. 2014). As such, 
p300ΔC mutants would be expected to be able to attenuate expression of transcription 
factor-specific target genes by preventing the interaction of transcription factors with 
other functionally intact coactivators or by directing the formation of altered scaffolds at 
sites of transcription. 
5.5 Effects of p300ΔC-1087 protein expression of REL/NF-κB target gene expression 
in RC-K8 cells 
Because of the widespread role of HAT domain coactivators in gene expression and the 
reduction in cell growth by knockdown of p300ΔC proteins in both RC-K8 and SUDHL2 
cells, we were interested in determining the effect of p300ΔC knockdown on gene 
expression in these cells. Most of these analyses were performed in the RC-K8 cell line 
because of our more extensive understanding of altered pathways and proteins in this cell 
line (Kalaitzidis et al. 2002, Kalaitzidis and Gilmore 2002, Compagno et al. 2009, 
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Garbati et al. 2010, Garbati et al. 2011) in large part due to the previous characterization 
of several NF-κB pathway mutations that are present in RC-K8 cells. Specifically, RC-
K8 cells have inactivating mutations in the direct REL/NF-κB inhibitor IκBα (Kalaitzidis 
et al. 2002) and in the NF-κB pathway inhibitor A20 (Compagno et al. 2009). Due to 
these mutations, RC-K8 cells have high levels of nuclear REL protein, REL DNA-
binding activity, and REL target gene expression (Kalaitzidis et al. 2002). Moreover, 
p300ΔC-1087 has been shown to interact with REL in RC-K8 cells (Garbati et al. 2010, 
Garbati et al. 2011). Finally, inactivation of either REL (by ectopic expression of IκBα) 
(Kalaitzidis et al. 2002) or p300ΔC-1087 (by shRNA knockdown) (Garbati et al. 2011) 
reduces the proliferation of RC-K8 cells. 
To analyze effects of p300ΔC-1087 on the expression of REL/NF-κB target 
genes, we first established pools of RC-K8 cells expressing either a retrovirally 
transduced shRNA to knock down p300ΔC-1087 or a control shRNA. Western blotting 
showed that p300ΔC-1087 expression was reduced by approximately 90% in RC-K8 
cells as compared to control cells. We then analyzed the expression of either select 
REL/NF-κB target genes (chapter 3) or large-scale changes in REL/NF-κB target gene 
expression (chapter 4).  
 In terms of select REL/NF-κB target genes, knockdown of p300ΔC-1087 resulted 
in increased expression of the NF-κB target genes IκBα and A20, (Figure 3.6a, b, Figure 
4.2a), as well a corresponding increase in protein expression from these two target genes. 
Furthermore, a ChIP analysis of the A20 promoter in RC-K8 cells showed occupancy by 
p300ΔC-1087 (Figure 3.6c), supporting a model in which p300ΔC-1087 reduces the 
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expression of NF-κB gene networks through REL-dependent recruitment to NF-κB target 
gene promoters. Overall, we used qPCR to measure the change in mRNA expression of 
seven NF-κB target genes that are expressed at high levels in RC-K8 relative to other 
DLBCL cell lines (Kalaitzidis et al. 2002), and are thus likely to be predominantly 
regulated by REL/NF-κB signaling, which is constitutively active in RC-K8 cells. We 
found that mRNAs for four of the seven genes were significantly upregulated in RC-K8 
cells upon p300 knockdown (Figure 3.6a), indicating that the expression of p300ΔC-1087 
in RC-K8 cells is normally associated with a reduction in NF-κB target gene expression. 
Of note to us, one highly expressed NF-κB target gene in RC-K8 cells whose expression 
was affected by p300ΔC-1087 was CD274 (Table 4.3, Figure 4.4), which is known to 
suppress the immune response (Wilcox et al. 2009, Huang et al. 2013), and thus may 
contribute to RC-K8 cell progression and escape from immunity. 
In chapter 4, genome-wide analysis of gene expression changes upon knockdown 
of p300ΔC in RC-K8 cells indicated that NF-κB-related and regulated gene networks are 
normally reduced by p300ΔC-1087 expression in these cells. That is, knockdown of 
p300ΔC-1087 in RC-K8 cells resulted in the up-regulation of many transcripts. An IPA 
investigation of gene expression changes in RC-K8 cells with p300ΔC-1087 knocked 
down showed that NF-κB complex was among the activated pathways with a significant 
and positive z-score (≥ 2.0) and a significant overlap p-value (p < 0.01). IPA analysis also 
reported four significantly altered pathways where the apex pathway molecule is either an 
NF-κB target gene and/or an activator of NF-κB. Pathways with significantly positive z-
scores in the IPA that are controlled by products of NF-κB target genes include TNF 
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(+3.783) (Collart et al. 1990), IL-1β (3.499) (Hiscott et al. 1993), TP53 (+3.147) (Kirch 
et al. 1999, Jacque et al. 2013), and NUPR1 (+3.083) (Kallwellis et al. 2006). Thus, the 
activated output of p300ΔC-1087 knockdown in RC-K8 cells appears to be largely 
activation and implementation of REL/NF-κB signaling. Finally, at least two of these 
pathways—TP53 and TNF—are, in several contexts, inhibitors of cell growth, which is 
consistent with the reduced proliferation phenotype of RC-K8 cells in which p300ΔC-
1087 is knocked down (Garbati et al. 2011). Given that the levels of REL and p65 protein 
were not altered in RC-K8 and SUDHL2 cells upon knockdown of p300ΔC (Figure 
4.4b), the increased NF-κB signaling is likely a result of an increase in NF-κB/REL 
protein activity, either due to reduced interaction with an IκB inhibitor or increased 
nuclear localization (or both). Consistent with this hypothesis, κB-site binding activity is 
increased in RC-K8 and SUDHL2 cells with p300ΔC knocked down (Figure 4.4c). 
5.6 How dampened NF-κB activity might contribute to DLBCL cell growth and 
survival 
Our results suggest a model by which truncated p300 proteins temper the ability of 
REL/NF-κB to activate target genes and their accessory pathways in order to maintain an 
optimal oncogenic gene program in certain DLBCL cell lines, e.g., as in RC-K8. This 
subtle modification in REL/NF-κB-dependent transcriptional activation by truncated 
p300 is essential for optimal cellular growth. Nevertheless, it is important to note that 
REL/NF-κB-dependent transcriptional activation is still overall high in RC-K8 and 
SUDHL2 cells as compared to many other DLBCL cell lines; however, it is not as high 
as it would be in the absence of moderating mutations, such as provided by p300ΔC. 
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Moreover, the REL/NF-κB-dependent and activated gene expression program is required 
for the growth of RC-K8 and SUDHL2 ABC-like DLBCL cells. 
Several studies have shown that reducing the transactivation activity of REL 
enhances its oncogenic activity. Firstly, REL mutants lacking either of its two 
transactivation domains (TADs) show decreased levels of gene expression, but have an 
enhanced ability to malignantly transform chicken spleen cells (Starczynowski et al. 
2003, Gilmore and Gelinas 2015). Furthermore, expression of a REL mutant with 
deletion of one TAD can enhance the transformed state of the human BJAB B-lymphoma 
cell line (Chin et al. 2009). Indeed, the viral oncoprotein v-Rel is a less potent 
transactivator than normal c-Rel, due to the deletion of a C-terminal TAD in v-Rel 
(Richardson and Gilmore 1991). Reduced transactivation activity of REL/NF-κB in these 
oncogenic situations is thought to cause chronic low-level signaling and gene regulatory 
activity, which is more suitable for oncogenic growth than no, high-level, or cycling 
REL/NF-κB-directed transactivation (reviewed in Gilmore 1999). Considering these 
previous findings as well as dampening effect that p300ΔC proteins have on the ability of 
REL to increase gene expression, we believe that p300ΔC contributes to oncogenicity in 
DLBCL by subtly reducing REL/NF-κB-directed transactivation. The interaction of REL 
and p300ΔC proteins, and the retention of p300ΔC expression in RC-K8 and SUDHL2 
cells in the absence of wild-type p300 expression are also consistent with p300ΔC 
proteins playing a role in REL-driven oncogenicity in these cells.  
Nevertheless, in preliminary experiments, co-expression of the p300ΔC proteins 
from RC-K8 and SUDHL2 cells did not enhance the ability of REL to transform primary 
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chicken spleen cells (Figure 4.7). Thus, the p300ΔC-REL complex may not be an 
efficient initiator of the transformed state in B cells. However, it is important to note that 
the chicken cell transformation assays were performed in cells that presumably express 
wild-type p300, and there are likely extensive differences between primary chicken 
lymphoid cells and highly selected and passaged human DLBCL cell lines (like RC-K8 
and SUDHL2). Furthermore, we did not confirm that the p300ΔC proteins were 
expressed in the chicken spleen cells that were directly infected with the retroviral 
vectors that we created and analyzed.  
 The SUDHL2 and RC-K8 cell lines are both of the activated B-cell (ABC) 
molecular subtype of DLBCL, which is characterized by high levels of nuclear NF-κB 
activity and elevated NF-κB target gene expression (Alizadeh et al. 2000). Thus, one can 
imagine that expression of the p300ΔC proteins in SUDHL2 and RC-K8 cells is 
maintained to ensure optimal growth by moderating their otherwise high (but likely 
suboptimal) NF-κB target gene expression. On one hand, NF-κB pathway activity is 
required for survival of ABC DLBCL cells (Lim et al. 2012), and may be responsible for 
initial oncogenic transformation (Staudt 2010). On the other hand, extremely high NF-κB 
activity may have cytotoxic effects, as has been shown in other cell systems (Bash et al. 
1997). There are several examples of complementary mutations in NF-κB signaling and 
activity that may mitigate the cytotoxic consequences of exceedingly high NF-κB activity 
(described in section 5.7). Additionally, RC-K8 cells have multiple mutations in the NF-
κB pathway (described in section 5.8), demonstrating that fine-tuning of NF-κB signaling 
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is a favorable event in these cells, and suggesting that similar fine-tuning occurs in other 
cancer cells that are dependent on NF-κB activity for growth and oncogenicity.  
 Overall, our results suggest that truncating mutations in p300 serve to attenuate 
NF-κB activity in a subset of DLBCL with particularly high NF-κB activity—namely, 
ABC DLBCLs (Alizadeh et al. 2000). In addition to RC-K8 and SUDHL2, both of which 
are classified as ABC DLBCL, the only other reported case of a truncating p300 mutation 
in a human DLBCL is the DLBCL cell line OCI-Ly10, which is also classified as an 
ABC DLBCL. Interestingly, the OCI-Ly10 cell line has a mutation in the B-cell receptor 
complex protein CD79A (Davis et al. 2010), which may contribute to its constitutive NF-
κB activation, and also a loss of one MYC allele (see Table 2.4). However, we note that 
only one (NOLC1) of the 20 genes reported as MYC-dependent genes in OCI-Ly10 cells 
by Dave et al. (2015) is contained in our lPA list of MYC-dependent genes (Table 4.4). 
Nevertheless, while mutations in p300/CBP occur in approximately 15% of DLBCL, 
only a subset of these mutations are nonsense mutations predicted to direct expression of 
a truncated p300 protein, all of which occur in DLBCL cell lines (RC-K8, SUDHL2, 
OCI-Ly10) that are characterized by and dependent on high NF-κB activity. Given the 
overlap between high NF-κB activity and truncating mutations in p300, as well as the 
reduced cell growth that follows inhibition of either p300 or NF-κB activity in these cell 
lines (Kalaitzidis et al. 2002, Garbati et al. 2011, Haery et al. 2014), we propose that there 
is functional cooperation between these two proteins/pathways and that this cooperation 
provides a growth advantage to these cancer cells. 
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5.7 p300ΔC reduces the expression of two NF-κB target genes that are cytotoxic in 
RC-K8 cells   
A20 is a tumor suppressor and a target gene of NF-κB, is biallelically inactivated in 
approximately 30% of DLBCL, and is mutated in the SUDHL2 and RC-K8 cell lines 
(Krikos et al. 1992, Wertz et al. 2004, Compagno et al. 2009). Knockdown of p300ΔC-
1087 resulted in increased expression of A20 mRNA and protein in RC-K8 cells (Figures 
3.6a, b). Those observations and the presence of p300ΔC-1087 at the A20 promoter 
(Figure 3.6c) suggest that p300ΔC-1087 directly reduces A20 gene expression in RC-K8 
cells, leading to reduced A20 protein. Reduced A20 protein activity appears to be 
essential for RC-K8 and SUDHL2 survival, as re-expression of wild-type A20 induces 
apoptosis in both cell types (Compagno et al. 2009). Therefore, it appears that A20 
activity is reduced in SUDHL2 and RC-K8 cells by both mutation (Compagno et al. 
2009) and transcriptional repression mediated by mutant p300.  
 Knockdown of p300ΔC-1087 in RC-K8 cells also resulted in increased IκBα 
expression (Figures 3.6a, b). We have previously shown that RC-K8 cells have 
inactivating mutations in three of four copies of the NFKBIA (IκBα) gene, express little 
wild-type IκBα protein, and consequently show high levels of both nuclear REL DNA-
binding activity and REL target gene expression (Kalaitzidis et al. 2002). Forced 
expression of wild-type IκBα protein slows the growth of RC-K8 cells, presumably due 
to inhibition of REL (Kalaitzidis et al. 2002).  
 These results represent two examples by which low NF-κB activity is cytotoxic in 
RC-K8. These examples suggest that RC-K8 cells harbor additional mutations that 
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counteract the cytotoxic consequences of highly active NF-κB, and suggest that the 
accumulation of multiple mutations fine tunes the oncogenic NF-κB signaling pathway to 
provide a growth advantage to these cells. 
5.8 The NF-κB pathway in RC-K8 cells is affected by multiple mutations  
In addition to inactivating mutations in the NF-κB target genes and negative regulators 
A20 and IκBα (described in section 5.7), there is at least one other mutations that affects 
REL/NF-κB signaling in RC-K8 cells. One of two REL alleles in these cells directs the 
expression of a C-terminally truncated REL protein (called REL-NRG) that contains a 
functional DNA-binding/dimerization domain, but lacks the C-terminal transactivation 
domain (Lu et al. 1991, Kalaitzidis et al. 2002, Kalaitzidis and Gilmore 2002). As a 
consequence of this C-terminal deletion, REL-NRG can reduce wild-type REL’s ability 
to bind to and activate REL-dependent promoters (Kalaitzidis et al. 2002).  
 Thus, there are two mutations (IκBα and A20) that increase REL signaling and 
two mutations (REL-NRG and p300ΔC-1087) that reduce REL signaling in RC-K8 cells. 
The results described in this thesis suggest that the balance of positive and negative 
effects on REL-dependent transactivation provides an optimal signal for oncogenic 
growth. In many respects, this is similar to the balancing effects that multiple mutations 
have on the activity of the v-Rel oncoprotein (Gilmore 1999).  
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5.9 IPA reveals that MYC activity is enhanced by p300ΔC-1087 expression in RC-
K8 cells 
IPA analysis of the gene expression changes in RC-K8 cells showed that activity of a 
MYC target gene network is reduced upon knockdown of p300ΔC-1087, suggesting that 
expression of p300ΔC-1087 is normally required for MYC activity in RC-K8 cells. This 
result is supported by qPCR analysis of several MYC target genes, which demonstrated 
that expression of these genes is decreased in RC-K8 cells following p300ΔC-1087 
knock down (Figure 4.5a). Mechanistically, the enhanced MYC signaling in RC-K8 cells 
is, in part, likely due to increased expression of the MYC protein in the presence of 
p300ΔC-1087 (Figure 4.5b). MYC has a short protein half-life (~30 min) and its activity 
for directly gene transcription is highly sensitive to changes in protein levels (Hann and 
Eisenman 1984). 
 Our results indicate that MYC, like REL/NF-κB, might also represent a 
transcription factor whose oncogenic activity can be optimized by HAT mutations. 
Unlike what we have found for NF-κB activity and target gene expression, MYC activity 
is enhanced by the presence of p300ΔC-1087 in RC-K8 cells, as MYC protein levels and 
gene expression profiles are decreased when p300ΔC-1087 levels are reduced by 
knockdown. Taken together, our cell growth and gene expression analyses suggest that 
p300ΔC-1087-dependent enhancement of MYC-directed gene expression programs 
contributes to the optimal growth of these cells. Enhanced MYC activity, for example by 
MYC gene translocation or amplification, has been shown to contribute to DLBCL cancer 
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cell growth (Karube and Campo 2015), and the expression of p300ΔC proteins may also 
provide a mechanism of enhancing MYC signaling. 
 The MYC oncoprotein is a transcription factor that regulates genes involved in 
proliferation, cell cycle regulation, DNA replication, metabolism, and many other cellular 
functions (Karube and Campo 2015). However, unscheduled MYC expression can also 
induce apoptosis, which is likely why MYC activation alone is generally not sufficient 
for oncogenic transformation, and often requires the cooperation of other oncogenic 
events (Meyer and Penn 2008). In DLBCL, activation of MYC is often found a context of 
other oncogenic events (e.g., BCL-2 or BCL-6 rearrangements) (Karube and Campo 
2015). In normal B cells, MYC plays a role in early B-cell development, but its 
expression is later repressed (Ott et al. 2013). Not surprisingly, MYC expression is 
deregulated in lymphoid malignancies by translocations in 5%-14% of DLBCLs and 
copy number gains/amplifications in 21%-38% of DLBCL cases, both of which lead to 
elevated MYC expression (reviewed in Karube and Campo 2015). Mutations in MYC are 
also found in 32% of DLBCL, and often occur in regions of the gene that lead to 
increased protein stability and decreased apoptotic function (Pasqualucci et al. 2001, 
Karube and Campo 2015). Furthermore, 28%-41% of DLBCL cases show increased 
MYC expression in the absence of MYC abnormalities (Valera et al. 2013, Karube and 
Campo 2015), suggesting that other mechanisms can lead to MYC activation. We 
propose that one such mechanism leading to increased MYC oncogenic activity, as in 
RC-K8 cells, is expression of p300ΔC mutant proteins. As far as we can tell, the RC-K8 
and SUDHL2 cell lines do not have MYC gene mutations. 
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 We have demonstrated that in RC-K8 cells, NF-κB output is likely to be reduced 
through an interaction between REL and p300ΔC-1087 at target gene promoters. On the 
other hand, p300ΔC-1087 does not strongly interact with MYC in whole-cell extracts 
from RC-K8 cells. The low amount of MYC protein in the p300ΔC-1087 
immunoprecipitation may reflect a weak interaction between these two proteins or an 
interaction of the two proteins at only a small subset of MYC-dependent gene enhancers. 
It is not clear whether the apparent low level of interaction between MYC and p300ΔC-
1087 is causally related to the activated MYC gene signature or the stabilized MYC 
protein that are normally seen in RC-K8 cells. The failure of p300ΔC-1087 to efficiently 
bind MYC may indirectly lead to MYC’s association with other (functional) HAT 
coactivators, such as CBP. It has been shown that the activity of MYC can be altered 
based on its interaction with other proteins. For example, MYC can repress gene 
expression directed by the TF MIZ1 by recruiting DNA-methyltransferases to silence 
MIZ1-bound promoters (Brenner et al. 2005). 
 Similar to what we have found in RC-K8 cells, the activity of MYC also appears 
to be important for the survival of SUDHL2 cells. Namely, the ability of a small-
molecule inhibitor of BET bromodomain proteins to induce apoptosis in SUDHL2 cells 
has been correlated with its ability to decrease expression of the MYC protein and 
consequently to reduce a MYC gene-expression signature, suggesting a dependence of 
SUDHL2 cells on MYC activity (Boi et al. 2015). 
 Although our p300ΔC-1087 knockdown results suggest that reduced levels of 
MYC activity lead to reduced growth of RC-K8 cells, increased expression of MYC has 
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also been shown to be incompatible with the optimal growth of RC-K8 cells. 
Specifically, up-regulation of MYC is associated with and required for IL-21-induced cell 
death in RC-K8 cells (Sarosiek et al. 2010). Therefore, based on those previous results 
and our results on the destabilizing effect of p300ΔC-1087 knockdown on MYC protein 
levels, it appears that MYC protein levels and activity must be maintained at a proper 
intermediate level for the optimal growth of RC-K8 cells. Of note, intermediate levels of 
REL protein activity have also been shown to be optimal for the transformation of 
chicken cells in culture (Starczynowski et al. 2003, Fan and Gelinas 2007). 
5.10 Activity of p300/CBP mutations in DLBCL and other cancers 
Chapter 4 describes a computational analysis of gene expression profiles that was 
performed to expand upon the limited analysis of C-terminally truncated p300 proteins in 
RC-K8 and SUDHL2 cells. Genome-wide expression and mutational analyses were 
obtained from the publically available Cancer Cell Line Encyclopedia (CCLE) (Barretina 
et al. 2012).  
CCLE expression and mutation data were used with GSEA to compare the gene 
expression profiles of all cancer cell lines predicted to express a truncated p300 protein 
(i.e., cell lines harboring a p300 nonsense mutation, n = 19, described in Appendix II) to 
cell lines expressing wild-type p300 and CBP (n = 853, listed in Appendix II). Results 
yielded three small (< 30 genes) but significantly (FDR < 0.25) enriched gene set, and 
showed that a MYC target gene set was expressed at higher levels in cell lines with wild-
type CBP/p300 (Table 4.6). These initial results suggest that MYC activity can be 
affected by C-terminally truncating p300 mutations in multiple cancer cell types, but that 
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the effects of p300ΔC-like mutations on MYC activity are dependent on the cell line, 
tissue type, and/or specific truncating mutation. 
Overall, our results suggest that p300ΔC-like proteins selectively affect NF-κB 
activity in DLBCL cells, which may be dependent on this lymphoid cell-specific 
oncogenic transcription factor. In contrast, MYC may represent a more general oncogenic 
driver that can be affected by p300 truncation mutations in several other cancer tissue 
types. That is, our analysis suggests that altered MYC activity is a consequence of 
truncating p300 mutations that occur in a variety of cancer types. This hypothesis is 
supported by the finding that REL overexpression can transform, for the most part, only 
lymphoid cells (Gilmore and Gerondakis 2011), whereas MYC can transform a variety of 
cell types in vitro (Gabay et al. 2014). Given that p300 is a promiscuous transcriptional 
coactivator that interacts with over 75 transcription factors, it is likely that the pathways 
whose activities are altered by p300 truncation mutations are dependent on the 
predominant oncogenic driver in a particular cancer cell. 
5.11 p300ΔC is associated with an altered histone acetylation pattern in RC-K8 and 
SUDHL2 cells 
Although the above discussion has focused on the effects of p300ΔC mutants on gene 
expression directed by specific transcription factors (i.e., NF-κB/REL and MYC), we 
have also found a general—albeit weak—correlation between the levels specific histone 
acetylation and DLBCL cells harboring p300/CBP mutations. Specifically, we have 
found that DLBCL cell lines with reduced expression of wild-type p300 generally have 
low levels of H3K14 and H3K18 acetylation (Figure 3.7a, b, Table 3.1). It has been 
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shown that p300 and CBP are able to acetylate H3K14 and H3K18 in vitro and that p300 
and CBP are required for H3K18 acetylation in vivo (Horwitz et al. 2008, Luebben et al. 
2010). Additionally, hypoacetylation of H3K18 due to inhibition of p300 and CBP has 
been shown to stimulate cell cycling in quiescent human cells and has been associated 
with recurrence of low-grade prostate cancer in patient studies (Seligson et al. 2005, 
Ferrari et al. 2008, Horwitz et al. 2008). Developmental studies in mice have shown that 
acetylation of H3K14 is associated with gene activation (Kueh et al. 2011), suggesting 
that reduction of H3K14 acetylation in RC-K8 and SUDHL2 cells prevents expression of 
target genes specifically related to growth inhibition and/or apoptosis. Consistent with 
this hypothesis, H3K14 acetylation at the promoter of the cell cycle inhibitor p21 is 
upregulated 10-fold in response to treatment with the topoisomerase II inhibitor 
doxorubicin, and is required for stress-induced cell-cycle arrest in human cancer cell lines 
(Love et al. 2012). We suggest that expression of truncated p300 proteins and the 
associated reduction of wild-type p300 acetylating activity is one mechanism that can 
lead to reduced acetylation of H3K14 and H3K18, which contributes to DLBCL cell 
growth. Of note, SUDHL2 and RC-K8 cells are sensitive to apoptosis induced by 
treatment with two HDAC inhibitors (Thompson et al. 2013). 
5.12 Do all mutations in CBP and p300 function in the same way in cancer cells? 
The research described in this thesis has focused on the molecular and biological 
properties of C-terminal truncations of p300 in two DLBCL cell lines. However, there are 
also a variety of point mutations that have been found in p300 and the related HAT CBP 
in DLBCL (Morin et al. 2011, Pasqualucci et al. 2011, Pasqualucci et al. 2011, Morin et 
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al. 2013). Are the effects and activities of all of these mutant HATs functionally 
identical?  
One clear consequence of the p300 and CBP HAT domain deletions is loss of 
catalytic acetyltransferase activity. Many of the point mutations in CBP and p300 occur 
in or near the HAT domain (reviewed in Haery et al. 2015), and several have been shown 
to affect the ability of CBP to acetylate p53 and BCL6 in cells in tissue culture 
(Pasqualucci et al. 2011). However, we believe that is it unlikely that C-terminal 
truncations of CBP/p300 are functionally identical to HAT domain mutations for at least 
two reasons. First, reduced acetylation of p300/CBP target proteins (which would occur 
with point mutants) is unlikely to be functionally identical to the absence of p300-
catalyzed acetylation of target proteins (as would occur with C-terminal truncations and 
their associated loss of wild-type p300 expression). Second, C-terminal truncations in 
CBP/p300 remove several protein-protein interactions domains, and not just the HAT 
domain. For example, there are C-terminal sequences in p300 (which are not present in 
p300ΔC-820 and p300ΔC-1087) that selectively interact with p53, MyoD, Src1, cFos, 
PU.1, GATA-1, Ets-1, among many others (Shiama 1997, Blobel 2000, Xu et al. 2006). 
  p300 and CBP have highly similar amino acid sequences, interact with many of 
the same proteins, and have overlapping functions. Nevertheless, their molecular and 
biological functions are not identical. Given that several studies have shown that genomic 
site occupancy by p300 and CBP has a high degree of overlap, there may be some 
overlap in the cellular consequences of p300 or CBP mutations in cancer cells. In one 
study of quiescent and stimulated human glioblastoma cells, over 16,000 genes were 
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bound by either p300 or CBP, with over 97% of these genes being bound by both 
(Holmqvist and Mannervik 2013); however, other studies have found lower levels of 
overlap between p300 and CBP genome occupancy (Ramos et al. 2010). Moreover, 
knockouts of p300 and CBP in mice can lead to different phenotypes, suggesting that 
truncating mutations in p300 or CBP in cancer cells would also have different 
consequences. For example, inactivation of one CBP allele led to splenomegaly and 
severe deficiencies in hematopoietic differentiation in mice, whereas similar p300 
heterozygotes had no statistically significant differences in hematopoietic differentiation 
or spleen size as compared to wild-type mice (Kung et al. 2000). Furthermore, only CBP 
heterozygotes developed hematologic tumors, which had loss of heterozygosity at the 
wild-type CBP allele while still expressing normal levels of p300 (Kung et al. 2000). 
Thus, p300 and CBP mutations may not have identical effects in lymphoid or other 
cancers.  
 In addition, there are multiple examples in which HAT-defective CBP/p300  
coactivators are functionally equivalent to wild-type versions of the protein. That is, the 
activity of HAT domain is not always required for the coactivator function of CBP/p300. 
In some promoter contexts, such HAT-independent activities appear to be sufficient for 
normal p300 function. For example, it has been shown that HAT deletion mutants of 
p300 can still enhance MyoD-dependent transcription, possibly by stabilizing a ternary 
complex between MyoD and other coactivators (Puri et al. 1997). Thus, it is likely that 
HAT-deficient p300 proteins have altered p300 activity in some settings (e.g., REL-
dependent transactivation), but not in others (e.g., MyoD-dependent transactivation). 
	  	  
176 
Therefore, we suggest the following four provocative hypotheses: 1) that cells expressing 
mutant p300 proteins are distinct from p300-null cells, 2) that p300 point mutations and 
p300 C-terminal truncations are likely different, 3) that different point mutations in 
p300/CBP have distinct activities; and 4) that p300 and CBP mutations have different 
consequences in cancer cells. Overall, we believe that specific mutations in the 
promiscuous CBP/p300 proteins are selected, often late in oncogenesis, for their ability to 
modify and optimize specific oncogenic driver pathways that are acting in individual 
tumor contexts. 
5.13 A model for mutations in epigenetic regulators as cancer cell-specific oncogenic 
modifiers 
This thesis has focused on the role of mutations in the HATs p300 and, to a lesser extent, 
CBP in DLBCL and cancer. Several recent studies have shown that other global 
epigenetic regulators of gene expression are mutated in cancers. These include histone 
acetyltransferases, DNA methyltransferases, lysine methyltransferases, and many other 
chromatin remodelers (Plass et al. 2013) (summarized in Table 5.1). How might such 
mutations contribute to the cancer phenotype? We propose that there are several 
mechanisms by which deregulation of epigenetic regulators can contribute to cell 
proliferation and survival (summarized in Figure 5.1). 
 Because of the prevalence of HAT domain deletions and mutations in CBP/p300, 
several papers (Giles et al. 1998, Kung et al. 2000) have suggested that CBP/p300 are 
tumor suppressors and that it is simply the loss of CBP/p300 activity that is contributing 
to the oncogenic state. For several of the reasons that are discussed above, we propose 
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that the mutant p300ΔC proteins actively contribute to cancer. For example, the 
expression of the p300ΔC proteins is retained in the RC-K8 and SUDHL2 cell lines; if 
expression of these proteins were deleterious or inconsequential to cell growth, their 
expression would likely have been abolished. Indeed, their expression pattern is more 
similar to that of oncogenes that undergo allelic silencing, i.e., where the wild-type allele 
shows reduced or completely silenced expression in the presence of an oncogenic mutant 
allele (Ahomadegbe et al. 2000). More importantly, knockdown of p300ΔC expression 
reduces the proliferation of both SUDHL2 and RC-K8 cells, strongly suggesting that 
p300ΔC contributes an important function to cell growth. Nevertheless, we acknowledge 
that we have only looked at the effects on cell proliferation and gene expression of single 
p300ΔC targeting shRNA, which could have off-target effects, and we have not restored 
DLBCL cell growth by re-introducing an shRNA-resistant p300ΔC expression vector. 
However, consistent with our findings, the expression of HAT-domain mutant proteins 
can stimulate the growth of p300-null mouse B cells in tissue culture (Kimbrel et al. 
2009). Based on the available data, we believe that p300 HAT-domain mutant proteins 
have specific growth promoting activity, which is selected for the particular oncogenic 
context in which the mutant p300 protein must act. Similar to what we are proposing for 
p300ΔC mutations, emerging evidence is demonstrating that certain mutations in the 
well-known tumor suppressor p53 simultaneously abolish its tumor suppressing activities 
and endow it with new oncogenic activities (Oren and Rotter 2010). In the case of p53, 
these new gain-of-function oncogenic activities include effects on cell-cycle progression, 
cell survival, suppression of AMP-activated protein kinase signaling, and resistance to 
	  	  
178 
anticancer treatment (Oren and Rotter 2010, Zhu et al. 2013, Zhou et al. 2014). Thus, 
what we are proposing for the combined effect of loss of wild-type p300 tumor-
suppressing activity and of the neo-oncogenic activity of p300ΔC proteins is not without 
precedent. 
 Assuming that mutant CBP/p300 do contribute to the oncogenic phenotype, how 
might they do so? Even though they are defective for HAT activity, C-terminally 
truncated p300 proteins appear to contribute to B-cell transformation, at least in part, by 
acting as aberrant scaffolds that organize altered transcription complexes at a variety of 
gene promoters/enhancers to cause a broad-range of transcriptional deregulation. For 
example, our work demonstrates that dampening of global REL/NF-κB-dependent gene 
transcription is one oncogenic effect of p300 mutants in DLBCL (Haery et al. 2014) (see 
also chapters 3 and 4). By REL-dependent recruitment to specific gene promoters, p300 
mutants can maintain reduced levels of transcriptional activation (1) due to their lack of 
acetyltransferase activity and thus lack of HAT-dependent coactivation, and (2) by 
preventing recruitment of other, functional coactivators (e.g., CBP) to REL-bound 
promoters. Indeed, although both p300ΔC-1087 and CBP can interact with REL in 
transfected in 293T cells, an analysis of the endogenous proteins in RC-K8 cells showed 
that p300ΔC-1087, but not CBP, can be co-immunoprecipitated with REL (Garbati et al. 
2010), which demonstrates that interaction with p300ΔC-1087 can alter the protein 
interactome of REL. 
 While wild-type p300 is known to interact with many binding partners, these 
interactions are largely localized to the p300 KIX and CH domains, which are distributed 
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along the length of the protein (Figure 1.3). Therefore, the absence of C-terminal 
sequences of p300 in p300ΔC proteins likely affects the profile of binding partners 
exhibited by these mutant versions of the protein. By virtue of p300ΔC’s sequestration by 
some TFs (e.g., REL), expression of p300ΔC may indirectly encourage the association 
between other TFs (e.g., MYC) and functional coactivators. Given that MYC is often an 
oncogenic driver and is expressed at high levels in hematopoietic malignancies (Karube 
and Campo 2015), it is likely that MYC reaps much of the benefit of the effective 
increase in available CBP. In cancers defined by the expression of other oncoproteins, 
however, the dominant effect of mutant p300 expression would likely be altered, and is 
therefore context (i.e., the activity of different oncogenic drivers may be affected by the 
expression of p300 mutants).  
 Given that treatment with HDACi can lead to apoptosis in a variety of cancer cell 
types (Chapter 1.9), it is clear that a general increase in cellular acetylation is associated 
with apoptosis, further suggesting that a general decrease in acetylation is associated with 
cell survival. The apoptotic effects of HDACi have often been attributed to histone 
acetylation-based activation of pro-apoptotic genes, although our understanding of the 
exact mechanisms behind the apoptotic effects of HDACi is likely incomplete (Chapter 
1.9). A similar broad-scale effect on histone and other protein acetylation levels may 
explain some of the pro-survival/anti-apoptotic effects of HAT gene mutations. 
Specifically, reduction or elimination of HAT activity may affect the transactivation 
abilities of specific transcription factors, and also generally cause a shift in global 
acetylation patterns of TFs and histones. Two TFs that may be affected by global shifts in 
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acetylation and are known to have roles in DLBCL survival are p53 and BCL6 (Table 
1.2). Acetylation of the tumor suppressor p53 increases its protein stability and DNA-
binding activity and thus is a pro-apoptotic event. The transcriptional repressor BCL6—
which is inhibited by p300/CBP mediated acetylation—inhibits cell cycle checkpoints 
and DNA damage responses, allowing cells to proliferate and maintain the germinal 
center early B-cell phenotypes (Ci et al. 2008). Sustained BCL6 activity, however, causes 
malignant B-cell transformation (Ci et al. 2008), and thus, deacetylated (and active) 
BCL6 can contribute to cell proliferation.  
 With respect to shifting the acetylation pattern of histones, we have shown that 
the RC-K8 and SUDHL2 cell lines, which harbor truncating p300 mutations and reduced 
expression of wild-type p300, had generally reduced levels of acetylation of histone H3 
K14 and K18 among a panel of B-lymphoma cell lines. Of note, p300/CBP are 
responsible for over 90% of H3K18 acetylation of this residue (Jin et al. 2011). Cancer 
genomes often harbor epigenetic alterations that can lead to large-scale alterations in the 
regulation of proliferation, apoptosis, and DNA repair (Esteller 2002), and in general are 
characterized by genomic instability. For example, cancer genomes are globally 
hypomethylated (which can lead to a higher rate of translocations or deletions), while the 
promoters of tumor suppressor genes are generally hypermethylated (repressing 
expression) (Plass et al. 2013). In addition, lymphoma cells from individuals with 
DLBCL display heterogeneous methylation patterns, and those with higher epigenetic 
diversity have inferior clinical outcomes when treated with chemotherapy (De et al. 2013, 
Jiang and Melnick 2015). Epigenetic diversity is thought to confer a greater tolerance to 
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chemotherapeutics through the selection of resistant epigenetic clones (Jiang and Melnick 
2015). Given the known effects of epigenetic changes on cancer progression and cancer 
cell survival, it is not surprising that epigenetic modifiers are mutated in many cancers. A 
summary of mutations in epigenetic modifiers in DLBCL is presented in Table 5.1. 
Mutations in DNA methyltransferases have predominantly been identified in leukemias, 
and inactivating mutations in DNA demethylases are frequently found in AML and 
glioblastoma (reviewed in Plass et al. 22013). While HATs are mutated in many cancer 
tissue types, HDACs are not frequently mutated in human cancers (reviewed by Haery et 
al. 2015) (see also Chapter 1). 
 Overall, the results presented in this thesis show that p300ΔC proteins have 
functional activities that contribute to survival of the DLBCL cell lines RC-K8 and 
SUDHL2, and that these functions may be generalizable to other DLBCL cell lines as 
well as to other cancer types. This work is the first to describe mechanisms by which 
truncating mutations in acetyltransferase proteins likely contribute to the growth of 
human cancer cell lines, and to propose mechanisms by which mutations in the 
acetyltransferase p300 can modify the transcriptional activity of oncogenic drivers to 
contribute to DLBCL and other human cancers. 
5.14 Conclusions and future directions 
Based on our continuing studies, we propose that elimination of p300 HAT activity and 
expression of HAT-deletion p300 mutants both play oncogenic roles in DLBCL. 
Specifically, the HAT-independent activities retained in the truncated p300 proteins 
contribute to the proliferation and soft agar growth of certain DLBCL cell lines in vitro. 
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Future studies will be aimed at identifying other pathways and genes in DLBCL cells that 
are affected by the expression of p300 mutants. Specifically, the BCL6 oncogene and the 
p53 tumor suppressor are two candidates that are both important for DLBCL cell growth, 
and are regulated by p300-dependent acetylation. Moreover, disrupted acetylation of 
these two proteins generally contributes to the overall oncogenic phenotype (i.e., 
acetylation inactivates oncogenic BCL6, while acetylation activates the tumor suppressor 
p53). Most importantly, many studies will be required to fully understand how mutations 
in epigenetic modifiers contribute to the landscape of altered molecular pathways that are 
found in individual tumors. 
 Other important questions include the following: 
1.  How is the apparently wild-type EP300 allele silenced in RC-K8 cells, and 
perhaps other cancer cells that have only the mutant allele expressed? For 
example, is the wild-type EP300 allele silenced by epigenetic or genetic (e.g., 
mutation) processes? 
2. What is the effect on gene expression of knockdown of p300ΔC-820 in SUDHL2 
cells?  And, is there overlap in the genes and pathways affected in SUDHL2 and 
RC-K8 cells following knockdown of p300ΔC proteins? The increase in NF-κB 
DNA-binding activity seen following knockdown of 300ΔC-820 suggests that a 
program of NF-κB genes will be increased. 
3. How does expression of p300ΔC dampen NF-κB activity and increase MYC 
protein expression in RC-K8 and SUDHL2 cells? 
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4. Do other cancer cell types that express C-terminally truncated p300 proteins also 
show reduced proliferation upon knockdown of these mutant p300 proteins?  And, 
if so, which gene expression signatures are affected by knockdown of p300ΔC 
proteins in these cancer cells? Other human cancer cell lines that have been 
reported to primarily express only truncated p300 proteins include HCT116 
(colon), PaTu8988t (pancreas), MaTu (mammary) (Gayther et al. 2000), and 
HCT15 (colon) (Özdağ et al. 2002). 
5. Do mutations in epigenetic modifiers occur late in the oncogenic progression of a 
tumor? We have suggested that mutations in epigenetic modifiers, such as the 
p300ΔC mutations described herein, serve to moderate the effects of extreme 
oncogenic driver mutations and as such, that mutations in epigenetic modifiers 
would occur late in cancer progression. This hypothesis needs experimental 
verification. 
 This research describes a new class of “cancer modifying” mutations that we 
believe represent an emerging class of oncogenic mutations. Potential candidates for this 
class of mutation include p300 truncation mutations, as well as other types of p300 
mutations (e.g., missense mutations in the HAT domain), mutations in the related HAT 
CBP, and mutations in other epigenetic modifiers. Furthermore, we propose that this 
class of mutation, at least in the case of p300ΔC, is a gain-of-function mutation—in that 
the truncated proteins possess new functions that are not normally exhibited by wild-type 
p300. Overall, we believe that mutations in cancer modifiers serve to resolve the chaos 
and likely suboptimal growth promoting properties caused by mutations in strong 
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oncogenic drivers (such as oncogenes and tumor suppressor genes). Mutations in cancer 
modifiers are likely selected for their ability to confer subtly increased growth and 
perhaps survival onto emerging tumors. This class of common cancer mutation differs 
from previously described cancer gene classes (namely, oncogenes, tumor suppressors 
and apoptosis regulators) in that epigenetic modifiers have hundreds and perhaps 
thousands of protein and chromatin targets and effects, whereas classic cancer gene 
mutation classes affect only single or small numbers of cellular pathways. Thus, 
mutations in cancer modifiers might be expected to provide a broad-based molecular 
milieu in which more classical oncogenic drivers can exert optimal effects. Future studies 
based on this research will be aimed at defining and characterizing the gain-of-function 
properties adopted by p300ΔC, as well as exploring whether these patterns apply to other 
“cancer modifying” mutations.  
 Given the broad range of modifications that are candidates for “cancer 
modifying” mutations, future studies will be also be aimed at developing three aspects of 
the “oncogenic modifier” hypothesis. First, we aim to identify the biological 
manifestations of these mutations—that is, which specific mutations in which genes 
represent “cancer modifying” mutations (e.g., p300ΔC-1087, p300ΔC-820). Second, 
studies will be aimed at characterizing the molecular mechanisms of these “cancer 
modifiers,” (e.g., enhancing MYC activity or attenuating NF-κB signaling in DLBCL). 
Third, studies will ultimately characterize the clinical implications of these mutations 
(e.g., whether cells expressing p300ΔC are candidates for a specific chemotherapeutic). 
Overall, these outcome of these continuing studies will describe a molecular mechanism 
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whereby a particular class of mutations contributes to the growth and oncogenicity of 
cancer, and will contribute to our understanding of how to best treat cancers containing 
these types of genetic alterations. 	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Table 5.1 Mutations of epigenetic modifiers in DLBCL 
Modifier Function Mutated cases References 
EZH2 HMT 21.7% (GCB only) (Jiang and Melnick 2015) 
EP300 HAT 5% - 10% (Jiang and Melnick 2015) 
CREBBP HAT 18% - 23% 
(preferentially GCB) 
(Jiang and Melnick 2015) 
KMT2D  HMT 23% - 27% (Jiang and Melnick 2015) 
MLL2 LMT 32% - 59% (Morin et al. 2011) 
 
Mutations of epigenetic modifiers reported in DLBCL. ‘Function’ lists the enzymatic 
activity associated with each modifier, HMT, histone lysine methytransferase; HAT, 
histone acetyltransferase; LMT, lysine methyl transferase. ‘Mutated cases’ indicates the 
percent of DLBCL patient samples and cell lines reported to have mutations in the 
indicated studies, which are cited under ‘References’. GCB, ‘Germinal center B-cell like’ 
subtype of DLBCL. 	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Figure 5.1 Model of C-terminally truncating mutations in p300 
Growth arrest/apoptosis Proliferation/survival 
Wild-type p300 p300ΔC 
Global hyperacetylation Global hypoacetylation 
Acetylated H3K14, K18 Deacetylated H3K14, K18 
Cycling of NF-κB signaling  
(Cycles of nuclear and cytoplasmic 
REL) 
Chronic low levels of NF-κB signaling  
(Constitutive nuclear REL localization) 
Low MYC signaling High MYC signaling  (High availability of cofactors) 
Ac-p53  
(Transcription factor and tumor 
suppressor; activated) 
Deacetylated-p53  
(Transcription factor and tumor 
suppressor; inactivated) 
Ac-Bcl6  
(Transcriptional repressor and oncogene; 
inactivated) 
Deacetylated-Bcl6  
(Transcriptional repressor and oncogene; 
activated) 
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APPENDIX I 
List of differentially expressed genes (n = 560, q < 0.05) in RC-K8 cells with p300ΔC-
1087 knocked down relative to control RC-K8 cells, as determined by microarray. 
Symbol fold  t p FDR q  
COL9A3 4.4 17.4 2.6E-06 3.3E-02 
IFNG 6.0 13.3 1.2E-05 3.9E-02 
PIPOX 3.3 12.7 1.6E-05 3.9E-02 
CREB5 3.5 12.0 2.2E-05 3.9E-02 
ISLR 5.3 11.3 3.1E-05 3.9E-02 
PARP14 3.2 10.4 5.1E-05 3.9E-02 
MS4A14 2.5 10.4 5.1E-05 3.9E-02 
HIP1 2.4 10.3 5.4E-05 3.9E-02 
PLAG1 3.2 10.1 5.9E-05 3.9E-02 
NUB1 2.5 10.0 6.3E-05 3.9E-02 
FAM49A 3.4 9.9 6.5E-05 3.9E-02 
HAPLN3 3.2 9.9 6.6E-05 3.9E-02 
RNU11 3.6 9.5 8.4E-05 4.0E-02 
SAMD4
A 
2.4 9.5 8.5E-05 4.0E-02 
SBF2 2.4 9.4 8.8E-05 4.0E-02 
HHLA2 2.7 9.3 9.5E-05 4.0E-02 
IRF1 2.1 9.1 1.1E-04 4.0E-02 
TNFSF4 2.5 9.1 1.1E-04 4.0E-02 
MIR29B
2 
2.2 9.1 1.1E-04 4.0E-02 
ITM2B 2.6 8.9 1.2E-04 4.0E-02 
RRM2B 2.5 8.8 1.3E-04 4.0E-02 
SESTD1 2.0 8.7 1.4E-04 4.0E-02 
MYBL1 2.2 8.6 1.4E-04 4.0E-02 
THRA 2.3 8.5 1.5E-04 4.0E-02 
LGSN 2.1 8.5 1.6E-04 4.0E-02 
TCFL5 2.8 8.3 1.8E-04 4.0E-02 
CD274 2.0 8.3 1.8E-04 4.0E-02 
SERPIN
E2 
2.1 8.2 1.8E-04 4.0E-02 
GBP2 2.3 8.2 1.9E-04 4.0E-02 
CUL9 2.1 8.1 2.0E-04 4.0E-02 
L1CAM 2.6 8.1 2.0E-04 4.0E-02 
FADS2 2.3 7.9 2.4E-04 4.2E-02 
AGRN 1.9 7.9 2.4E-04 4.2E-02 
LCAT 2.1 7.8 2.4E-04 4.2E-02 
NRCAM 2.7 7.8 2.5E-04 4.2E-02 
CCDC19 1.9 7.7 2.8E-04 4.2E-02 
DUSP8 2.8 7.6 3.0E-04 4.2E-02 
GLI1 1.9 7.5 3.1E-04 4.2E-02 
LOC100
505564 
2.2 7.5 3.1E-04 4.2E-02 
LOC374
443 
2.4 7.5 3.2E-04 4.2E-02 
C20orf11
2 
2.1 7.4 3.2E-04 4.2E-02 
TBC1D1 2.4 7.4 3.3E-04 4.2E-02 
LINC006
70 
2.5 7.4 3.4E-04 4.2E-02 
TMOD2 2.3 7.3 3.5E-04 4.2E-02 
LOC100
506546 
2.2 7.3 3.6E-04 4.2E-02 
HOTAIR
M1 
1.8 7.2 3.8E-04 4.2E-02 
HLA-E 2.0 7.2 3.9E-04 4.2E-02 
ANKRD
20A5P 
2.2 7.2 4.0E-04 4.2E-02 
1006530
16 
2.2 7.2 4.0E-04 4.2E-02 
LOC654
433 
1.8 7.1 4.1E-04 4.2E-02 
RAB11F
IP1 
1.8 7.1 4.1E-04 4.2E-02 
BCAS1 1.9 7.1 4.1E-04 4.2E-02 
ACRBP 1.8 7.1 4.2E-04 4.2E-02 
TFPI 2.5 7.1 4.2E-04 4.2E-02 
DDB2 2.0 7.0 4.4E-04 4.2E-02 
CCDC12
6 
1.8 7.0 4.5E-04 4.2E-02 
ZMAT3 2.1 6.9 4.7E-04 4.3E-02 
PRKAB2 1.8 6.9 4.9E-04 4.3E-02 
PTAR1 2.4 6.8 5.1E-04 4.3E-02 
PDXDC2
P 
2.0 6.8 5.1E-04 4.3E-02 
PLVAP 1.8 6.8 5.1E-04 4.3E-02 
TP53INP 2.6 6.8 5.2E-04 4.3E-02 
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1 
SESN1 1.9 6.8 5.3E-04 4.3E-02 
SNORA7
5 
3.1 6.8 5.3E-04 4.3E-02 
1005055
31 
1.9 6.7 5.5E-04 4.4E-02 
SMAD5 1.8 6.7 5.6E-04 4.4E-02 
AOC2 3.5 6.7 5.7E-04 4.4E-02 
THAP2 1.8 6.7 5.7E-04 4.4E-02 
CABP4 1.7 6.7 5.8E-04 4.4E-02 
LOC100
129924 
2.0 6.7 5.8E-04 4.4E-02 
FUT1 1.8 6.7 5.9E-04 4.4E-02 
EIF2C2 1.7 6.6 6.0E-04 4.4E-02 
OTOF 1.9 6.6 6.1E-04 4.4E-02 
CTSB 2.5 6.6 6.1E-04 4.4E-02 
ZBED6 1.8 6.6 6.1E-04 4.4E-02 
SLFN5 1.9 6.5 6.4E-04 4.4E-02 
ZNF652 1.8 6.5 6.4E-04 4.4E-02 
ZBTB20 1.8 6.5 6.6E-04 4.4E-02 
RAB12 1.8 6.5 6.7E-04 4.4E-02 
BDKRB
1 
2.1 6.5 6.9E-04 4.4E-02 
HMGN3 1.9 6.4 7.2E-04 4.4E-02 
HLA-B 1.7 6.4 7.2E-04 4.4E-02 
CSNK1E 1.8 6.4 7.5E-04 4.4E-02 
DPH3P1 2.1 6.3 7.5E-04 4.4E-02 
ACRC 1.7 6.3 7.5E-04 4.4E-02 
LAMB3 1.8 6.3 7.6E-04 4.4E-02 
HNRNP
U-AS1 
1.7 6.3 7.8E-04 4.4E-02 
PRTG 1.7 6.3 7.8E-04 4.4E-02 
SLC5A3 1.7 6.3 7.8E-04 4.4E-02 
TNNC1 1.7 6.3 8.0E-04 4.4E-02 
FERMT2 1.8 6.3 8.1E-04 4.4E-02 
ZNF484 1.7 6.3 8.1E-04 4.4E-02 
TNFSF8 1.8 6.3 8.2E-04 4.4E-02 
RBM33 1.9 6.2 8.3E-04 4.4E-02 
BIRC3 1.9 6.2 8.4E-04 4.4E-02 
PLA1A 2.0 6.2 8.4E-04 4.4E-02 
GADD45
B 
1.7 6.2 8.4E-04 4.4E-02 
PTK2B 1.9 6.2 8.5E-04 4.4E-02 
LOC401 2.4 6.2 8.9E-04 4.4E-02 
317 
ZNF385
C 
1.7 6.1 9.0E-04 4.4E-02 
CD80 1.9 6.1 9.1E-04 4.4E-02 
MIR5047 1.7 6.1 9.1E-04 4.4E-02 
NEDD4 1.8 6.1 9.3E-04 4.5E-02 
ZC3H12
A 
1.7 6.1 9.5E-04 4.5E-02 
MIR21 1.7 6.1 9.6E-04 4.5E-02 
MIR4506 3.1 6.1 9.6E-04 4.5E-02 
BMF 1.9 6.1 9.7E-04 4.5E-02 
GADD45
A 
1.6 6.0 9.9E-04 4.5E-02 
CR1L 2.7 6.0 9.9E-04 4.5E-02 
GAB2 1.8 6.0 1.0E-03 4.5E-02 
STS 1.8 6.0 1.0E-03 4.5E-02 
IL1A 1.8 6.0 1.0E-03 4.5E-02 
LYST 1.7 6.0 1.0E-03 4.5E-02 
LSAMP 1.7 6.0 1.1E-03 4.5E-02 
HLA-F 1.7 5.9 1.1E-03 4.5E-02 
IFRD1 1.7 5.9 1.1E-03 4.5E-02 
SNORA7
B 
1.9 5.9 1.1E-03 4.5E-02 
SEMA7
A 
1.7 5.9 1.1E-03 4.5E-02 
1005066
13 
1.7 5.9 1.1E-03 4.5E-02 
E2F7 1.6 5.9 1.1E-03 4.5E-02 
SNORD8
9 
1.8 5.9 1.1E-03 4.5E-02 
IFITM2 2.1 5.9 1.1E-03 4.5E-02 
SCARN
A21 
1.6 5.9 1.1E-03 4.5E-02 
APOBE
C3H 
1.7 5.9 1.1E-03 4.5E-02 
SCARN
A22 
1.7 5.8 1.2E-03 4.6E-02 
SP140L 1.6 5.8 1.2E-03 4.6E-02 
CALML
4 
2.0 5.8 1.2E-03 4.6E-02 
LOC541
471 
1.7 5.8 1.2E-03 4.6E-02 
ANKRA
2 
2.2 5.8 1.2E-03 4.6E-02 
C1orf54 1.6 5.8 1.2E-03 4.6E-02 
HCG26 2.0 5.7 1.3E-03 4.7E-02 
BEND4 1.7 5.7 1.3E-03 4.7E-02 
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1006528
00 
2.0 5.7 1.3E-03 4.7E-02 
PTGER4 1.7 5.7 1.3E-03 4.7E-02 
CASZ1 2.3 5.7 1.3E-03 4.7E-02 
ZHX1-
C8ORF7
6 
1.6 5.7 1.3E-03 4.7E-02 
ZNF211 1.7 5.7 1.3E-03 4.7E-02 
DRAM2 1.6 5.7 1.3E-03 4.7E-02 
FRMPD2 1.9 5.7 1.3E-03 4.7E-02 
CREBRF 1.6 5.7 1.3E-03 4.7E-02 
TRIP10 1.7 5.7 1.3E-03 4.7E-02 
ZNF354
A 
1.6 5.7 1.3E-03 4.7E-02 
SCARN
A10 
2.0 5.7 1.3E-03 4.7E-02 
GSTM4 1.8 5.7 1.4E-03 4.7E-02 
SNORD7
1 
2.0 5.7 1.4E-03 4.7E-02 
RALGPS
2 
1.6 5.6 1.4E-03 4.7E-02 
WNK4 2.3 5.6 1.4E-03 4.7E-02 
RCAN2 2.0 5.6 1.4E-03 4.7E-02 
SNN 1.9 5.6 1.4E-03 4.7E-02 
RASSF8 1.7 5.6 1.4E-03 4.7E-02 
LOC284
632 
1.8 5.6 1.5E-03 4.7E-02 
LAMB2
P1 
2.0 5.6 1.5E-03 4.7E-02 
LPCAT4 1.7 5.6 1.5E-03 4.8E-02 
DCUN1
D2 
1.8 5.6 1.5E-03 4.8E-02 
FAM65B 2.4 5.5 1.5E-03 4.8E-02 
PEA15 1.6 5.5 1.5E-03 4.8E-02 
MIR579 1.7 5.5 1.6E-03 4.8E-02 
WHSC1
L1 
1.6 5.5 1.6E-03 4.8E-02 
RNF157 1.7 5.5 1.6E-03 4.9E-02 
MIR4757 1.6 5.5 1.6E-03 4.9E-02 
CAB39L 1.8 5.5 1.6E-03 4.9E-02 
EFCAB5 1.6 5.5 1.7E-03 4.9E-02 
P2RX7 1.6 5.5 1.7E-03 4.9E-02 
RUFY3 1.6 5.4 1.7E-03 4.9E-02 
RBFOX3 1.6 5.4 1.7E-03 4.9E-02 
FRY 1.6 5.4 1.7E-03 4.9E-02 
EFNA2 1.8 5.4 1.7E-03 4.9E-02 
CCDC50 1.6 5.4 1.7E-03 4.9E-02 
MANBA 1.6 5.4 1.7E-03 4.9E-02 
ANO6 2.0 5.4 1.7E-03 4.9E-02 
1002872
23 
1.6 5.4 1.8E-03 4.9E-02 
MBD5 1.6 5.4 1.8E-03 4.9E-02 
GH1 2.0 5.4 1.8E-03 4.9E-02 
DUSP22 1.7 5.4 1.8E-03 4.9E-02 
ATXN1 2.2 5.4 1.8E-03 4.9E-02 
CD48 1.7 5.4 1.8E-03 4.9E-02 
ANG 1.6 5.4 1.8E-03 4.9E-02 
NINJ1 1.9 5.4 1.8E-03 4.9E-02 
NFKBIZ 1.6 5.4 1.8E-03 4.9E-02 
SYT1 1.7 5.3 1.8E-03 4.9E-02 
GPC5 1.7 5.3 1.8E-03 4.9E-02 
KLF12 1.7 5.3 1.8E-03 4.9E-02 
SCARN
A5 
1.8 5.3 1.8E-03 4.9E-02 
SOCS1 1.7 5.3 1.8E-03 4.9E-02 
1006528
76 
1.6 5.3 1.9E-03 4.9E-02 
ARHGA
P5 
1.6 5.3 1.9E-03 4.9E-02 
WDR78 1.8 5.3 1.9E-03 4.9E-02 
SNORD7 1.6 5.3 1.9E-03 4.9E-02 
ASS1 1.8 5.3 1.9E-03 4.9E-02 
SGK1 1.6 5.3 2.0E-03 4.9E-02 
NR1D2 1.5 5.3 2.0E-03 4.9E-02 
1005060
79 
2.1 5.3 2.0E-03 4.9E-02 
FAM116
B 
1.5 5.2 2.0E-03 4.9E-02 
ZNF92 1.7 5.2 2.0E-03 4.9E-02 
ZNF862 1.8 5.2 2.0E-03 4.9E-02 
SPIC 1.6 5.2 2.0E-03 4.9E-02 
KIAA19
58 
1.6 5.2 2.0E-03 5.0E-02 
TACC1 1.6 5.2 2.1E-03 5.0E-02 
LOC619
207 
1.6 5.2 2.1E-03 5.0E-02 
WDFY2 1.6 5.2 2.1E-03 5.0E-02 
SNORA3
3 
2.2 5.2 2.1E-03 5.0E-02 
ZC3H6 1.7 5.2 2.1E-03 5.0E-02 
ZNF483 2.3 5.2 2.1E-03 5.0E-02 
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LOC639
30 
2.2 5.2 2.1E-03 5.0E-02 
GUCA1
B 
1.9 5.2 2.1E-03 5.0E-02 
HIPK1 1.7 5.2 2.2E-03 5.0E-02 
TEX14 1.7 5.2 2.2E-03 5.0E-02 
MIR632 1.8 5.2 2.2E-03 5.0E-02 
BTG3 1.6 5.2 2.2E-03 5.0E-02 
TESK2 1.7 5.2 2.2E-03 5.0E-02 
LOC907
84 
-1.7 -5.2 2.2E-03 5.0E-02 
DBI -1.5 -5.2 2.2E-03 5.0E-02 
EXTL2 -1.5 -5.2 2.2E-03 5.0E-02 
ELAC1 -1.5 -5.2 2.2E-03 5.0E-02 
AP4S1 -1.8 -5.2 2.1E-03 5.0E-02 
EIF4EBP
2 
-1.9 -5.2 2.1E-03 5.0E-02 
HDAC1 -1.7 -5.2 2.1E-03 5.0E-02 
DHCR7 -1.7 -5.2 2.1E-03 5.0E-02 
LOC253
039 
-1.8 -5.2 2.1E-03 5.0E-02 
CDK2AP
1 
-1.6 -5.2 2.1E-03 5.0E-02 
OSGEP -1.8 -5.2 2.1E-03 5.0E-02 
PSENEN -1.6 -5.2 2.1E-03 5.0E-02 
AFG3L2 -1.6 -5.2 2.1E-03 5.0E-02 
PLA2G1
2A 
-1.6 -5.2 2.1E-03 5.0E-02 
HEATR3 -1.8 -5.2 2.1E-03 5.0E-02 
NDUFA
F4 
-1.6 -5.2 2.1E-03 5.0E-02 
PHB -1.7 -5.2 2.1E-03 5.0E-02 
PRDX1 -1.6 -5.2 2.1E-03 5.0E-02 
TBCB -1.9 -5.2 2.1E-03 5.0E-02 
OGG1 -1.9 -5.2 2.1E-03 5.0E-02 
ZW10 -1.6 -5.2 2.0E-03 5.0E-02 
RBM3 -1.9 -5.2 2.0E-03 5.0E-02 
NAT10 -1.6 -5.2 2.0E-03 4.9E-02 
DNAJB1
1 
-1.6 -5.2 2.0E-03 4.9E-02 
MRPL40 -1.6 -5.2 2.0E-03 4.9E-02 
SNRNP2
5 
-1.7 -5.2 2.0E-03 4.9E-02 
ACAD8 -1.7 -5.3 2.0E-03 4.9E-02 
WDR12 -1.7 -5.3 2.0E-03 4.9E-02 
EHBP1L
1 
-1.6 -5.3 2.0E-03 4.9E-02 
GBAP1 -1.5 -5.3 1.9E-03 4.9E-02 
PKI55 -1.9 -5.3 1.9E-03 4.9E-02 
PABPC4 -2.5 -5.3 1.9E-03 4.9E-02 
TTC27 -1.7 -5.3 1.9E-03 4.9E-02 
GBE1 -1.7 -5.3 1.9E-03 4.9E-02 
FAM86A -1.7 -5.3 1.9E-03 4.9E-02 
UTP15 -1.7 -5.3 1.9E-03 4.9E-02 
PPIL2 -1.6 -5.3 1.9E-03 4.9E-02 
NOL10 -1.5 -5.3 1.9E-03 4.9E-02 
WWC1 -1.6 -5.3 1.9E-03 4.9E-02 
SETMA
R 
-1.6 -5.3 1.9E-03 4.9E-02 
DCPS -1.6 -5.3 1.9E-03 4.9E-02 
SERPIN
B8 
-1.6 -5.3 1.9E-03 4.9E-02 
SELRC1 -1.7 -5.3 1.9E-03 4.9E-02 
COL4A6 -1.6 -5.3 1.9E-03 4.9E-02 
FAM216
A 
-1.6 -5.3 1.9E-03 4.9E-02 
IFRD2 -1.8 -5.3 1.9E-03 4.9E-02 
RNF5 -1.6 -5.3 1.8E-03 4.9E-02 
TRIT1 -1.7 -5.3 1.8E-03 4.9E-02 
SEH1L -1.7 -5.3 1.8E-03 4.9E-02 
CD3EAP -1.7 -5.3 1.8E-03 4.9E-02 
GPR75 -1.6 -5.4 1.8E-03 4.9E-02 
1006528
05 
-2.0 -5.4 1.8E-03 4.9E-02 
ACADM -1.8 -5.4 1.8E-03 4.9E-02 
C12orf4 -1.7 -5.4 1.8E-03 4.9E-02 
ARMC6 -1.9 -5.4 1.8E-03 4.9E-02 
ZMPSTE
24 
-1.8 -5.4 1.8E-03 4.9E-02 
PRIM2 -1.6 -5.4 1.8E-03 4.9E-02 
AHSA1 -1.8 -5.4 1.8E-03 4.9E-02 
LOC284
009 
-1.7 -5.4 1.8E-03 4.9E-02 
NOP14 -1.7 -5.4 1.7E-03 4.9E-02 
ATP5G3 -1.7 -5.4 1.7E-03 4.9E-02 
PSMG1 -1.9 -5.4 1.7E-03 4.9E-02 
ADPGK -1.6 -5.4 1.7E-03 4.9E-02 
DHX37 -1.8 -5.4 1.7E-03 4.9E-02 
HGSNA
T 
-1.7 -5.4 1.7E-03 4.9E-02 
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PPIF -1.8 -5.4 1.7E-03 4.9E-02 
THOC7 -1.6 -5.4 1.7E-03 4.9E-02 
SURF6 -1.6 -5.4 1.7E-03 4.9E-02 
PDCD6 -1.7 -5.4 1.7E-03 4.9E-02 
PHYHD1 -1.7 -5.4 1.7E-03 4.9E-02 
ZNHIT6 -1.8 -5.4 1.7E-03 4.9E-02 
MRPL24 -1.8 -5.4 1.7E-03 4.9E-02 
MRPS17 -1.6 -5.4 1.7E-03 4.9E-02 
C12orf52 -1.6 -5.4 1.7E-03 4.9E-02 
TMEM1
94B 
-1.6 -5.4 1.7E-03 4.9E-02 
UBIAD1 -1.7 -5.4 1.7E-03 4.9E-02 
C11orf48 -1.7 -5.4 1.7E-03 4.9E-02 
DPAGT1 -1.7 -5.4 1.7E-03 4.9E-02 
CHAC2 -1.7 -5.5 1.7E-03 4.9E-02 
KMO -2.0 -5.5 1.6E-03 4.9E-02 
ADCK1 -2.2 -5.5 1.6E-03 4.9E-02 
UBE2J1 -1.7 -5.5 1.6E-03 4.9E-02 
PSPH -1.9 -5.5 1.6E-03 4.8E-02 
ZNF804
A 
-2.0 -5.5 1.6E-03 4.8E-02 
PXMP2 -1.9 -5.5 1.6E-03 4.8E-02 
CECR5 -1.7 -5.5 1.6E-03 4.8E-02 
C9orf37 -1.7 -5.5 1.6E-03 4.8E-02 
C9orf41 -1.6 -5.5 1.6E-03 4.8E-02 
MCAT -2.3 -5.5 1.6E-03 4.8E-02 
CDKN3 -1.6 -5.5 1.5E-03 4.8E-02 
LTB -1.7 -5.5 1.5E-03 4.8E-02 
GEMIN4 -1.7 -5.5 1.5E-03 4.8E-02 
CCDC11
0 
-1.7 -5.5 1.5E-03 4.8E-02 
NHP2 -1.7 -5.5 1.5E-03 4.8E-02 
TWISTN
B 
-1.6 -5.5 1.5E-03 4.8E-02 
PPP1R10 -1.6 -5.5 1.5E-03 4.8E-02 
HMGB3 -1.7 -5.5 1.5E-03 4.8E-02 
IDNK -1.8 -5.5 1.5E-03 4.8E-02 
TTC5 -1.9 -5.6 1.5E-03 4.8E-02 
ITPA -1.8 -5.6 1.5E-03 4.7E-02 
AVEN -2.1 -5.6 1.5E-03 4.7E-02 
BDH2 -1.8 -5.6 1.5E-03 4.7E-02 
FIBP -1.9 -5.6 1.5E-03 4.7E-02 
DHX9 -1.9 -5.6 1.5E-03 4.7E-02 
SDAD1 -1.6 -5.6 1.5E-03 4.7E-02 
TUFM -1.6 -5.6 1.5E-03 4.7E-02 
ZNF860 -1.6 -5.6 1.4E-03 4.7E-02 
NIP7 -1.6 -5.6 1.4E-03 4.7E-02 
HCG18 -1.8 -5.6 1.4E-03 4.7E-02 
LOC401
109 
-1.7 -5.6 1.4E-03 4.7E-02 
RABEP
K 
-1.7 -5.6 1.4E-03 4.7E-02 
TMA16 -1.6 -5.6 1.4E-03 4.7E-02 
GFM1 -1.6 -5.6 1.4E-03 4.7E-02 
REXO2 -1.8 -5.6 1.4E-03 4.7E-02 
PMVK -1.7 -5.6 1.4E-03 4.7E-02 
GLIPR2 -1.6 -5.6 1.4E-03 4.7E-02 
POLR3G -1.8 -5.6 1.4E-03 4.7E-02 
TEX261 -1.7 -5.6 1.4E-03 4.7E-02 
SFXN2 -1.9 -5.6 1.4E-03 4.7E-02 
MPI -1.8 -5.7 1.4E-03 4.7E-02 
ELAC2 -1.6 -5.7 1.4E-03 4.7E-02 
ESCO2 -2.3 -5.7 1.4E-03 4.7E-02 
DCAF4 -2.1 -5.7 1.4E-03 4.7E-02 
RNF125 -1.9 -5.7 1.4E-03 4.7E-02 
TYW3 -2.1 -5.7 1.3E-03 4.7E-02 
CDC45 -1.6 -5.7 1.3E-03 4.7E-02 
PTCD2 -1.7 -5.7 1.3E-03 4.7E-02 
EMC10 -1.8 -5.7 1.3E-03 4.7E-02 
UTP11L -1.6 -5.7 1.3E-03 4.7E-02 
CETN2 -1.9 -5.7 1.3E-03 4.7E-02 
IVD -1.7 -5.7 1.3E-03 4.7E-02 
DYNLL1 -2.1 -5.7 1.3E-03 4.7E-02 
MFSD1 -2.2 -5.8 1.2E-03 4.6E-02 
C21orf59 -1.6 -5.8 1.2E-03 4.6E-02 
CTNS -1.9 -5.8 1.2E-03 4.6E-02 
C14orf12
6 
-2.0 -5.8 1.2E-03 4.6E-02 
MGAT2 -1.8 -5.8 1.2E-03 4.6E-02 
MED17 -1.6 -5.8 1.2E-03 4.6E-02 
RNMTL
1 
-1.6 -5.8 1.2E-03 4.6E-02 
C17orf28 -1.6 -5.8 1.2E-03 4.6E-02 
GEMIN5 -1.9 -5.8 1.2E-03 4.6E-02 
IARS2 -1.6 -5.8 1.2E-03 4.6E-02 
PFDN6 -1.6 -5.8 1.2E-03 4.6E-02 
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LCLAT1 -1.7 -5.8 1.2E-03 4.6E-02 
INA -1.8 -5.8 1.2E-03 4.6E-02 
ESPL1 -1.8 -5.8 1.2E-03 4.6E-02 
UNG -1.7 -5.8 1.2E-03 4.6E-02 
DIEXF -1.7 -5.8 1.2E-03 4.6E-02 
SPC24 -2.4 -5.8 1.2E-03 4.6E-02 
DHFR -2.0 -5.8 1.2E-03 4.6E-02 
ALG1 -1.7 -5.8 1.2E-03 4.6E-02 
IFT52 -1.7 -5.9 1.1E-03 4.5E-02 
COQ7 -2.6 -5.9 1.1E-03 4.5E-02 
PGK1 -2.0 -5.9 1.1E-03 4.5E-02 
IGLC2 -1.9 -5.9 1.1E-03 4.5E-02 
MIR142 -1.9 -5.9 1.1E-03 4.5E-02 
TMEM2
41 
-1.8 -5.9 1.1E-03 4.5E-02 
GPAM -1.6 -5.9 1.1E-03 4.5E-02 
ATG10 -1.8 -5.9 1.1E-03 4.5E-02 
SRPRB -1.7 -5.9 1.1E-03 4.5E-02 
HIST1H2
BK 
-1.8 -5.9 1.1E-03 4.5E-02 
EXOSC6 -1.6 -5.9 1.1E-03 4.5E-02 
MRPL20 -1.6 -5.9 1.1E-03 4.5E-02 
NUFIP1 -1.9 -5.9 1.1E-03 4.5E-02 
ALG5 -1.6 -5.9 1.1E-03 4.5E-02 
LINC003
37 
-1.7 -5.9 1.1E-03 4.5E-02 
POLR1B -1.9 -5.9 1.1E-03 4.5E-02 
ZNF165 -1.9 -5.9 1.1E-03 4.5E-02 
MIR4521 -2.6 -5.9 1.1E-03 4.5E-02 
WDR4 -1.7 -5.9 1.1E-03 4.5E-02 
DHODH -1.7 -5.9 1.1E-03 4.5E-02 
TAF9B -1.8 -5.9 1.1E-03 4.5E-02 
CDK10 -1.7 -6.0 1.0E-03 4.5E-02 
PRMT5 -1.7 -6.0 1.0E-03 4.5E-02 
CYP51A
1 
-1.8 -6.0 1.0E-03 4.5E-02 
WDR73 -1.7 -6.0 1.0E-03 4.5E-02 
FBXW4
P1 
-1.8 -6.0 1.0E-03 4.5E-02 
PKHD1 -1.7 -6.0 9.9E-04 4.5E-02 
FBXL2 -1.9 -6.0 9.8E-04 4.5E-02 
TIMM22 -1.8 -6.0 9.8E-04 4.5E-02 
TMEM4
3 
-1.7 -6.0 9.7E-04 4.5E-02 
CDK4 -1.8 -6.0 9.7E-04 4.5E-02 
NOLC1 -1.7 -6.0 9.7E-04 4.5E-02 
DDX52 -1.7 -6.1 9.5E-04 4.5E-02 
WDR46 -1.7 -6.1 9.4E-04 4.5E-02 
MOCS3 -1.9 -6.1 9.3E-04 4.5E-02 
MRPL27 -1.7 -6.1 9.2E-04 4.4E-02 
TXNDC1
7 
-1.7 -6.1 9.1E-04 4.4E-02 
DET1 -1.6 -6.1 9.1E-04 4.4E-02 
LOC100
506325 
-2.3 -6.1 9.0E-04 4.4E-02 
NAGK -1.7 -6.1 9.0E-04 4.4E-02 
ALYREF -1.9 -6.1 9.0E-04 4.4E-02 
HAUS7 -1.7 -6.2 8.9E-04 4.4E-02 
NVL -1.9 -6.2 8.9E-04 4.4E-02 
TOMM4
0 
-2.0 -6.2 8.9E-04 4.4E-02 
L3MBTL
2 
-1.9 -6.2 8.8E-04 4.4E-02 
TIMM8A -1.7 -6.2 8.7E-04 4.4E-02 
SYNCRI
P 
-1.7 -6.2 8.6E-04 4.4E-02 
SMARC
AD1 
-1.8 -6.2 8.5E-04 4.4E-02 
LAMTO
R1 
-1.7 -6.2 8.4E-04 4.4E-02 
ROPN1L -2.0 -6.2 8.4E-04 4.4E-02 
NCLN -1.8 -6.2 8.4E-04 4.4E-02 
CIAPIN1 -1.7 -6.2 8.4E-04 4.4E-02 
PNO1 -1.8 -6.2 8.3E-04 4.4E-02 
C17orf79 -1.7 -6.2 8.3E-04 4.4E-02 
C6orf108 -1.7 -6.2 8.3E-04 4.4E-02 
HIST2H2
BA 
-1.8 -6.2 8.2E-04 4.4E-02 
YIF1B -2.0 -6.2 8.2E-04 4.4E-02 
SREBF1 -1.8 -6.3 8.1E-04 4.4E-02 
MRPS33 -1.7 -6.3 8.1E-04 4.4E-02 
SRD5A3 -2.1 -6.3 8.1E-04 4.4E-02 
MAGT1 -1.7 -6.3 8.1E-04 4.4E-02 
HIST1H2
BM 
-2.5 -6.3 8.1E-04 4.4E-02 
PRKAR1
B 
-1.7 -6.3 8.1E-04 4.4E-02 
RBFA -1.9 -6.3 8.0E-04 4.4E-02 
SLIRP -1.7 -6.3 8.0E-04 4.4E-02 
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TMEM2
18 
-1.8 -6.3 7.9E-04 4.4E-02 
SNORD1
8B 
-2.0 -6.3 7.9E-04 4.4E-02 
LOC100
129083 
-1.7 -6.3 7.9E-04 4.4E-02 
CD200R
1 
-1.9 -6.3 7.9E-04 4.4E-02 
SCD -2.0 -6.3 7.8E-04 4.4E-02 
TMEM1
35 
-1.9 -6.3 7.7E-04 4.4E-02 
CENPI -2.1 -6.3 7.7E-04 4.4E-02 
WDR77 -2.0 -6.3 7.7E-04 4.4E-02 
FLNA -1.7 -6.3 7.7E-04 4.4E-02 
ANAPC1
5 
-2.3 -6.3 7.7E-04 4.4E-02 
SEC11C -1.9 -6.3 7.6E-04 4.4E-02 
SLC25A
13 
-2.4 -6.3 7.6E-04 4.4E-02 
CLN6 -1.9 -6.4 7.5E-04 4.4E-02 
SRM -2.5 -6.4 7.3E-04 4.4E-02 
DPH2 -1.8 -6.4 7.3E-04 4.4E-02 
NME1 -2.3 -6.4 7.2E-04 4.4E-02 
NDUFB2 -1.8 -6.4 7.0E-04 4.4E-02 
MRTO4 -1.8 -6.4 6.9E-04 4.4E-02 
PWP2 -2.3 -6.5 6.8E-04 4.4E-02 
PIGO -2.1 -6.5 6.8E-04 4.4E-02 
MAT2A -1.8 -6.5 6.7E-04 4.4E-02 
TMEM1
80 
-1.8 -6.5 6.7E-04 4.4E-02 
LOC100
506620 
-2.1 -6.5 6.4E-04 4.4E-02 
SMPD3 -2.3 -6.5 6.4E-04 4.4E-02 
POLR2L -2.0 -6.6 6.3E-04 4.4E-02 
LRWD1 -2.2 -6.6 6.3E-04 4.4E-02 
ALG6 -1.7 -6.6 6.3E-04 4.4E-02 
PYROX
D1 
-1.8 -6.6 6.3E-04 4.4E-02 
FAM173
B 
-1.9 -6.6 6.2E-04 4.4E-02 
WDR74 -1.7 -6.6 6.0E-04 4.4E-02 
SFN -2.1 -6.6 6.0E-04 4.4E-02 
NDUFA
F6 
-1.9 -6.6 6.0E-04 4.4E-02 
HMMR -1.8 -6.6 6.0E-04 4.4E-02 
FBXL17 -1.8 -6.6 5.9E-04 4.4E-02 
ACTG2 -
10.0 
-6.6 5.9E-04 4.4E-02 
MINA -1.8 -6.6 5.9E-04 4.4E-02 
RPGRIP
1L 
-2.5 -6.7 5.6E-04 4.4E-02 
MFSD3 -2.1 -6.7 5.6E-04 4.4E-02 
TRA2B -1.8 -6.7 5.6E-04 4.4E-02 
HIST1H2
AI 
-1.9 -6.7 5.6E-04 4.4E-02 
1005057
73 
-1.8 -6.7 5.5E-04 4.4E-02 
MEF2B
NB 
-2.8 -6.8 5.3E-04 4.3E-02 
CARS2 -1.9 -6.8 5.2E-04 4.3E-02 
LOC100
507535 
-1.8 -6.8 5.1E-04 4.3E-02 
METAP1
D 
-1.8 -6.8 5.0E-04 4.3E-02 
LDHA -2.0 -6.8 5.0E-04 4.3E-02 
RRP15 -2.1 -6.9 5.0E-04 4.3E-02 
NDUFA
F1 
-1.8 -6.9 4.9E-04 4.3E-02 
MMAB -2.3 -6.9 4.8E-04 4.3E-02 
APOO -1.8 -6.9 4.8E-04 4.3E-02 
SDF2L1 -1.9 -6.9 4.8E-04 4.3E-02 
LOC100
130476 
-2.2 -6.9 4.8E-04 4.3E-02 
LMLN -1.8 -6.9 4.7E-04 4.3E-02 
NSUN5P
1 
-1.9 -7.0 4.5E-04 4.2E-02 
ITGB1B
P1 
-2.1 -7.0 4.5E-04 4.2E-02 
QTRTD1 -1.9 -7.0 4.4E-04 4.2E-02 
DGAT2 -1.8 -7.0 4.4E-04 4.2E-02 
NCOA5 -1.9 -7.0 4.4E-04 4.2E-02 
SLC25A
15 
-2.0 -7.1 4.3E-04 4.2E-02 
PLCD3 -1.8 -7.1 4.3E-04 4.2E-02 
FAM86D
P 
-2.0 -7.1 4.2E-04 4.2E-02 
SFTPA1 -4.3 -7.1 4.1E-04 4.2E-02 
POLR1A -1.8 -7.1 4.1E-04 4.2E-02 
MTCH2 -2.3 -7.1 4.1E-04 4.2E-02 
NABP2 -1.9 -7.1 4.0E-04 4.2E-02 
HNRNP
M 
-2.8 -7.2 3.8E-04 4.2E-02 
SFPQ -1.8 -7.2 3.8E-04 4.2E-02 
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FKBP11 -2.2 -7.2 3.7E-04 4.2E-02 
ALKBH8 -1.9 -7.3 3.7E-04 4.2E-02 
HSPA5 -1.9 -7.3 3.6E-04 4.2E-02 
MRPS12 -1.9 -7.3 3.6E-04 4.2E-02 
GRAP -2.2 -7.3 3.6E-04 4.2E-02 
CHML -1.8 -7.3 3.6E-04 4.2E-02 
BOLA3 -2.4 -7.3 3.5E-04 4.2E-02 
TTPAL -2.1 -7.3 3.5E-04 4.2E-02 
SH2D2A -2.1 -7.3 3.5E-04 4.2E-02 
POLR2G -2.1 -7.4 3.4E-04 4.2E-02 
CCDC99 -1.8 -7.4 3.3E-04 4.2E-02 
HIST1H2
AE 
-2.1 -7.4 3.3E-04 4.2E-02 
FASN -2.9 -7.4 3.3E-04 4.2E-02 
TRUB2 -2.0 -7.4 3.3E-04 4.2E-02 
URB1 -2.0 -7.4 3.2E-04 4.2E-02 
PPIL1 -1.9 -7.4 3.2E-04 4.2E-02 
SRRT -2.1 -7.5 3.2E-04 4.2E-02 
HIST1H4
D 
-2.5 -7.5 3.2E-04 4.2E-02 
RUVBL1 -2.1 -7.5 3.1E-04 4.2E-02 
MANF -1.9 -7.5 3.1E-04 4.2E-02 
ACAD9 -2.3 -7.6 2.8E-04 4.2E-02 
LOC644
669 
-2.1 -7.6 2.8E-04 4.2E-02 
CAD -2.2 -7.7 2.7E-04 4.2E-02 
KIF20A -2.0 -7.7 2.6E-04 4.2E-02 
POP1 -2.3 -7.8 2.6E-04 4.2E-02 
AIMP2 -2.1 -7.8 2.6E-04 4.2E-02 
EBNA1B
P2 
-2.4 -7.8 2.4E-04 4.2E-02 
COQ2 -2.1 -7.9 2.4E-04 4.2E-02 
GRWD1 -2.5 -7.9 2.4E-04 4.2E-02 
LOC100
506123 
-2.5 -7.9 2.3E-04 4.2E-02 
NR4A3 -2.3 -8.0 2.1E-04 4.0E-02 
RPS26 -2.1 -8.0 2.1E-04 4.0E-02 
RBM45 -2.0 -8.1 2.1E-04 4.0E-02 
PFAS -2.2 -8.1 2.1E-04 4.0E-02 
NUDT9P
1 
-2.2 -8.1 2.1E-04 4.0E-02 
FDXAC
B1 
-2.3 -8.1 2.0E-04 4.0E-02 
UTP20 -2.6 -8.1 2.0E-04 4.0E-02 
MIR548
AM 
-4.4 -8.2 2.0E-04 4.0E-02 
LOC440
461 
-2.2 -8.2 1.9E-04 4.0E-02 
NOL6 -2.0 -8.2 1.9E-04 4.0E-02 
1005062
40 
-2.1 -8.3 1.8E-04 4.0E-02 
ARPC4 -2.2 -8.3 1.8E-04 4.0E-02 
SNRPF -2.1 -8.3 1.8E-04 4.0E-02 
IKBKE -2.0 -8.3 1.8E-04 4.0E-02 
LANCL2 -2.5 -8.4 1.7E-04 4.0E-02 
ACAT1 -2.1 -8.4 1.7E-04 4.0E-02 
METTL1 -2.3 -8.5 1.5E-04 4.0E-02 
COQ3 -2.1 -8.6 1.5E-04 4.0E-02 
NOP16 -2.5 -8.8 1.3E-04 4.0E-02 
PRMT6 -2.3 -8.8 1.2E-04 4.0E-02 
HMGA1
P4 
-2.5 -8.9 1.2E-04 4.0E-02 
POLR3B -2.7 -9.0 1.1E-04 4.0E-02 
TSEN2 -2.3 -9.0 1.1E-04 4.0E-02 
RAB39A -2.3 -9.1 1.1E-04 4.0E-02 
MIR4436
A 
-2.4 -9.2 1.0E-04 4.0E-02 
ODC1 -3.2 -9.4 8.8E-05 4.0E-02 
RWDD2
B 
-2.2 -9.6 7.7E-05 4.0E-02 
FUS -3.3 -9.9 6.7E-05 3.9E-02 
GDAP1 -3.0 -
10.1 
6.0E-05 3.9E-02 
ATP5G1 -2.7 -
10.3 
5.3E-05 3.9E-02 
DARS2 -2.4 -
10.5 
4.7E-05 3.9E-02 
POLR3H -2.7 -
10.7 
4.4E-05 3.9E-02 
RPP40 -3.2 -
10.7 
4.4E-05 3.9E-02 
CCL17 -4.2 -
10.7 
4.2E-05 3.9E-02 
GPATC
H4 
-2.8 -
11.3 
3.1E-05 3.9E-02 
CRYZ -3.2 -
12.2 
2.0E-05 3.9E-02 
SNHG4 -3.0 -
13.0 
1.4E-05 3.9E-02 
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Genes are listed by gene symbol, or the Entrez Gene ID for those genes without symbols. 
‘Fold’ lists the expression fold change in RC-K8 cells with p300ΔC-1087 knocked down 
compared to control RC-K8 cells. ‘t’ lists the t-statistic, ‘p’ lists the p-value, and ‘FDR q’ 
lists the FDR corrected p value (‘q’ value) associated with each expression change. FDR 
q was calculated after removing genes with low expression values. Genes are listed by 
descending t statistic.
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APPENDIX II 
Samples used for Gene Set Enrichment Analysis comparing cell lines with p300 nonsense 
mutations (n = 19) to cell lines with wild-type p300/CBP (n = 853) 
Cell line  Site Primary Histology Subtype EP300 CREBBP 
639-V urinary tract transitional cell carcinoma P802L, R1055*, 
R1645* 
R601Q 
647-V urinary tract transitional cell carcinoma Q993* Wild-type 
AGS stomach Adenocarcinoma E1025*, E643*, 
K350R 
Wild-type 
BxPC-3 pancreas ductal carcinoma R397* Wild-type 
CW-2 large intestine NS G2159*, R1773Q R14fs 
GP2d large intestine Adenocarcinoma K423T, Q1661* H1804Y, P949L 
HCT-15 large intestine Adenocarcinoma E1014* D1521 splice, 
P1150H 
HEC-151 endometrium Adenocarcinoma R1950G,R86* Wild-type 
HRT-18 large intestine adenocarcinoma E1014* Wild-type 
JHUEM-1 endometrium adenocarcinoma R397* Wild-type 
KU-19-19 urinary tract transitional cell carcinoma S1754* Wild-type 
LOU-NH91 lung squamous cell carcinoma Q476* Wild-type 
MFE-319 endometrium adenocarcinoma A1902V, Q1661*, 
Q2005* 
P2371L, Q929*, 
T872K 
MOR/CPR lung adenocarcinoma Q1725* Wild-type 
RCM-1 large intestine adenocarcinoma Q1740* Wild-type 
RL haematopoietic 
and lymphoid 
tissue 
B cell lymphoma 
unspecified 
E1011*,H1415P Wild-type 
SNU-81 large intestine NS E1229*, E643*, 
R1234I 
R1446H 
VM-CUB1 urinary tract transitional cell carcinoma Q1874E, Q2023* R1341Q 
YD-15 salivary gland mucoepidermoid 
carcinoma 
Q813* Wild-type 
 Cohort of human cancer cell lines with p300 nonsense mutations (n = 19). Cell line 
primary name, site primary, and histology subtype list the classifications as reported by 
the Cancer Cell Line Encyclopedia (CCLE); NS, non-specified. EP300 and CREBBP list 
the mutation status of the indicated locus, all mutations result in protein-coding changes; 
*, nonsense mutation; fs, frame shift; splice, splice site mutation.  
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Human cancer cell lines with wild-type p300 and CBP. 
autonomic ganglia TC-32 MDA-MB-436 MOG-G-CCM COLO-677 
CHP-126 TC-71 MDA-MB-453 MOG-G-UVW Daudi 
CHP-212 U-2 OS MDA-MB-468 NMC-G1 DB 
IMR-32 Breast SK-BR-3 ONS-76 DOHH-2 
KELLY AU565 T-47D SF-172 EB1 
KP-N-RT-BM-1 BT-20 UACC-812 SF-295 EB2 
KP-N-SI9s BT-474 UACC-893 SF126 EHEB 
KP-N-YN BT-483 YMB-1 SF767 EJM 
MHH-NB-11 BT-549 ZR-75-1 SNB-19 EM-2 
NB-1 CAL-120 ZR-75-30 SNU-1105 EOL-1 
NH-6 CAL-148 central nervous sys. SNU-201 F-36P 
SH-SY5Y CAL-51 1321N1 SNU-466 GA-10 
SIMA CAL-85-1 42-MG-BA SNU-489 GDM-1 
SK-N-AS DU4475 8-MG-BA SNU-626 GRANTA-519 
SK-N-BE(2) EFM-19 A1207 SNU-738 HEL 
SK-N-FI EFM-192A A172 SW 1783 HEL 92.1.7 
SK-N-SH HCC1143 AM-38 T98G HH 
biliary tract HCC1187 Becker TM-31 HL-60 
HuCCT1 HCC1419 CAS-1 U-118 MG Hs 611.T 
HuH28 HCC1428 CCF-STTG1 U-138 MG Hs 616.T 
SNU-1079 HCC1500 CH-157MN U-178 Hs 751.T 
SNU-1196 HCC1569 D283 Med U-251 MG HuNS1 
SNU-245 HCC1599 D341 Med U-87 MG HuT 102 
SNU-308 HCC1806 Daoy U343 HuT 78 
SNU-478 HCC1937 DBTRG-05MG YKG1 JeKo-1 
bone HCC1954 DK-MG endometrium JJN-3 
143B HCC202 F5 EFE-184 JM1 
A-673 HCC2157 GAMG HEC-50B JURKAT 
CADO-ES1 HCC38 GB-1 JHUEM-2 JURL-MK1 
CAL-78 HCC70 GOS-3 JHUEM-3 JVM-2 
EW8 HDQ-P1 H4 KLE JVM-3 
EWS502 HMC-1-8 Hs 683 MFE-280 K-562 
G-292, clone A141B1 HMEL IOMM-Lee SNU-685 KARPAS-299 
HOS Hs 274.T KALS-1 haematopoietic and 
lymphoid tissue 
KARPAS-422 
Hs 706.T Hs 281.T KG-1-C KASUMI-1 
Hs 737.T Hs 343.T KNS-42 697 KASUMI-2 
Hs 819.T Hs 578T KNS-60 A3/KAW Kasumi-6 
Hs 822.T Hs 606.T KNS-81 A4/Fuk KE-37 
Hs 863.T Hs 739.T KS-1 ALL-SIL KE-97 
Hs 870.T Hs 742.T LN-215 AML-193 KG-1 
Hs 888.T JIMT-1 LN-229 AMO-1 KHM-1B 
MG-63 KPL-1 LN-235 BCP-1 Ki-JK 
MHH-ES-1 MB 157 LN-319 BDCM KM-H2 
OUMS-27 MCF7 LN-340 BL-41 KMM-1 
RD-ES MDA-MB-134-VI LN-428 CA46 KMS-11 
Saos-2 MDA-MB-157 LN-443 CI-1 KMS-12-BM 
SK-ES-1 MDA-MB-175-VII LN-464 CMK KMS-18 
SK-N-MC MDA-MB-231 LN382 CMK-11-5 KMS-20 
SW 1353 MDA-MB-361 LNZ308 CMK-86 KMS-21BM 
T1-73 MDA-MB-415 M059K COLO 775 KMS-26 
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KMS-27 PEER SLR 21 SW837 DMS 153 
KMS-34 PL-21 SLR 23 T84 DMS 273 
KO52 Raji SLR 24 liver DMS 454 
KOPN-8 RCH-ACV SLR 25 Alexander cells DMS 53 
KU812 REC-1 SLR 26 C3A DMS 79 
KYO-1 Reh SNU-1272 Hep 3B2.1-7 EBC-1 
L-1236 RPMI 8226 SNU-349 Hep G2 HCC-1171 
L-363 RPMI-8402 TUHR10TKB HLE HCC-1195 
L-428 RS4;11 TUHR14TKB HLF HCC-1359 
LAMA-84 SEM TUHR4TKB huH-1 HCC-1438 
Loucy Set-2 UMRC2 HuH-6 HCC-1588 
LP-1 SIG-M5 UMRC6 HuH-7 HCC-1833 
M-07e SK-MM-2 UOK101 JHH-2 HCC-1897 
MC116 SKM-1 VMRC-RCW JHH-4 HCC-2108 
ME-1 ST486 VMRC-RCZ JHH-6 HCC-2279 
MEC-1 SU-DHL-1 large intestine JHH-7 HCC-2814 
MEC-2 SU-DHL-4 C2BBe1 Li-7 HCC-366 
MEG-01 SU-DHL-5 CL-11 NCI-H684 HCC-78 
MHH-CALL-2 SUP-B15 CL-14 PLC/PRF/5 HCC-827-GR5 
MHH-CALL-3 SUP-T1 CL-40 SK-HEP-1 HCC-95 
MHH-CALL-4 SUP-T11 COLO 201 SNU-182 HCC2935 
Mino TALL-1 COLO 205 SNU-387 HCC364 
MJ TF-1 COLO-320 SNU-398 HCC4006 
MM1-S THP-1 COLO-678 SNU-423 HCC827 
MOLM-13 TO 175.T DLD-1 SNU-449 HLC-1 
MOLM-6 U-937 HCC-56 SNU-475 HLF-a 
MOLP-8 U266B1 HCT-8 SNU-878 Hs 229.T 
MOLT-13 UT-7 Hs 255.T SNU-886 Hs 618.T 
MOLT-16 Kidney Hs 675.T lung IA-LM 
MOLT-4 769-P Hs 698.T A549 KNS-62 
MONO-MAC-1 786-O HT-29 ABC-1 LC-1/sq-SF 
MONO-MAC-6 A-498 HT55 BEN LC-1F 
MOTN-1 A-704 LS1034 CAL-12T LCLC-103H 
MUTZ-3 ACHN LS123 Calu-1 LCLC-97TM1 
MUTZ-5 BFTC-909 LS513 Calu-3 LK-2 
MV-4-11 Caki-1 MDST8 Calu-6 LU65 
NALM-1 Caki-2 NCI-H716 ChaGo-K-1 LUDLU-1 
NALM-19 CAL-54 NCI-H747 COLO 668 LXF-289 
NAMALWA HEK TE OUMS-23 COR-L105 NCI-H1092 
NCI-H929 HK-2 SNU-1033 COR-L23 NCI-H1155 
NCO2 KMRC-1 SNU-1197 COR-L24 NCI-H1184 
NOMO-1 KMRC-2 SNU-283 COR-L279 NCI-H1299 
NU-DUL-1 KMRC-20 SNU-503 COR-L311 NCI-H1341 
OCI-AML2 KMRC-3 SNU-61 COR-L47 NCI-H1355 
OCI-AML3 OS-RC-2 SNU-C1 COR-L51 NCI-H1373 
OCI-LY3 RCC-4 SNU-C4 COR-L88 NCI-H1385 
OPM-2 RCC10RGB SW1116 COR-L95 NCI-H1395 
P12-ICHIKAWA SK-RC 31 SW1417 CPC-N NCI-H1435 
P3HR-1 SK-RC-20 SW1463 DFCI024 NCI-H1436 
PCM6 SLR 20 SW480 DMS 114 NCI-H1437 
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NCI-H146 NCI-H446 OE21 TYK-nu NCI-H2452 
NCI-H1563 NCI-H460 OE33 pancreas NCI-H28 
NCI-H1568 NCI-H510 TE-11 AsPC-1 RS-5 
NCI-H1573 NCI-H522 TE-15 Capan-1 prostate 
NCI-H1581 NCI-H526 TE-4 Capan-2 DU 145 
NCI-H1623 NCI-H596 TE-6 CFPAC-1 MDA PCa 2b 
NCI-H1650 NCI-H647 TE-9 DAN-G NCI-H660 
NCI-H1666 NCI-H661 ovary HPAC PC-3 
NCI-H1693 NCI-H69 A2780 HPAF-II PrEC LH 
NCI-H1694 NCI-H727 Caov-3 Hs 766T VCaP 
NCI-H1734 NCI-H810 Caov-4 HUP-T3 salivary gland 
NCI-H1755 NCI-H82 COV318 HUP-T4 A-253 
NCI-H1781 NCI-H838 COV362 KCI-MOH1 skin 
NCI-H1792 NCI-H841 COV434 KLM-1 A101D 
NCI-H1793 NCI-H889 COV504 KP-1N A2058 
NCI-H1838 PC-14 COV644 KP-1NL BJ hTERT 
NCI-H1869 RERF-LC-Ad1 EFO-21 KP-2 C32 
NCI-H1915 RERF-LC-Ad2 ES-2 KP-3 CJM 
NCI-H1930 RERF-LC-AI FU-OV-1 KP4 COLO 741 
NCI-H1944 RERF-LC-KJ Hey-A8 MIA PaCa-2 COLO 829 
NCI-H196 RERF-LC-MS Hs 571.T PA-TU-8988S COLO-679 
NCI-H1963 RERF-LC-Sq1 JHOC-5 PA-TU-8988T COLO-783 
NCI-H1975 SALE JHOM-1 Panc 02.03 COLO-800 
NCI-H2023 SBC-5 JHOM-2B Panc 02.13 COLO-818 
NCI-H2029 SCLC-21H JHOS-2 Panc 03.27 COLO-849 
NCI-H2030 SHP-77 JHOS-4 Panc 04.03 G-361 
NCI-H2066 SK-LU-1 KURAMOCHI Panc 05.04 GR-M 
NCI-H2073 SK-MES-1 MCAS Panc 08.13 HMCB 
NCI-H2081 Sq-1 NIH:OVCAR-3 Panc 10.05 Hs 294T 
NCI-H2085 SW 1271 OAW28 PANC-1 Hs 600.T 
NCI-H209 SW 1573 OAW42 PK-1 Hs 688(A).T 
NCI-H2110 SW 900 OC 314 PK-45H Hs 695T 
NCI-H2122 T3M-10 OC 315 PK-59 Hs 839.T 
NCI-H2126 TIG-3 TD OELE PL45 Hs 852.T 
NCI-H2141 VMRC-LCD ONCO-DG-1 PSN1 Hs 895.T 
NCI-H2171 VMRC-LCP OV-90 QGP-1 Hs 934.T 
NCI-H2172 oesophagus OV7 SNU-213 Hs 936.T 
NCI-H2227 COLO-680N OVISE SNU-324 Hs 939.T 
NCI-H226 EC-GI-10 OVK18 SNU-410 Hs 940.T 
NCI-H2286 JH-EsoAd1 OVKATE SU.86.86 Hs 944.T 
NCI-H2291 KYSE-140 OVMANA SUIT-2 IGR-1 
NCI-H23 KYSE-150 OVSAHO SW 1990 IGR-37 
NCI-H2342 KYSE-180 OVTOKO pleura IGR-39 
NCI-H2405 KYSE-270 RMG-I DM-3 IPC-298 
NCI-H2444 KYSE-30 RMUG-S IST-MES1 LOX IMVI 
NCI-H292 KYSE-410 SNU-119 IST-MES2 Malme-3M 
NCI-H322 KYSE-450 SNU-8 JL-1 MDA-MB-435S 
NCI-H3255 KYSE-520 SNU-840 MPP 89 MEL-HO 
NCI-H358 KYSE-70 TOV-112D MSTO-211H MEL-JUSO 
NCI-H441 OE19 TOV-21G NCI-H2052 MeWo 
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Human cancer cell lines with wild-type p300 and CBP, continued. 
RPMI-7951 MES-SA LMSU TT SNU-899 
RVH-421 RD MKN-45 TT2609-C02 YD-10B 
SH-4 RH-18 MKN1 upper aerodigestive tract YD-38 
SK-MEL-1 RH-30 MKN7 BHY YD-8 
SK-MEL-24 RH-41 NCC-StC-K140 BICR 16 urinary tract 
SK-MEL-28 RKN NCI-N87 BICR 18 5637 
SK-MEL-3 S-117 NUGC-2 BICR 22 253J 
SK-MEL-30 SJRH30 NUGC-4 BICR 31 253J-BV 
SK-MEL-31 SK-LMS-1 OCUM-1 BICR 6 BC-3C 
SK-MEL-5 SK-UT-1 RERF-GC-1B CAL-33 BFTC-905 
UACC-257 TE 125.T SH-10-TC Detroit 562 CAL-29 
UACC-62 TE 159.T SNU-1 FaDu Hs 172.T 
WM-115 TE 441.T SNU-16 HN HT-1197 
WM-266-4 TE 617.T SNU-216 Hs 840.T HT-1376 
WM-793 stomach SNU-5 HSC-3 J82 
WM-88 23132/87 SNU-620 HSC-4 JMSU-1 
WM-983B AZ-521 SNU-668 PE/CA-PJ15 KMBC-2 
WM1799 ECC10 thyroid PE/CA-PJ34 (clone C12) RT-112 
small intestine ECC12 8305C SCC-15 RT112/84 
HuTu 80 FU97 8505C SCC-25 RT4 
soft tissue GCIY B-CPAP SCC-4 SCaBER 
A-204 GSS BHT-101 SCC-9 SW-1710 
G-401 GSU CGTH-W-1 SNU-1041 T24 
G-402 Hs 746T FTC-133 SNU-1066 TCCSUP 
Hs 729 HuG1-N FTC-238 SNU-1076 U-BLC1 
HT-1080 KATO III ML-1 SNU-1214 UM-UC-1 
KYM-1 KE-39 SW579 SNU-46 UM-UC-3 
 
Cohort of human cancer cell lines with both wild-type p300 and CBP (n = 853). Cell line 
primary names are listed under primary site classifications as reported by the Cancer Cell 
Line Encyclopedia (CCLE). All cell lines harbor wild-type p300 and CBP gene loci.
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